



A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma

Version: 4.0

Date: 26th January 2026

Chief Investigator:	Professor Juliet Gray
Coordinating Sponsor:	University of Birmingham
Coordinating Sponsor reference number:	RG_22-136
ISRCTN number	12532102
CRCTU reference number:	BN2013
IRAS Gateway ID:	1006346
EU CT Number:	2024-516115-24

This project was supported by the Fight Kids Cancer Funding Programme, supported by Contributors listed



Page i

CRCTU-PRT-QCD-001 v2.0
QCD effective date: 22-Jul-2022

RESTRICTED

V4.0 26-Jan-2026
CR IRAS ID:1006346



BIRMINGHAM
CANCER RESEARCH UK
CLINICAL TRIALS UNIT



UNIVERSITY OF
BIRMINGHAM

CONTACT DETAILS

Chief Investigator

Prof Juliet Gray

Professor and Consultant in Paediatric Oncology, Centre for Cancer Immunology
University of Southampton, UK, B15 2TT
+ 44(0) 790 1507929
✉ juliet.gray@uhs.nhs.uk

Co-Investigator:

Prof Simon Gates

Professor of Biostatistics and Clinical Trials, Cancer Research UK Clinical Trials Unit (CRCTU)
University of Birmingham, UK, B15 2TT
(+44 (0) 121 371 8453
✉ s.gates@bham.ac.uk

Prof Amos Burke

Head of Department and Director, Cancer Research UK Clinical Trials Unit (CRCTU)
University of Birmingham, UK, B15 2TT
+44 (0)121 414 4092
✉ g.a.a.burke@bham.ac.uk

Co-Investigators/Clinical Coordinators

Dr Lucas Moreno

Division Head of Paediatric Oncology & Haematology Division, Vall d'Hebron Barcelona
Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
+34 93 489 3000 6 +34 93 489 4060
✉ lucas.moreno@vallhebron.cat

Dr Cormac Owens

Consultant Paediatric Oncologist, Children's Health Ireland, Crumlin Road, Crumlin, Dublin 12,
Ireland
(+35314096659
✉ Cormac.owens@olchc.ie

Dr Aditi Vedi

Consultant Paediatric Oncologist, Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK, CB2 0QQ
✉ a.vedi@nhs.net

Trial Management Group

Dr Pablo Berlanga

Consultant Paediatric Oncologist, Institut Gustave-Roussy, Villejuif, France
✉ pablo.berlanga@gustaveroussy.fr

Dr Alba Rubio San Simón

Paediatric Haematology Oncology Doctor, Nino Jesus University Children's Hospital, Madrid,
Spain
✉ alba.rubio@salud.madrid.org

Dr Aditi Vedi

Consultant Paediatric Oncologist, Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK, CB2 0QQ
✉ a.vedi@nhs.net

Dr Toby Trahair

Paediatric Haematologist and Oncologist
Kids Cancer Centre, Sydney Children's Hospital High Street Randwick NSW 2031 Australia
✉ Toby.Trahair@health.nsw.gov.au

Mr Nicholas Bird

Patient and Public Involvement and Engagement Collaborator
Chair of Trustees, Solving Kids' Cancer UK

Ms Lucy Jones

Patient and Public Involvement and Engagement Collaborator
CEO, Neuroblastoma Australia

National Coordinating Investigators

Australia / New Zealand (ANZCHOG)

Dr Toby Trahair

Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW 2031, Australia
☎ +61 2 9382 2970
✉ Toby.Trahair@health.nsw.gov.au

Austria

Dr Heidrun Boztug

St Anna Kinderkrebsforschung GmbH (CCRI), Kinderspitalgasse 6, A-1090, Vienna, Austria
☎ +43 1 40170 2800
✉ heidrun.boztug@stanna.at

Belgium

Prof Dr Bram de Wilde

Pediatric Hemato-Oncologist, Ghent University Hospital, Department of Pediatric Hemato-Oncology, Corneel Heymanslaan 10, 9000 Ghent, Belgium
☎ +3293322416
✉ Bram.DeWilde@uzgent.be

Czech Republic

Dr Josef Malis

University Hospital Motol, Prague, V Úvalu 84, 150 06 Praha 5, Czechia
✉ josef.malis@fnmotol.cz

Denmark

Dr Karsten Nysom

Pediatric Oncologist, Consultant, Rigshospitalet, Section 5092, Blegdamsvej 9, DK-2100, Copenhagen, Denmark
☎ 0045 35450809
✉ karsten.nysom@regionh.dk

Finland

Dr Susanna Vuorenoja

Tampere University Hospital / The Wellbeing Services County of Pirkanmaa (PIRHA), Elämänaukio 2, 33520 Tampere, Finland
✉ susanna.vuorenoja@pirha.fi

France

Dr Marion Gambart

CHU Toulouse, Hôpital des Enfants Hématologie, Oncologie 330, avenue de Grande-Bretagne, TSA 70034 31059 TOULOUSE CEDEX 9, France
✉ gambart.m@chu-toulouse.fr

Germany

Prof Hedwig Deubzer

Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
✉ hedwig.deubzer@charite.de
Ireland

Dr Cormac Owens

Children's Health Ireland, Crumlin Road, Crumlin, Dublin 12, Ireland
(+35314096659
✉ Cormac.owens@olchc.ie
Israel

Dr Shifra Ash

Schneider Children's Medical Center of Israel, Kaplan 14, Petah Tikva, Israel
✉ s_ash@rambam.health.gov.il
Italy

Dr Carla Manzitti

Paediatrician Specialist (Consultant), IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147, Genova, Italy
☎ +3301056362714
✉ carlamanzitti@gaslini.org
The Netherlands

Dr Natasha van Eijkelenburg

Paediatric Oncologist, Princess Maxima Center for Padiatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
☎ +31650006529
✉ N.K.A.vanEijkelenburg@princessmaximacentrum.nl
Norway

Dr Aina Ulvmoen

Pediatric Oncologist, Oslo University Hospital, Postboks 4950 Nydalen, 0424 Oslo, Norway
☎ +4723074560
✉ ainulv@ous-hf.no
Spain

Dr Lucas Moreno

Hospital Universitari Vall d'Hebron, Paseo Vall d'Hebron s/n, 08035 Barcelona, Spain
✉ lucas.moreno@vallhebron.cat
Sweden

Dr Kleopatra Georgantzi

Pediatric Oncologist, Karolinska University Hospital, Pediatric Oncology Department C12:33, Eugeniavägen 23, 17176 Stockholm Sweden
☎ +46812376185
✉ kleopatra.georgantzi@regionstockholm.se
Switzerland

Dr Manuel Diezi

Swiss Paediatric Oncology Group, Effingerstrasse 40, CH-3008 Bern, Switzerland
✉ Manuel.Diezi@chuv.ch
Coordinating Sponsor (CRCTU) Trials Office
BEACON2 Trial Office

Trial Office	Cancer Research UK Clinical Trials Unit (CRCTU), School of Medical Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom ☎ +44 (0)121 4143799 ✉ beacon2@trials.bham.ac.uk	
Trial Entry	https://v4.viedoc.net For emergency randomisation/registration (9.00 am till 5.00 pm Monday to Friday): +44 (0)121 4143799 or +44 (0)121 4148040	
Serious Adverse Event Reporting	✉ Reg@trials.bham.ac.uk	
Senior Biostatistician	Ms Charlotte Gaskell	
Trial Biostatistician	Ms Rebekah Weston	
Trial Management Team Leader	Dr Charlotte Firth	
Senior Trial Coordinator	Mrs Rebecca Reid	
Trial Coordinator	Mr Mohammed Ravat	
Translational Sub-Studies		
SIOPEN Liquid Biopsy Manager	Nicky Hollebrandse (+31 88 9 72 72 72) ✉ Liquidbiopsymanagement@prinsesmaximacentrum.nl ✉ n.l.hollebrandse-3@prinsesmaximacentrum.nl	
SIOPEN Liquid Biopsy Committee Chair/Co-chair	Dr. Lieve (G) Tytgat ✉ G.A.M.Tytgat@prinsesmaximacentrum.nl	Prof. Sue Burchill ✉ S.A.Burchill@leeds.ac.uk
SIOPEN Biology Committee Chair/Co-chair	Dr. Gudrun Schleiermacher ✉ gudrun.schleiermacher@curie.fr	Dr. Sabine Taschner Mandl ✉ sabine.taschner@ccri.at
Reference Laboratory Personnel		
UK	Prof. Sue Burchill / Prof. Deborah Tweddle	
Australia/New Zealand (ANZCHOG)	Dr. Toby Trahair	
Belgium	Prof. Tim Lammens	
Czech Republic	Prof. Dr. Ales Vicha	
Denmark	Dr. Maria Rossing	
Finland	Dr. Soili Kytölä	

France	Tumor Biology and cfDNA studies: Dr Gudrun Schleiermacher / Dr Gaelle Pierron / Dr Julien Masliah Planchon / Dr Olivier Delattre / Dr. Alexander Valent / Dr. Nathalie Auger / Dr. Valérie Combaret / Dr Valéry Attignon Molecular Monitoring: Prof. Andrei Tchirkov Sample collection/distribution of tubes: Nadège Rouel Rabiau
Germany	PD Dr. med. Hedwig Deubzer
Ireland	Sindhu Augustine
Israel	Dr. Yehudit Birger / Dr. Michal Hameiri-Grosman
Italy	Dr. Maria Valeria Corrias
The Netherlands	Dr. Lieve (G) Tytgat
Norway	Dr. Rakel Brendsdal Forthun
Spain	Dr. Irene Jimenez / Dr Lucas Moreno
Sweden	Dr. Catarina Träger
Switzerland	Dr. Annick Muhlethaler

Coordinating Sponsor

University of Birmingham	University of Birmingham, Edgbaston, Birmingham, B15 2TT
---------------------------------	--

National Coordinating Centres

Australia / New Zealand (ANZCHOG)	Hudson Institute Victoria 27-31 Wright St, Clayton 3168, Victoria, Australia
Austria	St Anna Kinderkrebsforschung GmbH (CCRI) Kinderspitalgasse 6, A-1090, Vienna, Austria
Belgium	Ghent University Department of Pediatric Hemato-Oncology, De Pintelaan 185, 9000 Ghent, Belgium
Czech Republic	University Hospital Motol, Prague V Úvalu 84, 150 06 Praha 5, Czechia
Denmark	Rigshospitalet, Copenhagen Clinical Trials Unit for Children and Adolescents with Cancer, Department of Paediatrics & Adolescent Medicine, Rigshospitalet, Section 5092, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
Finland	Tampere University Hospital / The Wellbeing Services County of Pirkanmaa (PIRHA), Elämänaukio 2, 33520 Tampere, Finland

France	CHU Toulouse Hôpital des Enfants Hématologie, Oncologie 330, avenue de Grande-Bretagne, TSA 70034 31059 Toulouse CEDEX 9, France
Germany	Charité – Universitätsmedizin Berlin Augustenburger Platz 1, 13353 Berlin, Germany
Ireland	Childrens Health Ireland Cooley Rd, Crumlin, Dublin, D12 N512, Republic of Ireland
Israel	Schneider Children's Medical Center of Israel Kaplan 14, Petah Tikva, Israel
Italy	IRCCS Istituto Giannina Gaslini Via Gerolamo Gaslini 5, 16147 Genova, Italy
The Netherlands	Princess Máxima Center, Utrecht Princess Máxima Center for pediatric oncology, P.O. Box 113, 3720 AC Bilthoven, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
Norway	Oslo University Hospital Department of Paediatric Haematology and Oncology, Oslo university hospital, Postbox 4950 Nydalen, 0424 Oslo, Norway
Spain	Vall d'Hebron University Hospital Institute Of Research (VHIR), Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain
Sweden	Karolinska University Hospital Solna: Eugeniavägen 3, SE-171 76 Stockholm, Sweden Huddinge: Hälsovägen, Flemingsberg, SE-141 86 Stockholm, Sweden
Switzerland	Swiss Paediatric Oncology Group Effingerstasse 40, CH-3008 Bern, Switzerland

SIGNATURE PAGE

BEACON2 Trial Protocol v4.0 (26-Jan-2026)

This protocol has been approved by:

Name:

Professor Simon Gray

Trial Role:

Chief Investigator

Signature:



Date:

27 / 01 / 2026

This protocol describes the BEACON2 trial and provides information about procedures for participants taking part in the BEACON2 trial. The protocol should not be used as a guide for treatment of participants not taking part in the BEACON2 trial.

Sponsor Statement:

Where the University of Birmingham takes on the sponsor role for protocol development oversight, the signing of the Integrated Research Application System (IRAS) Form by the sponsor will serve as confirmation of approval of this protocol.



AMENDMENTS

The following amendments and/or administrative changes have been made to this protocol since the implementation of the first approved version.

Amendment number	Date of amendment	Protocol version number	Type of amendment	Summary of amendment
1	24-Oct-2025	3.0	Substantial Amendment 04	Substantial changes: • Updates/clarification to trial objectives • Minor amendments to the Schedule of Events: ○ Follow up timepoints • Update to Statistical considerations • Update to biological samples collected <i>Note: A number of these changes have been included for regulatory purposes to address FDA's recommendations.</i> Non-substantial changes: • Addition of ISRCTN reference numbers. • Update of trial personnel
2	26-Jan-2026	4.0	Substantial Amendment 05	Substantial changes: • Change of Chief Investigator from Dr Lucas Moreno to Prof Juliet Gray

CONTENTS

Trial Synopsis	13
Schedule of Events	21
1 Background and Rationale	23
1.1 Background	23
1.2 Trial rationale.....	26
2 Trial Design	33
2.1 TIER 1 (Main Randomisation)	33
2.2 TIER 2 (Dose Expansion Cohort)	34
3 Aims, Objectives and Outcome Measures	36
3.1 Aims	36
3.2 Objectives.....	36
3.3 Outcome Measures	37
4 Eligibility.....	38
4.1 Tier 1 Eligibility	38
4.2 Tier 2 Eligibility	40
5 Screening and Consent.....	43
5.1 Participant Identification	43
5.2 Screening	43
5.3 Informed Consent.....	44
6 Trial Entry.....	45
6.1 Time Frame for Trial Entry.....	45
6.2 Trial Entry Process	45
7 TIER 1 (MAIN RANDOMISATION)	47
7.1 Tier 1 Screening	47
7.2 Tier 1 Screening Assessments (Assessment Timepoint A)	47
7.3 Tier 1 Randomisation	48
7.4 Tier 1 Emergency Randomisation	49
7.5 Tier 1 Treatment Details	49
7.6 Tier 1 Treatment Verification	53
7.7 Tier 1 Treatment Breaks and Compensation	53
8 TIER 2 (Dose Confirmation Cohort)	53
8.1 Tier 2 Screening	53
8.2 Tier 2 Screening Assessments (Assessment Timepoint A)	53
8.3 Tier 2 Registration	54
8.4 Emergency Registration	55
8.5 Tier 2 Treatment Details	55
8.6 Tier 2 Investigational Medicinal Products	55
8.7 Tier 2 Treatment Verification	58
8.8 Tier 2 Treatment Breaks and Compensation	58
9 Assessments	59

9.1	Tumour Assessment.....	59
9.2	Urinalysis.....	60
9.3	GFR.....	60
9.4	Haematology and Blood chemistry.....	61
9.5	Physical examination / symptom assessment.....	61
10	Sample Collection	62
10.1	Tumour tissue.....	62
10.2	Blood Samples	63
11	Dose modifications	65
11.1	Dose modifications for dinutuximab beta.....	66
11.2	Dose modifications for bevacizumab.....	68
11.3	Chemotherapy dose modifications	71
12	Supportive Treatment.....	74
12.1	Supportive Care	74
12.2	Pain management	75
13	Concomitant Medication	76
14	Contraception	77
15	Treatment Compliance.....	78
16	Participant Follow Up.....	78
16.1	Tier 1: Follow up visits until progression or relapse occurs will include:	78
16.2	After progression or relapse occurs:.....	79
17	Trial Treatment Discontinuation and Participant Withdrawal.....	80
17.1	Treatment Discontinuation.....	80
17.2	Participant Withdrawal.....	80
18	Adverse Event Reporting.....	81
18.1	Reporting Requirements.....	81
18.2	Reporting Period	84
18.3	Reporting Procedure	84
19	Central Review Processes	86
20	Quality Of Life Study	87
20.1	Purpose of Quality of Life	87
20.2	Questionnaires	87
20.3	Target Accrual	88
20.4	Time Points and Procedure	88
21	Translational Sub-Study/ Biological Studies	89
21.1	Purpose of Translational Sub-study.....	89
21.2	Samples to be Collected.....	90
21.3	End of Trial Arrangements.....	91
22	Data Handling and Record Keeping.....	92
22.1	Data Collection	92
22.2	Archiving.....	93
23	Quality Management	93

23.1	Site Set-up and Initiation	93
23.2	On-site Monitoring	93
23.3	Central Monitoring	94
23.4	Audit and Inspection	94
23.5	Notification of Serious Breaches	94
24	End of Trial Definition	95
25	Statistical Considerations.....	95
25.1	Definition of Outcome Measures	95
25.2	Trial Design	97
25.3	Analyses.....	99
25.4	Analysis of Outcome Measures.....	102
26	Trial Organisational Structure	104
26.1	Sponsor	104
26.2	Coordinating Sponsor.....	104
26.3	National Coordinating Centres	104
26.4	Trial Management Group.....	104
26.5	Trial Steering Committee.....	105
26.6	Data Monitoring Committee.....	105
26.7	Participant and Public Involvement and Engagement	105
26.8	Peer Review	106
27	Finance.....	106
28	Ethical And Regulatory Considerations	107
29	Confidentiality and Data Protection.....	107
30	Insurance and Indemnity	108
31	Publication Policy.....	108
32	Data And Sample Sharing.....	109
33	Reference List.....	110
	Appendix 1 – Abbreviations	115
	Appendix 2 - Tumour Staging - INRC Classification [2]	119
	Appendix 3 - SIOPEN scoring methods for neuroblastoma	123
	Appendix 4 – Lanksy and Karnofsky	124
	Appendix 5 – Temozolomide Dosing	126
	Appendix 6 - WMA Declaration of Helsinki.....	127
	Appendix 7 - Definition of Adverse Events	130
	Appendix 8 - Common Toxicity Criteria Gradings.....	132
	Appendix 9 – PedsQL™ Administration Guidelines.....	133

TRIAL SYNOPSIS

Title

BEACON2: A multi-arm multi-stage platform trial for relapsed neuroblastoma.

Trial Design

BEACON2 is a platform multi-arm multi-stage (MAMS) randomised phase I/II/III, open-label, international trial.

The trial comprises of two tiers: Tier 1 is a phase II/III MAMS trial and is the main randomisation within the trial. This tier aims to compare novel treatment therapies, starting with the randomisation of Arm A (comparator arm) vs B (novel therapy). Participants will be randomised at trial entry to receive one of the available regimens. Tier 2 is a phase I dose confirmation cohort (Arm C and future arms), to determine whether the chosen doses of novel therapies are tolerable within this patient population, before potential introduction to Tier 1. The MAMS design allows for the introduction of novel agents or regimens as new arms into Tier 1, if appropriate. The introduction of new arms will take place pending approval of a substantial amendment by each relevant Competent Authority.

Aims

- o To improve progression free survival, a clinically relevant indicator of overall survival, for participants with relapsed neuroblastoma by developing novel combinations that are ready for clinical implementation.
- o To establish a platform trial to evaluate novel combinations in relapsed neuroblastoma, within a seamless phase 1-2 trial that can contribute to regulatory approvals and impact clinical practice; allowing dose confirmation cohorts for novel combinations
- o To evaluate safety, activity, efficacy and quality of life for these novel combinations in relapsed neuroblastoma participants
- o To improve our understanding of relapsed neuroblastoma biology, tumour clonal evolution, tumour microenvironment and develop biomarkers of response and resistance to direct the development targeted therapies by conducting a comprehensive biomarker sample collection.

Objectives

Primary

- o To determine whether new novel therapy regimens improve progression free survival in relapsed neuroblastoma compared to dbIT – Tier 1 (randomised comparison)
- o To determine a safe and tolerable dose for novel treatment combinations in relapsed neuroblastoma – Tier 2 (dose confirmation cohort)

Secondary

All secondary outcomes will compare treatment arms to dbIT

Clinical

- o To evaluate the effect of novel therapy regimens on overall survival
- o To evaluate the effect of novel therapy on objective response and clinical benefit
- o To evaluate the effect of novel therapy on duration of response
- o To evaluate the effect of novel therapy on quality of life.

- o To evaluate the effect of novel therapy on safety.

Tier 1 Arm A Specific Laboratory

- o To measure dinutuximab beta serum concentration immediately pre-Db infusion and immediately post-Db infusions
- o To measure ADA to dinutuximab beta immediately pre-Db infusions
- o To measure CDC immediately pre-Db and immediately post-Db infusions

Tertiary

To evaluate of the role of circulating biomarkers and tumour molecular profiles in blood and tumour as prognostic and predictive biomarkers in relapsed neuroblastoma, including neuroblastoma mRNAs, circulating DNA, biomarkers of immune response and the tumour microenvironment and analysis of genomic aberrations in relapsed tumours

Outcome Measures**Primary Endpoint**

- o Progression-Free Survival time (as per INRC 2017) – for Tier 1 (randomised comparison)
- o Definition of a safe and tolerable combination regimen – for Tier 2 (dose confirmation cohorts)

Tier 1 - Overarching Secondary Endpoints

- o Best objective response (complete or partial response) as per INRC 2017 during trial treatment (12 cycles) as per investigator assessment.
- o Clinical benefit (complete, partial, minor response or stable disease) as per INRC 2017 as per investigator assessment.
- o Duration of response (for responders (CR or PR) only)
- o Overall Survival time
- o Quality of life measured by Peds-QL questionnaires
- o Incidence and Severity of toxicities (AEs & SAEs)

Tier 1 - BICR Specific Secondary Endpoints (Arms A and B)

- o Confirmed Objective Response (complete or partial response) as per INRC 2017 at any time during 6 and 12 cycles of treatment, responses confirmed by BICR. (N.B. the 6 cycle time point forms the primary outcome for the purposes of BLA submission)
- o Duration of Confirmed Objective Response (for BICR confirmed responders (CR or PR))
- o Confirmed Objective Response (complete or partial response) as per INRC 2017 at the end of 6 cycles of treatment, responses confirmed by BICR.
- o Extended Confirmed Objective Response (complete, partial or minor response) as per INRC 2017 at any time during 6 cycles and 12 cycles of treatment, responses confirmed by BICR.
- o Duration of Extended Confirmed Response (for BICR confirmed responders (CR, PR, MR))

Tier 2 - Secondary Endpoints

- o Best objective response (complete or partial response) as per INRC 2017 during trial treatment (12 cycles)
- o Clinical benefit (complete, partial, minor response or stable disease) as per INRC 2017.
- o Quality of life measured by Peds-QL questionnaires

Page 14

- Incidence and Severity of toxicities (AEs & SAEs)

Tier 1 – Arm A Specific Laboratory Endpoints

- To measure trough (immediately pre-Db infusions) and Cmax (immediately post-DB infusions) dinutuximab beta serum concentrations
- To measure ADA to dinutuximab beta immediately pre-Db infusion
- To measure CDC immediately pre-Db and immediately post-Db infusion

Exploratory Endpoints

- Quality of life of caregivers measured by Peds-QL questionnaires
- Correlation between objective response using INRC 2017 and PFS/OS
- Changes in circulating biomarkers and tumour molecular profiles in tumour and blood, including mRNA levels, analysis of immune response and tumour microenvironment, analyses of genomic aberrations in relapsed neuroblastoma (e.g. MYCN, ALK, RAS/MAPK pathway, ATRX) and development of novel biomarkers.

Participant Population

Participants aged ≥ 1 with relapsed neuroblastoma.

Sample Size

This is a multi-arm multi-stage phase I/II trial with a possible phase III expansion, hence modifications to the sample size, with the addition of new arms during the conduct of the trial are expected.

For each arm in Tier 1, a maximum of 75 participants per arm will be recruited to complete phase II investigation. In exceptional circumstances, should the DMC deem a treatment suitable for further investigation, an additional 37 participants per arm will be recruited (112 participants total per arm) to complete phase III investigation. For each arm in Tier 2, 10 evaluable participants are required to complete the phase I investigation. Recruitment into Tier 2 arms may be higher than 10 participants due to the need to replace any participants that are deemed to be not evaluable.

Initially a minimum of 160 participants are planned to be recruited to the trial, 75 in each arm of Tier 1 and 10 evaluable participants for one dose-confirmation cohort in Tier 2, this could be fewer should any arm in either Tier be stopped due to futility or tolerability. Should new novel therapies be added to either Tier of the trial, either as a new randomised comparison, or as a new confirmation cohort, the expected sample size will increase, and recruitment will be extended to reflect this.

Main Inclusion and Exclusion Criteria**Inclusion Criteria (Common to Tier 1 and Tier 2)***Disease specific*

- Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS)[1] definition
- High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma)

- o Measurable disease by cross sectional imaging or evaluable disease (uptake on MIBG or FDG PET/CT/MRI scan with or without bone marrow histology), as per INRC [2, 3]. Participants with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study

General

- o Age ≥ 1 year
- o Signed informed consent from participant, parent or guardian

Performance and organ function

- o Performance Status
 - o Lansky (for patients ≤ 12 years of age) or Karnofsky (for those > 12) $\geq 50\%$, (Participants who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score)
- o Life expectancy of ≥ 12 weeks
- o Bone marrow function (within 72 hours prior to randomisation):
 - o Platelets $\geq 50 \times 10^9/L$ (unsupported for 72 hours)
 - o ANC $\geq 0.50 \times 10^9/L$ (no G-CSF support for 72 hours)
 - o Haemoglobin > 8 g/dL (transfusions allowed)
- o Renal function (within 72 hours prior to randomisation):
 - o Absence of clinically significant proteinuria (either early morning urine dipstick $\leq 2+$) or if dipstick urinalysis shows $> 2+$ proteinuria, protein: creatinine (Pr/Cr) ratio must be < 0.5 or a 24 hour protein excretion must be $< 0.5g$
 - o Serum creatinine ≤ 1.5 ULN for age, if higher, a measured GFR (radioisotope or 24 hour urine calculated creatinine clearance) must be ≥ 60 ml/min/1.73 m²
- o Liver function (within 72 hours prior to randomisation):
 - o Absence of clinically significant signs of liver dysfunction. AST or ALT ≤ 3.0 ULN and total bilirubin ≤ 1.5 ULN. In patients with liver metastases, AST or ALT ≤ 5 ULN and total bilirubin ≤ 2.5 ULN is allowed.
- o Coagulation:
 - o Participants must not have an active uncontrolled coagulopathy.
 - o Anticoagulation is permitted as long as the INR or APTT is within therapeutic limits (according to the medical standard of the institution) and the participant has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment.
- o Blood pressure below 95th centile for age and sex. Participants ≥ 18 years of age should have a blood pressure $\leq 150/90$ mmHg (within 72 hours prior to randomisation). Use of antihypertensive medication is permitted.

Tier 2 Specific Inclusion Criteria

- o More than one relapse event or ineligible for Tier 1.

NB- The following previous treatments are allowed provided that the principal investigator expects a favourable benefit/risk assessment (e.g. patients could derive potential benefit from the Tier 2 combination):

- o bevacizumab,
- o any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy')
- o previous treatment with temozolomide with irinotecan

Exclusion Criteria (Common to Tier 1 and Tier 2)

- o Known contraindication or hypersensitivity to:
 - o Any study drug or component of the formulation
 - o Chinese hamster ovary products or other recombinant human or humanised antibodies.

- Participants with mild previous hypersensitivity reactions to anti-GD2 antibodies may be included, but those with severe (or G4) hypersensitivity reactions to anti-GD2 antibodies will be excluded.
- Clinically significant neurological toxicity, uncontrolled seizures or objective peripheral neuropathy (> grade 2). (Unresolved neurological deficits from previous spinal cord compression or surgeries are acceptable). Participants with previous $\geq$ Grade 3 motor neurotoxicity secondary to anti-GD2 are excluded, even if recovered
- Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) or any ongoing arterial thrombo-embolic events
- A history of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
- Patients that are allergic to all therapies for *Pneumocystis jirovecii* pneumonia and can thus not receive prophylaxis for PJP
- Uncontrolled infection
- Inadequate recovery from prior surgery with ongoing $\geq$ Grade 3 surgical complications. Grade $\geq$ 2 wound dehiscence.
- Recent surgical procedures (at start of trial treatment). Patient can be randomised up to 48hr prior to these periods being completed provided that trial treatment only starts after complying with all of them:
 - Core biopsies within previous 24hr
 - Open excisional biopsies within previous 48hr
 - Major surgery within previous 2 weeks
 - Bone marrow aspirates/trephines, within previous 48hr
 - Tunnelled central line insertion within previous 48hr
- Washout from prior treatments (at start of trial treatment):
 - Chemotherapy within previous 2 weeks (1 week for oral metronomic chemotherapy regimens)
 - Any anti-GD2 therapy within previous 2 weeks
 - Craniospinal radiotherapy or MIBG therapy within previous 6 weeks
 - Radiotherapy to the tumour bed within previous 2 weeks (no washout for palliative radiotherapy)
 - Myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant) within previous 8 weeks
 - Allogeneic stem cell transplant within previous 12 weeks (with absence of active $\geq$ G2 acute GVHD)
 - 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial
- Bleeding metastases (participants with CNS metastases can be enrolled as long as the metastases are not bleeding). At least 6 months from any $\geq$ G3 haemoptysis or pulmonary haemorrhage
- Use of enzyme inducing anticonvulsants within 72hr of start of trial treatment
- Conditions that increase the risk of bevacizumab-related toxicities:
 - History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
 - History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment
 - Current chronic intestinal inflammatory disease/bowel obstruction
- Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose
- Males or females of reproductive potential may not participate unless they agree to use a highly effective method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the duration of study therapy and for up to 6 months after the last dose of trial drugs. A negative urine or serum pregnancy test must be obtained within 72 hours prior to dosing in females who are post-menarche.
- Pregnant or lactating participant
- Live or live-attenuated vaccines given within previous 28 days prior to study enrolment
- Any uncontrolled medical condition that poses an additional risk to the participant

Tier 1 Specific Exclusion Criteria

- o More than one relapse/progression event after the start of high risk neuroblastoma therapy
- o Previous treatments that are not allowed
 - o Bevacizumab for *relapsed* neuroblastoma. Patients who have received BIT for *refractory* disease are not excluded, providing no progression of disease during this treatment occurred
 - o Treatment with any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy') for treatment of *relapsed* neuroblastoma. Prior treatment with chemo-immunotherapy for *refractory* disease is allowed, provided no disease progression during this therapy.

Trial Treatment

Tier 1:

Arm A: dbIT

Dinutuximab beta 10 mg/m²/day iv days 1-7, Irinotecan 50 mg/m² iv days 1-5, Temozolomide 100 mg/m² po days 1-5
3 weekly x12 cycles

Arm B: BIT

Bevacizumab 15 mg/kg iv day 1, Irinotecan 50 mg/m² iv days 1-5, Temozolomide 100 mg/m² po days 1-5
3 weekly x12 cycles

Tier 2:

Arm C: dbBIT

Bevacizumab 15 mg/kg/day iv day 1, Dinutuximab beta 10 mg/m²/day iv days 1-7, Irinotecan 50 mg/m² iv days 1-5, Temozolomide 100 mg/m² po days 1-5
3 weekly x12 cycles

Sub Studies

Translational Sub Study

Primary Tumour Tissue

Samples of tumour tissue collected at the time of diagnosis, during frontline therapy and/or at the time of relapse (where possible) will be collected for genome and expression profile of DNA and RNA. **This sample is mandatory for study entry; if no tumour or subsequent molecular profiling is available this will be discussed with the Coordinating Sponsor and the Chief Investigator/clinical coordinator before study entry.**

Liquid Biopsy Samples

Blood samples for the analysis of circulating biomarkers and immunological studies should be collected from all participants at the same time points as those required for standard clinical care:

- Baseline

- Pre cycles 3, 5, 7, 10
- Post Cycle 12 or End of Treatment

Constitutional DNA taken once at any time will be required for pharmacogenetic studies and is *optional*.

Bone marrow aspirate taken at baseline will be required for circulating biomarker analysis and is *optional*.

Pharmacokinetic/dynamic Samples

Blood samples for PK/PD analysis will be taken from UK and EU participants at Cycles 1, 2, 5 and 12 at dinutuximab pre-dose and at end of infusion.


Trial Duration

Initially, trial duration is 3 years of participant recruitment; which will be extended if new arms are incorporated into either Tier, plus 5 years of participant follow up.

BEACON2 Trials Office Contact Details

Children's Cancer Trials Team CCTT-D
Cancer Research UK Clinical Trials Unit (CRCTU)
School of Medical Sciences
University of Birmingham
Birmingham,
UK B15 2TT
☎ +44 (0) 121 4143799
✉ beacon2@trials.bham.ac.uk

Trial Schema



SCHEDULE OF EVENTS

Refer to Section 9 Assessments and Section 10 Sample Collection for details.

Table 1 - Schedule of Events

Protocol Activity	Screening / Baseline	Pre Dosing (All Cycles)	Pre-Cycles 3, 5, 7, 10	End of Treatment	Follow Up – 6-24 months ³	Follow Up – 36-60 months ³
Window (days)	Prior to trial entry ¹	Within 3 days prior to starting treatment	Within 7 days of starting next cycle	21 days after last Cycle 12 dose or last dose ²	±28	±60
Informed Consent / Assent	X					
Medical History ⁴	X					
Physical Examination and Performance status ⁵	X	X		X	X	
Weight and Height ⁶	X	X		X	X	X
Health-related quality of life (HRQoL) ⁷	X		X	X		
Laboratory Tests						
Haematology ⁸	X	X		X		
Blood Chemistry ⁸	X	X		X		
Clotting ⁸	X	Repeat if clinically indicated				
Urinalysis ⁹	X	X <i>For participants receiving bevacizumab only</i>		X		
Pregnancy Test ¹⁰	X	X		X		
Estimated Glomerular Filtration Rate (GFR) ¹¹	X					
Tumour Assessment¹²						
MRI (preferred) or CT scan of brain	X		Repeat if clinically indicated			
MRI (preferred) or CT scan of tumour	X		X	X	X	X ¹⁴
¹²³ I-mIBG (ideally with SPECT as well as planar imaging) (¹⁸ F FDG PET/CT/MRI scan if mIBG negative)	X		X	X	X ¹³	X ¹⁴
Bilateral Bone Marrow Aspirate and Trephine ¹⁵	X		X	X		
Sample Collection¹⁶						
Tumour Tissue	X					
Blood samples	X		X	X		
Bone marrow aspirate	X					
Miscellaneous						

Adverse Events	X (assess throughout study)
Concomitant Medications	X (assess throughout study)

- ¹ Screening period window: (Assessments performed outside of these windows should be repeated for screening)
 - Medical History – Within 4 weeks prior to trial entry
 - Physical examination and Performance status – Within 24h prior to trial entry
 - Health-related quality of life (HRQoL) – Within 1 week prior to trial entry
 - Haematology – Within 72 hours prior to trial entry
 - Biochemistry - Within 72 hours prior to trial entry
 - Clotting – Within 72 hours prior to trial entry
 - Urinalysis – Within 72hours prior to trial entry
 - Pregnancy testing – Within 72 hours prior to trial entry
 - GFR - Within 7 days prior to trial entry
 - Tumour Assessment - Within 6 weeks prior to trial entry
- ² Assessments performed at the end of treatment should be performed 21 days after the last cycle 12 dose or last dose if patient discontinued treatment early. However, the assessments can be performed before 21 days if a new treatment is planned to commence within that timeframe if the patient has progressed.
- ³ Follow up assessments will be scheduled 3 monthly for 2 years after end of treatment, and then annually at 3, 4 and 5 years after the registration date, unless the patient withdraws consent. Participants that progress, relapse or start a non-trial therapy without progression may have follow up scan assessments scheduled as per local standard practice. Additional follow up visits will be scheduled as needed to monitor any sustained unresolved, treatment emergent adverse events.
- ⁴ Data on prior exposure to GD2 antagonists - administered product, dose and dosing regimen, duration of treatment and time between prior treatment and start of dB treatment in this study will be collected
- ⁵ Performance status will be reported using the Lansky scale for 1-12 year olds and using the Karnofsky scale for older participants. Performance status and physical examination (including blood pressure, heart rate, temperature, oxygen saturation, weight and height) will be performed at screening and within 24hr prior to each cycle in all treatment arms. In participants where bevacizumab infusions become not synchronised with chemotherapy administration, physical examination will also be performed prior to each injection of bevacizumab. Menstrual status (regularity of menstruation) in females of childbearing potential should be assessed at screening, end of treatment and during follow up. A clinical assessment of pupil responses should be conducted before starting each cycle. If there are any concerns about vision or pupil responses during treatment or follow up, a referral to an ophthalmologist should be considered.
- ⁶ Patient's weight will be measured at screening, on day 1 of each cycle prior to dosing and at the end of treatment. Body height will be measured at screening, on day 1 of each cycle prior to dosing and at the end of treatment. After end of treatment, weight and height will be performed at each follow up visit.
- ⁷ HRQoL: HRQoL assessment using PedsQL for participants and parent/guardian, and PedsQL Family Impact Module for parent/guardian will be performed at baseline (in 1 week prior to study entry), Pre-Cycles 3, 5, 7 and at the End of treatment visit. It is highly recommended that all questionnaires will be collected on the visits prior to subject's drug administration or any other interaction with site staff.
- ⁸ Haematology, biochemistry and clotting blood tests must be done at screening and within 72hr prior to cycle 1 dosing. Unless required by the investigator, safety tests will not be repeated at cycle 1, day 1 prior to dosing. Beginning in cycle 2 and continuing for all subsequent cycles, predose activities can be done within 72hr pre-dose. It is recommended that blood counts are monitored weekly for all participants. Additional safety assessments may be done according to institutional standard of care. Laboratory tests and clinical visits as part of standard care can be performed at the participant's local hospital, provided they are conducted on time and the local hospital and trial site have a procedure to receive and review them timely. Participants should be visited in between cycles as per routine practice. These tests must also be performed at end of treatment. Haematology includes - haemoglobin (Hb), white blood cells (WBC) with differential count, neutrophils, lymphocytes and platelets. Biochemistry includes - sodium, potassium, calcium, urea, creatinine, total protein, albumin, bilirubin, ALT or AST. If both ALT and AST are not measured at screening, the same measurement must consistently be performed throughout the trial duration. Clotting includes INR and APTT and should only be performed at baseline and when clinically indicated.
- ⁹ Urinalysis: A Urinalysis test (early morning urine dipstick and/or protein/creatinine ratio) will be performed at screening and within 24hr prior to each bevacizumab injection and the start of each cycle of treatment. This will also be repeated at the end of treatment. If there are signs of proteinuria, a sample must be sent for determination of albumin/protein and creatinine in urine, and the albumin or protein/creatinine ratio must be calculated.
- ¹⁰ For girls who are post-menarchal, a urine (preferred) or serum pregnancy test will be done at screening (within 72hr of dosing), prior to each cycle and at end of treatment. Additional tests may be performed as required by institutional policy or local regulations. If the results are inconclusive, a repeat test must be performed using a serum sample to definitively determine pregnancy status. In addition, a pregnancy test will be done whenever one menstrual cycle is missing during treatment or a potential pregnancy is suspected. Females who become pregnant while on study will be discontinued immediately and the outcome of the pregnancy will be followed.
- ¹¹ Estimated GFR should be carried out at screening up to 7 days prior to eligibility assessment. A measured GFR must be carried out in participants with a level of serum creatinine ≥ 1.5 ULN for age.
- ¹² Tumour assessments: The minimum requirement is a cross sectional image of site of measurable disease by MRI (preferred) or CT, performed within 6 weeks prior to trial entry. A scan including the brain (either CT or MRI) must also be performed at screening to assess participant's eligibility with regard to the presence of bleeding brain metastases. At baseline, MIBG scans, ideally with SPECT as well as planar images, (or ¹⁸FDG PET/CT or ¹⁸FDG PET/MRI scan for patients with MIBG negative disease) and bilateral bone marrow aspirates and trephine are to be done within 6 weeks prior to trial entry. Additional investigations of possible metastatic sites should be done upon presentation of signs and symptoms. To ensure comparability, the same scanner, equipment, method and technique used during baseline should be consistently used throughout the study. Tumour lesions previously irradiated will be considered measurable only if progressing. Scans should be completed up to 7 days prior to cycles 3, 5, 7, 10 and at end of treatment. Response assessment will be performed with the same modalities used at screening. Tumour assessments do not have to be repeated where the following cycle is delayed due to toxicity.
- ¹³ I-mIBG (ideally with SPECT as well as planar images) /PET-CT is required at 6, 12, 18 and 24 months follow-up.
- ¹⁴ I-mIBG/PET-CT and CT/MRI is only required post 36 months if this is the local standard.
- ¹⁵ See Section 9.1 Tumour Assessment. As per INRC guidelines, evaluation of bone marrow involvement at each timepoint is required for tumour response assessment and effort will be made to comply with INRC. However, due to the invasiveness of the procedure, the risks and complications, bone marrow evaluation at all timepoints may not be clinically justified. For patients without BM involvement at enrolment or for patients who achieve a BM CR confirmed by two consecutive BM evaluations, a BM evaluation will be required only at alternating evaluations (i.e. baseline, pre-cycle 5, 10 and EOT). Bone marrow slides should be stored for each patient and made available for Blinded Independent Central Review according to INRC guideline.
- ¹⁶ **Please refer to Section 10.2 Sample Collection and the BEACON2 Laboratory Manual before taking samples.** Tumour molecular profiling: Samples of tumour tissue collected at the time of diagnosis or during frontline therapy and/or at the time of relapse will be collected. **This sample**

is mandatory for study entry, if no tumour or subsequent molecular profiling is available this will be discussed with the Coordinating Sponsor and the Chief Investigator before study entry. For participants participating in other sequencing programs, it is acceptable to share DNA or sequencing data extracted from the tumour samples. Archival tumour tissue either as paraffin embedded or frozen material will be collected. Blood samples will be obtained at baseline, pre-cycles 3, 5, 7, 10 and end of treatment for the biomarker analysis. Samples for constitutional DNA analyses are optional (samples can be collected the same day as starting the next cycle, but have to be collected before study drug administration). Bone marrow aspirate at baseline for circulating biomarkers and circulating tumour cells may be taken at baseline and is optional. Samples will be taken from all participants

1 BACKGROUND AND RATIONALE

1.1 Background

1.1.1 Overview of high-risk neuroblastoma

Neuroblastoma is the most common extracranial solid tumour in childhood and the principal cause of death due to cancer in infancy. More than 1200 cases/year are diagnosed in USA and Europe. Half of those cases are considered high-risk disease (metastatic >18 months of age or harbouring *MYCN* amplification) [4]. Despite intensive multi-modal therapies, over 50% of patients with high-risk neuroblastoma experience relapse or have disease which is refractory to front-line chemotherapy. Outcome for patients with relapsed or refractory neuroblastoma is dismal, with less than 10% long-term survival [5-9]. There is an unmet need to develop new therapeutic strategies and test new agents in children with neuroblastoma.

1.1.2 Results of phase 2 trials in relapsed neuroblastoma

A number of second-line strategies have been tested in patients with relapsed or refractory neuroblastoma over the last 30 years, including chemotherapy, immunotherapy or targeted radionuclide therapy. The majority of these are single-arm phase 2 trials and show a wide range of response rates (0 to 64%) [5, 10, 11] and provide limited data about survival outcomes. Heterogenous inclusion criteria and study designs make any comparison between studies very difficult and randomised studies have been lacking. Results of studies conducted internationally are summarised below [12-15]:


Table 2 – Results of Phase 2 trials in relapsed neuroblastoma

Regimen (reference)	N	Objective Response Rate	1-year PFS
Irinotecan-temozolomide: Bagatell JCO 2011	55	Bagatell: 15% [in BEACON: 17%]	Bagatell: Not reported [in BEACON: 35%]
Topotecan-temozolomide: Di Giannatale Eur J Cancer 2013	38	Di Giannatale: 24% [in BEACON: 28%]	Di Giannatale: 45% [in BEACON: 42%]
Bevacizumab-irino-tem: Moreno, J Clin Oncol 2024[16]	30	23%	67%
DIT: Dinutuximab-GM-CSF-Irino-tem: Mody JCO 2021	53	42%	67%
Topo-tem-dinutuximab beta: Gray ASCO 2022	42	35%	49%
HITS: Naxitamab-GM-CSF-Irino-tem: Mora ASCO 2022	46	39%	Not reported
Hu14.18K322A-GM-CSF-IL2-Chemotherapy: Federico, Clin Cancer Res 2017	13	61%	Median time to progression 274 days
RIST ([17] rapamycin, irinotecan, dasatinib, temozolomide): Corbacioglu ASCO 2023	62		Median PFS 11 months

1.1.3 Results of BEACON-Neuroblastoma trial

The BEACON Neuroblastoma trial was a pan-European ITCC and SIOPEX collaboration in partnership with an ITCC-accredited academic sponsor; Birmingham's Cancer Research UK Clinical Trials Unit. The trial recruited 225 participants from 10 European countries from 2013-2021. It evaluated three chemotherapy regimens: temozolomide, irinotecan-temozolomide and topotecan-temozolomide, and two novel agents (bevacizumab and dinutuximab beta) added to chemotherapy. It is the largest randomised study conducted in patients with relapsed / refractory neuroblastoma. The trial used a factorial 3x2 design which grouped participants on different arms according to the randomisation (see figure 1 below) e.g. for the bevacizumab randomisation, all participants receiving chemotherapy plus bevacizumab were compared to all participants receiving chemotherapy without bevacizumab, a design that allows multiple questions in a small sample size when no interactions between the different arms are present.

Figure 1 – BEACON-Neuroblastoma Trial Design



1.1.3.1 Chemotherapy backbone:

International cooperative groups have developed several temozolomide based chemotherapy regimens such as temozolomide, irinotecan-temozolomide or topotecan-temozolomide [18-20] which have been tested in patients

with relapsed/refractory neuroblastoma regimens; the BEACON-Neuroblastoma trial compared these, testing the addition of irinotecan, and then topotecan, to a temozolomide backbone. The addition of irinotecan or topotecan to temozolomide did not achieve higher response rates. However, more patients seem to achieve disease stabilisation and hence, PFS is prolonged. Toxicity profiles are consistent with what had been previously reported, confirming that the addition of irinotecan is associated with more diarrhoea and other gastrointestinal symptoms, which can be severe and debilitating in a proportion of patients, whereas the addition of topotecan is associated with increased myelotoxicity. On the basis of this it was concluded that there is benefit in adding either irinotecan or topotecan to temozolomide, but there is insufficient evidence to choose one of these as superior to the other.

1.1.3.2 Addition of bevacizumab to a temozolomide based chemotherapy backbone:

The testing of the addition of an anti-angiogenetic agent (bevacizumab) to the chemotherapy backbone in BEACON-Neuroblastoma was based on strong preclinical rationale of therapeutic benefit of antiangiogenic agents in neuroblastoma [21-26], particularly in combination with irinotecan-temozolomide-based chemotherapy [27]. Bevacizumab is among the most established of antiangiogenic drugs and has gained approval in many adult indications at the beginning of the era of targeted therapies. In the BEACON-Neuroblastoma trial, objective responses were seen in 21/80 patients (Objective Response Rate [ORR]=26%, [95% CI 17% - 37%]) in the bevacizumab arms, and in 14/80 patients (ORR=18%, [95% CI 10% - 28%]) in the non-bevacizumab arms; risk ratio (RR) was 1.52, [95% CI 0.83 – 2.77], $p=0.17$. HR for PFS was 0.89 [95% CI 0.63-1.27]. One-year PFS in the bevacizumab arms was 0.46 [95% CI 0.34 – 0.56] compared with 0.38 [95% CI 0.27 – 0.49] in the non-bevacizumab arms. The pre-defined success criterion for PFS (improvement of 15% in PFS at $1p=0.15$) was met. HR for OS was 1.01 [95% CI 0.70-1.45]. One-year OS was 0.69 [95% CI 0.57 – 0.77] for bevacizumab arms compared with 0.58 [95% CI 0.47 – 0.68] for non-bevacizumab arms.

Thus, the success criteria were met for response and PFS; within the limitations of evidence generated within a randomised phase 2 trial. The addition of bevacizumab also increased toxicity, mainly related to increased myelotoxicity. Consistently with other large trials in the paediatric population, bevacizumab-specific toxicities seen in adults were rare, although proteinuria occurred in 13% of patients, being grade 3-4 in 5% [28, 29]. Hence, within the recognised burden of toxicities related to chemotherapy administration in relapsed/refractory neuroblastoma, the toxicity profile of the addition of bevacizumab was acceptable.

Of note, 1 and 2-year PFS estimates for patients in the bevacizumab-irinotecan-temozolomide arm were particularly promising 0.67 [95% CI 0.47 – 0.80] and 0.50 [95% CI 0.31 – 0.66] respectively. One and 2-year OS estimates for bevacizumab-irinotecan-temozolomide were 0.77 [95% CI 0.57 – 0.88] and 0.73 [95% CI 0.54 – 0.86], respectively. While the trial had a factorial design, assuming no interaction between bevacizumab and the different chemotherapy regimens, heterogeneity testing for PFS showed some evidence of a potential interaction between irinotecan and bevacizumab; showing that the BIT combination could be synergistic in this patient population. Notwithstanding the challenges of interpretation of factorial trials in small populations, the promising outcomes from the BIT arm warrant further evaluation.

1.1.3.3 Addition of dinutuximab beta to the chemotherapy backbone:

Anti-GD2 antibody, given alone, or with cytokines, has been demonstrated to improve outcome when given as maintenance therapy to patients with high-risk neuroblastoma [30, 31]. More recently, a number of studies have reported impressive response rates, in both relapse/refractory and upfront settings, when anti-GD2 is given in conjunction with chemotherapy [32-34]. The BEACON-Immuno trial investigated the addition of dinutuximab beta to chemotherapy (temozolomide or temozolomide/topotecan). Significant improvements were demonstrated in both objective response rate (ORR) and progression free survival when the anti-GD2 antibody was given with chemotherapy. ORR was approximately twice as high in patients receiving concurrent dinutuximab beta (30.2% vs 18.2%), with an adjusted risk ratio for response of 1.42 (80% CI 0.74-2.72) and one-sided p -value for the main analysis showing difference of 0.23 (Fisher's exact test). This met the pre-defined success criteria for the trial (one-sided $p = 0.23$ for response) and represented a substantial and clinically significant benefit for patients. This also

translated into an improvement in PFS with chemo-immunotherapy, with 1-year PFS of 44% compared to 27% for patients receiving chemotherapy alone (adjusted HR of 0.80 (95% CI 0.44 – 1.46) (p=0.48)). These results are in line with previously reported smaller and/or non-randomised trials in this setting. The US Children's Oncology Group (COG) ANBL1221 study reported ORR 52.9% (9/17) of an initial randomised cohort and 13/36 (36.1%) of a non-randomised expansion cohort of patients administered dinutuximab with irinotecan, temozolomide and GM-CSF [33]. Importantly, dinutuximab beta given with TTo was adequately tolerated by the majority of patients. The incidence of adverse events, with the exception of neurological toxicities, was similar to patients receiving chemotherapy alone, with no increase in myelosuppression or infection. Neurological toxicities were more common in patients receiving dBT/dBTT. The majority of these were mild ($\leq$ Grade 2) other than one case of Grade 3 myelitis, which improved but did not fully resolve within the follow up period. This requires further monitoring in future studies, but the overall toxicity burden of this chemoimmunotherapy in this population of heavily pre-treated patients appears acceptable. This therefore provides very encouraging phase 2 evidence supporting the efficacy of dinutuximab beta based chemoimmunotherapy in patients with relapsed and refractory neuroblastoma. Further clinical trials are required to provide definitive evidence of efficacy, and also to evaluate in comparison with other combinational therapies.

1.1.4 New targets and novel combinational therapies in relapsed neuroblastoma

In the current landscape of multimodal therapy for high-risk neuroblastoma, chemo-immunotherapy and ALK targeted therapy (for participants with ALK aberrations) will be tested in the frontline setting by both the COG and SIOPEN regimens. The top priority for the relapsed setting is to develop combinations of chemotherapy with other immunotherapeutic or molecularly targeted agents [35]. Several novel immunotherapy combinations have shown potent therapeutic effects in pre-clinical neuroblastoma models. Prioritising which of these should be identified for inclusion in a clinical trial is challenging, given that there is no agreed 'standard' immunocompetent murine model and models vary considerably in their immunogenicity and aggressiveness, such that it is hard to compare efficacy of therapies tested in different models. To overcome this challenge, our group will work with clinicians and scientists across the globe to accelerate preclinical testing. Novel arms will be validated by SIOPEN and ITCC collaborators. A further challenge is the lack of clinical paediatric safety and preliminary activity data on the specific combinations. The 'Tier 2' aspect of this trial will facilitate rapid clinical translation of such novel combinations of agents to generate initial data in small cohorts that can then be taken forward into the main trial randomisation (named Tier 1).

Future arms in combination with existing arms will be incorporated after data on ongoing phase 1/1b paediatric trials of targeted and immunotherapy agents currently ongoing internationally is available; and could include anti-CD47 monoclonal antibodies, Aurora kinase inhibitors, GSK3 β inhibitors, or even novel CAR-T cell based therapies.

1.2 Trial rationale

1.2.1 Justification for participant population

Despite advances with the introduction of anti-GD2 immunotherapy, there is a major unmet need to develop new drugs for treatment of high-risk neuroblastoma. Around half of participants relapse despite intensive therapies, and outcome following relapse is dismal (<10% long term survival) [9, 36]. Combining chemotherapy with anti-GD2 therapy has been the most significant advance in relapsed therapy but implementing this into clinical practice faces numerous challenges and is still largely unavailable across Europe [37].

The BEACON trial established a pan-European platform to compare different relapse regimens and identified two promising regimens (combining chemotherapy with either anti-GD2 or anti-VEGF) in the phase 2 setting. Additional evidence is required to establish the future first relapse regimen to build on novel combinations, and to obtain regulatory and health care provider approval for these novel therapies to become standard of care. Still, further innovation is required to cure the majority of children who still die from disease.

A recent participant advocate-led editorial in the topic highlights key challenges [38]: 1) improve access to innovation through clinical trials, 2) ensure appropriate options for participants after trial closure and 3) forward planning for positive results. Indeed, the multi-stakeholder platform ACCELERATE recently initiated a working group on “Innovation after a first paediatric regulatory approval”, a situation where the barriers to implement chemo-immunotherapy combinations are paradigmatic.

European neuroblastoma experts from ITCC and SIOPEN and patient advocacy groups strongly support the need to develop a new platform trial focused on relapsed neuroblastoma. Building on the results of BEACON, the trial will confirm which combination should be taken forward and identify novel combinations that further improve survival in this participant group.

Based on our experience, the BEACON platform will be modified to focus on relapse participants, retaining the ability to compare multiple arms, but avoiding factorial design, and will have two tiers (Tier 1, a first relapse randomisation and Tier 2, to facilitate smaller dose confirmation cohorts of novel regimens) to be most efficient. The network of sites will be significantly enlarged to facilitate rapid recruitment and widen access to novel drugs globally.

Refractory patients will not be included in this trial. The analyses of results from BEACON and BEACON Immuno trials and other studies conducted internationally show that relapse and refractory patients represent different patient populations that cannot be merged for a common analysis. While both have a major unmet need to develop new therapies, patients with refractory disease need therapies that achieve a rapid and robust antitumour response, in order to proceed rapidly to consolidation and maintenance strategies (e.g. tandem high dose chemotherapy and maintenance anti-GD2 therapy). Hence, the SIOPEN group is currently including refractory patients within the frontline high risk neuroblastoma strategy.

Eligibility criteria in terms of organ function have been adapted to the needs of the population with relapsed neuroblastoma, that often suffers from bone marrow metastases or is heavily pretreated. Given the experience of the BEACON trial where grade 3-4 haematological and non-haematological events were reversible and manageable, the required platelet or neutrophil count, or ALT/AST have been adapted.

Median age for children recruited in the BEACON trial was 5 (range 1-21 years). Relapsed high risk neuroblastoma is exceptional in children younger than 1 year of age, given that 1) infants <18 months of age are mostly considered intermediate risk and 2) even some patients diagnosed as infants, by the time a relapse occurs, these have become >1 year of age. For these reasons, and given the lack of data on bevacizumab therapy and chemo-immunotherapy in this very young population, lower age at trial entry will be one year of age. Neuroblastoma can occur in older adolescents and young adults, hence no upper age limit has been included.

The trial will include patients with first relapsed neuroblastoma with adequate organ function; and be open across multiple sites in 15+ countries, thus providing wide access to the trial across all the countries where it opens. The trial population will be highly representative of the whole population of children with first relapsed neuroblastoma.

1.2.2 Justification for design

The BEACON2 trial is a platform trial comprising of one main randomisation (Tier 1) and a dose confirmation element (Tier 2). The main randomisation (Tier 1) has a multi-arm multi-stage randomised phase II/III design. Following this design, each arm will have two stages for completion of phase II. The multi-stage nature of the trial will greatly maximise the efficiency of treatment evaluation, allowing the possible completion of both phase I, 2 and, in exceptional circumstances, potentially 3 within the same trial.

Regarding its multi-arm nature, Tier 1 of the trial will start with two treatment arms, based on the most promising regimens identified from previous trials conducted by SIOPEN and others across the globe. However, the design allows flexibility for the incorporation of additional treatment arms as the trial evolves, if the evidence supports it. For pragmatic reasons, no more than 3 arms will be open in Tier 1 at a time. The rEECur trial for relapsed Ewing

sarcoma (NCT02727387) has used a similar multi-arm multi-stage trial proving highly efficient addressing multiple treatments over time [39].

Despite multiple novel anticancer drugs becoming increasingly available for paediatric use, most of the available phase 1 data is as single agent and the data on combinations with standard of care therapies is still very limited. For this reason, Tier 2 of the trial will allow rapid confirmation of novel combination schedules. Regimens with no expected overlapping toxicities will be included, and testing within the Tier 2 will provide confirmation that the doses and schedules are safe. Patients will only be eligible for Tier 2 when not eligible for Tier 1 (e.g. Tier 2 will not compete for recruitment of Tier 1). More than one treatment arm may be available in Tier 2 at any given time.

The majority of tests and procedures performed during screening (see section 7.1 and section 8.1) and the scans performed throughout (see section 9.1), are routinely considered as standard of care in relapsed neuroblastoma and would likely be performed whether the participant was entered into the trial or not; or are internationally agreed procedures required to evaluate neuroblastoma patients in trials as per INRC. Furthermore, the assessments undertaken during treatment, after treatment and during follow up (see section 9) are also very similar to standard of care. Additional biopsies, procedures and surgeries for the collection of tumour or bone marrow, will not be required as a consequence of trial participation. This is because samples will be collected from procedures performed as part of standard of care, provided informed consent has been obtained. Throughout the participant's treatment additional blood samples, equivalent to around 40 ml of blood, will be collected. The participant will also have the option of consenting to the collection, storage, and DNA analysis of an additional blood sample to be analysed for use in research associated with this trial. When possible, the blood will be drawn from the long line, Hickman or Port-a-cath at the same time as blood being taken for routine blood tests. Therefore, the characteristics of the BEACON2 trial intervention are considered as being comparable to normal clinical practice. Combinations of chemotherapy with both anti-GD2 therapy and bevacizumab are currently widely used across Europe and North America in children with relapsed neuroblastoma.

1.2.3 Justification for dosage of IMPs

All of the IMPs used within this clinical trial have marketing authorisation issued by the European Medicines Agency (EMA) but are being used outside of their licenced indication for the purposes of this trial, with the exception of temozolomide oral suspension which is not yet licensed. Further information can be found in the Pharmacy Manual. There is a need for temozolomide as an oral suspension as it offers a solution for infants and young children who may not be able to swallow capsules, thus not excluding this patient population.

1.2.4 Benefit Risk Assessment

As discussed in section 1.2.1 Justification for participant population and section 1.2.2 Justification for design, there are numerous benefits associated with the proposed study regime. Please see the following information relating to known and expected risks associated to the proposed study regime, as well as measures taken in accordance to the risk profile of the medicinal product.

1.2.4.1 Trial Treatment

All IMPs within the trial regimens have been widely used (within trials and/or as part of standard of care) in this indication in paediatrics and the safety profiles of the IMPs used in Tier 1 on this trial are well characterised. However, new combinations may give increased risk of toxicity, and the combinations are not fully established practice.

The study involves a phase I dose confirmation element (Tier 2) in which we are aiming to establish that the chosen dose(s) and combination of treatment(s) are safe and tolerable to take forward into the Phase II/III randomised element of the trial (Tier 1). Treatments will be included within the Tier 2 element of this trial, if they have not been explored previously in patients with relapsed neuroblastoma.

In the randomised component of this trial (Tier 1), there is a risk that participants may not be assigned to the treatment group that they or their parents would prefer. The treatment that participants receive cannot be selected by choice. If a patient does not wish to have their treatment allocated by chance i.e. by randomisation, then they cannot be part of this study and will receive alternative treatment as recommended by their doctor.

As the efficacy of the BIT, dbIT and dbBIT drug combinations have not been fully established in a paediatric population, the patient group includes participants for whom no treatment of greater curative potential is available and the alternative management, including best supportive care/palliation will be explained to the patient and/or family, to enable an informed decision regarding trial participation.

As with all clinical trial studies the drug treatments may involve risks that are already known, as well as risks that are currently unknown. Participants will be closely monitored for side effects throughout the course of the treatment and during follow up.

1.2.4.2 Pregnancy

There is a risk that if a patient (or their partner) becomes pregnant while receiving trial treatment or immediately after, that the unborn baby could be affected. For this reason, sites will ensure that all females of childbearing potential undergo a urine pregnancy test prior to receiving trial medications, prior to each treatment cycle and at the end of treatment. We will also educate all participants of childbearing potential regarding the need for adequate contraception whilst they are receiving trial drugs and for 6 months afterwards. Should a patient or their partner become pregnant between the time of commencing study treatment and up to six months after completion, treatment should be discontinued immediately, trial participation will be terminated for safety reasons and the pregnancy outcome will be monitored. If a patient's partner becomes pregnant during this period, we would also like to collect details of the outcome of the pregnancy with their permission.

1.2.4.3 Collection and use of Samples

During the trial, participants will have blood samples taken for trial related purposes. The risks of having blood taken from a vein include pain, bruising or infection at the site where the blood was taken, and fainting. Where possible blood will be taken from a patient's Hickman line or Portacath rather than directly from a vein, there is still a small risk of infection associated with doing this. Where possible blood samples taken for research purposes will be taken at the same time as routine blood sampling to minimise distress to participants. Guidance from the European Medicines Agency and Medicines for Children Research Network will be adhered to regarding the maximum volumes of blood collected for research purposes.

During this study, optional samples of bone marrow will be taken so that we can see if any neuroblastoma has spread to this area. Risks of bone marrow sampling include pain, bleeding and infection at the sampling site. If a patient is allocated to receive bevacizumab there is an additional risk of poor wound healing after having this test. For this reason, participants who have no neuroblastoma in their bone marrow at the beginning of the study will not have bone marrow samples repeated again during the study. Participants will likely be given either a general anaesthetic or sedative to make them drowsy whilst the test is performed. Sedatives are usually well tolerated but there is a small chance participants may experience an allergic reaction to this, feel sick or develop an irregular heartbeat.

During the informed consent process, participants or their parents (if aged under 16 years) will be given the option of the patient contributing a blood sample for genetic germline DNA analysis. It is possible in rare cases that the analysis of this sample could uncover findings that may have direct implications on the participants' clinical care (e.g. a rare genetic abnormality). Participants/parents are fully informed that should they agree to having this sample taken and if this situation arises, their study doctor will be informed and will take the necessary steps to refer the patient for the relevant clinical care.

1.2.4.4 Scans

Page 29

By participating in this trial participants may have up to 17 CT or MRI and 11 nuclear medicine (MIBG) scans depending on the location of their tumour. Radiation may cause cell damage which can, after many years or decades, become cancerous.

In order for some scans to be performed, “contrast agents” are given through the patient’s central line or cannula. Whilst these contrast agents allow doctors to gain a clear picture of what is happening inside the body they also carry a small risk themselves. A small number of people have an allergic reaction to them which, while usually mild and easily treatable, can be life threatening. For this reason, we ask that all participants/parents tell their doctor if they have experienced a previous reaction to contrast agents.

1.2.5 Choice of treatment arms for BEACON2 – Tier 1

The BEACON-Neuroblastoma trial has identified two arms which require further evaluation:

1.2.5.1 Dinutuximab beta-irinotecan-temozolomide (Arm A)

The combination of chemotherapy with anti-GD2 immunotherapy has achieved improved results compared to chemotherapy alone. In the BEACON Immuno trial, ORR was approximately twice as high in patients receiving concurrent dinutuximab beta (30.2% vs 18.2%), with an adjusted risk ratio for response of 1.42 (80% CI 0.74-2.72) and one-sided p-value for the main analysis (Fisher’s Exact test) of 0.23. There was also an improvement in PFS with the chemo-immunotherapy, with 1-year PFS 44% compared to 27% for patients receiving chemotherapy alone (adjusted HR of 0.80 (95% CI 0.44 – 1.46) (p=0.48)[12]. This data is in line with that of the ANBL1221 trial conducted by the COG with dinutuximab-GM-CSF-irinotecan-temozolomide, which showed an ORR of 42% (95% CI, 28.2% to 54.8%) and 1-year PFS of 67.9% (95% CI, 55.4% to 80.5%) for children with RR-NB [32, 33] and other studies with chemo-immunotherapy conducted internationally using several anti-GD2 antibodies and chemotherapy regimens (see Table 2).

The BEACON trial has provided sufficient evidence showing that chemotherapy alone (e.g. irinotecan-temozolomide or topotecan-temozolomide) have inferior outcomes compared to the combinations with bevacizumab or dinutuximab beta. Hence, there is strong agreement in the scientific and patient advocacy communities that it is not acceptable to include chemotherapy alone arms in the BEACON2 trial.

Chemo-immunotherapy trials conducted in North America have also included GM-CSF, which is not available in Europe. While no comparative data is available, given the promising results shown in BEACON Immuno with chemo-immunotherapy without GM-CSF, the BEACON2 trial will also not include GM-CSF.

The dose of dinutuximab beta-irinotecan-temozolomide has now been aligned with the regimen used by the Children’s Oncology Group, with dinutuximab beta (10mg/m²/day) now given for 7 days every 3 weeks coupled with irinotecan-temozolomide chemotherapy. This dose is equivalent to the current use of dinutuximab beta approved for maintenance of high risk neuroblastoma (10mg/m²/day for 10 days every 5 weeks).

1.2.5.2 Bevacizumab-irinotecan-temozolomide (Arm B)

Bevacizumab-irinotecan-temozolomide (BIT) arm demonstrated very promising 1-year PFS and OS (0.67 and 0.77 respectively)[40]. The toxicity and tolerability of the regimen has been demonstrated to be acceptable.

To date, there has been no direct comparison between the BIT regimen and anti-GD2 chemoimmunotherapy based. The first objective of the BEACON2 study will be therefore to directly compare these regimens to identify the regimen with the best efficacy. Irinotecan and temozolomide will be used in both regimens to allow direct comparison of the effects of the additional bevacizumab/dinutuximab beta. Although the BEACON Immuno trial used topotecan rather than irinotecan, other international trials have shown similar results with irinotecan containing anti-GD2 chemo-immunotherapy [33, 41].

1.2.6 Choice of treatment arms for BEACON2 – Tier 2 (Testing novel combinational arms)

It is likely that improvements in outcome for patients with relapsed neuroblastoma will only be achieved by combinational therapies. Our focus will be on testing regimens which build on current established combinational therapies (e.g. BIT, anti-GD2/chemotherapy) based on solid scientific rationale and/or pre-clinical data.

1.2.6.1 Dinutuximab beta-Bevacizumab-Irinotecan-Temozolomide (Arm C)

As discussed above, the addition of each of bevacizumab and dinutuximab beta both met their phase 2 success criteria for improving PFS in BEACON. Although the exact mechanism of action accounting for the therapeutic benefits of adding these respective agents to a chemotherapy backbone is not clear, it is likely they are different, given that bevacizumab is an anti-angiogenic agent, and anti-GD2 is an immunotherapy. Therefore, there is potential for there to be additive benefit of giving both agents with the chemotherapy backbone. In addition, as well as 'normalising' the tumour vasculature, enhancing delivery of chemotherapy + immunotherapy, bevacizumab may also favourably modify the immune microenvironment, including promotion of tumour infiltrating lymphocytes and suppression in the number and function of inhibitory populations, including myeloid derived suppressor cells, regulatory T cells and M2 macrophages [42-44]. In pre-clinical neuroblastoma models, it has been reported to augment infiltration and efficacy of anti-GD2 CAR T cells [45] and there are a number of clinical studies in adult tumours, indicating benefit in combining bevacizumab with checkpoint blockade [46-48]. There is therefore rationale beyond just potential additive effects, for combining bevacizumab with anti-GD2 plus chemotherapy, with the aim of favourably modifying the tumour immune and vascular microenvironment to improve the efficacy of chemo-immunotherapy.

Given the different mechanisms of action and toxicity profiles of dinutuximab beta and bevacizumab, it is anticipated that the addition of both agents together to a chemotherapy backbone would also be acceptable in terms of toxicity and tolerability.

1.2.6.2 Other novel combinations for testing in Tier 2

There are a number of potential combinational regimens which show promise, but that are not yet ready for clinical testing. Our group has formed a network of international collaborators to accelerate preclinical testing and on-going discussions within SIOPEN and ITCC consortia, will prioritise and validate these for inclusion in Tier 2, as new data becomes available.

1.2.7 Rationale for biological studies and future data sharing

Biomarkers have been defined as biological characteristics that can be objectively measured and evaluated as an indicator of normal biological, pathological processes, or pharmacological responses to a therapeutic intervention [49].

In regards to anticancer drug development, three main types of biomarkers have been defined [50]:

- Prognostic biomarkers, give information on prognostic features helping to distinguish between cases with good or poor outcome, independent of treatment.
- Predictive biomarkers assess the probability that a patient will benefit from a particular treatment.
- Pharmacological/Pharmacodynamic (PD) biomarkers, measure effects of the drug on the tumour. PD biomarkers are of major value in making "go-no-go" decisions and assess performance of new drugs.

The use of biomarkers will accelerate and improve drug development [51-53]. In this study, a comprehensive biomarker evaluation has been developed taking into account all considerations for research in the paediatric population. Details on when to collect specific samples and how to process them are described in the BEACON2 Laboratory manual. Samples and images will only be collected for research when required as per standard of care for the participants, and volumes of blood will comply with local, national and international policies.

Importantly, the status of molecular genetic alterations known to be clinically decision making should be known upon study entry, including tumour MYCN amplification status, and ALK amplification/mutation status.

1.2.8 Exploratory biomarker assays performed in blood, blood-derived plasma, bone marrow aspirates and tumour samples


Blood and plasma samples will be taken at study entry, during and at the end of treatment for exploratory biomarker studies; see BEACON2 Laboratory manual. Bone marrow aspirates at study entry may be collected for exploratory molecular studies of circulating biomarkers, neuroblastoma cells and the bone marrow microenvironment. Biological studies include, but are not limited to:

- Tumour molecular profiling. Tumour and blood-derived plasma DNA will be sequenced and tumour gene expression profiling performed to explore possible associations between the tumour molecular profile, candidate molecular predictors and clinical outcome. This will be performed in tumour samples collected at baseline study entry (for clinical purposes) or at the time of diagnosis. Existing genomic and biomarker data collected from participants prior to entry into BEACON2 will be sought to provide a complete genomic and biomarker profile of participants.
- Circulating tumour DNA and RNA will be assessed at study entry, during and at the end of treatment as potential surrogate markers of tumour burden, response of participants to treatment or development of resistance mechanisms.
- Biomarker analyses on blood samples will include identifying potential markers of prognosis or response to new therapies, and the biology of neuroblastoma.
- Optional exploratory studies in bone marrow aspirates at study entry will investigate the molecular genotype and phenotype of neuroblastoma cells in the bone marrow and the bone marrow microenvironment.

2 TRIAL DESIGN

BEACON2 is a platform multi-arm multi-stage (MAMS) randomised phase I/II/III, open-label, international trial. The trial comprises of two tiers: Tier 1 is the main randomisation, starting with the randomisation of Arm A vs B. Participants will be randomised at trial entry to receive one of the available regimens. Tier 2 will include a dose confirmation cohort (Arm C and future arms), before considering introduction into Tier 1. Using the MAMS design will allow the introduction of novel agents or regimens as new arms, if appropriate. The introduction of new arms will take place pending approval of a substantial amendment by each relevant Competent Authority.

Figure 2 – Trial Scheme



2.1 TIER 1 (Main Randomisation)

Arm A: dinutuximab beta, irinotecan and temozolomide (dbIT)

Arm B: bevacizumab, irinotecan and temozolomide (BIT)

40 participants will be recruited to each arm in the first stage. A further 35 per arm (total n=75 per arm) will be recruited following an interim analysis.

Stratification variables used in this trial include:

- Measurable (disease can be measured in cross-sectional imaging as per RECIST v1.1, e.g. soft tissue disease measures >1cm longest diameter) vs evaluable disease (e.g. disease that is non-measurable per RECIST 1.1 or only detectable by MIBG or PET/CT scan)[54]
- MYCN amplification / no amplification / unknown
- Prior Chemo-Immunotherapy (e.g. chemotherapy with anti-GD2 therapy)
- Prior Bevacizumab, Irinotecan and Temozolomide (BIT) treatment

2.2 TIER 2 (Dose Expansion Cohort)

Arm C: dinutuximab beta, bevacizumab, irinotecan and temozolomide (dbBIT).

A dose confirmation cohort of 10 evaluable participants will be recruited from selected sites. The sites selected to participate in Tier 2 will be decided by the TMG, whose decision will be based on whether they are ITCC Phase 1 centres, have experience in early phase trials, their historical site data return and capacity of their NCC to provide the monitoring required. The primary endpoint of this cohort will be the occurrence of adverse events of special interest (AESIs) defined using standard definitions [55].

An AESI is defined as a trial IMP-related adverse event occurring during the AESI assessment period (first cycle, i.e. 3 weeks) that meets 1 of the following criteria:

- o Recurrent Grade 3 bronchospasm
- o Grade 4 anaphylaxis or allergic reaction
- o Grade ≥ 3 serum sickness
- o Grade ≥ 3 neurological or vision toxicity (as defined in section 11.1)
- o Severe, unrelenting neuropathic pain not controlled by maximal analgesia
- o Recurrent Grade ≥ 3 capillary leak syndrome
- o Grade 4 hyponatremia (<120 mmol/L) lasting >24 hours despite appropriate fluid management
- o Grade 4 skin toxicity
- o Grade ≥ 3 cardiac toxicity
- o Any Grade 4 toxicity (laboratory abnormality or non-hematological toxicity) that leads to change of management defined as: chemotherapy dose reduction or delay of next cycle more than >14 days
- o Any grade ≥ 4 toxicity leading to any intensive care unit hospitalization for mechanical ventilation/ionotropic support/hemofiltration
- o Any toxic death (Grade 5 toxicity)
- o Persistent (>72 h) Grade 3 nausea, vomiting or diarrhea despite optimal therapy
- o Grade 3 total bilirubin lasting >72 h
- o $\geq$ Grade 3 ALT/AST unless resolves in ≤ 7 days
- o Any laboratory abnormality that meets the definition of drug-induced liver injury (DILI) as defined per Hy's law
- o Grade 4 anemia
- o Grade 4 febrile neutropenia
- o Grade 4 thrombocytopenia requiring transfusions >7 days or associated with $\geq$ Grade 3 bleeding

Specific for arms containing treatment with Bevacizumab:

- o Grade ≥ 3 hypertension not controlled by antihypertensive therapy
- o Grade >3 proteinuria
- o All other haematological toxicities will be not be considered AESIs

Participants will only be considered evaluable for safety evaluation provided they are eligible, have received at least 75% of each of the planned treatment components or an AESI was the reason not to complete dosing, and they have not received any other anti-cancer treatment that is not allowed in the protocol. These participants not contributing to the AESI assessment will be replaced.

All AESIs will be evaluated by the trial CI/Clinical coordinator as well as by the Trial Management Group (TMG) and DMC.

The investigator will fill in the AESI form as soon as an AESI occurs and/or at the end of the AESI period. At the latest, the form has to be sent to Sponsor within two working days after end of the AESI period. All AESIs require

continued monitoring and follow-up reporting until they resolve to grade 1 or less, until the patient begins another treatment regimen or until the toxicity is determined to be unresolvable or stabilized.

Recruitment to Tier 2:

Before a patient can be registered to Tier 2, the local team must contact the Coordinating Sponsor to confirm a slot is available.

Initial recruitment to this Tier is restricted to minimise exposure of participants to treatments that may be intolerable. Recruitment to Tier 2 will follow the below process:

- First 3 patients are recruited without any time restrictions
- 4th patient can only be recruited once one patient has completed 1 full cycle of treatment
- 5th patient can only be recruited once 2 patients have completed 1 full cycle of treatment
- 6th -10th patients can only be recruited once 3 patients have completed 1 full cycle of treatment, these participants can be recruited without any time restrictions

The above ensures that for the first 6 participants recruited, no more than 3 patients will be undergoing the first cycle of treatment at any one time. Recruitment of 6th-10th patients without time restrictions is not prescriptive and should the DMC feel this is not appropriate based on accumulating data, a recommendation can be made to continue to open slots one at a time, as patients are appraised.

If 3 participants experience ≥ 1 AESIs then the treatment under investigation will be deemed non-tolerable and won't be considered for inclusion into Tier 1.

Inclusion of Tier 2 treatment in Tier 1:

The decision to move an arm from Tier 2 to the main randomisation (Tier 1) will be taken by the TMG based on preclinical rationale, mechanism of action, early signs of activity lack of overlapping toxicities and feasibility of the combination. The DMC will validate this decision.

Treatment Duration

Participants will receive treatment for 12 courses, lasting approximately 36 weeks.

For participants pursuing other consolidation-type therapies, it is acceptable to withdraw from BEACON2 trial treatment after 6 cycles. Data about subsequent therapies received before and after subsequent progression/relapse will be collected in the Case Report Form (CRF).

3 AIMS, OBJECTIVES AND OUTCOME MEASURES

3.1 Aims

- o To improve progression free survival, a clinically relevant indicator of overall survival, for patients with relapsed neuroblastoma by developing novel combinations that are ready for clinical implementation
- o To establish a platform trial to evaluate novel combinations in relapsed neuroblastoma, within a seamless phase I, II and potentially III, trial that could lead to regulatory approvals and impact clinical practice, allowing dose confirmation cohorts for novel combinations
- o To evaluate safety, activity, efficacy and quality of life for these novel combinations in relapsed neuroblastoma participants
- o To improve our understanding of relapsed neuroblastoma biology, tumour clonal evolution, tumour microenvironment and develop biomarkers of response and resistance to direct the development targeted therapies by conducting a comprehensive biomarker sample collection.

3.2 Objectives

3.2.1 Primary

- o To determine whether new novel therapy regimens improve progression free survival in relapsed neuroblastoma compared to dbIT – Tier 1 (randomised comparison)
- o To determine a safe and tolerable dose for novel treatment combinations in relapsed neuroblastoma – Tier 2 (dose confirmation cohort)

3.2.2 Secondary

All secondary outcomes will compare treatment arms to dbIT

- o To evaluate the effect of novel therapy regimens on overall survival
- o To evaluate the effect of novel therapy on objective response and clinical benefit
- o To evaluate the effect of novel therapy on duration of response
- o To evaluate the effect of novel therapy on quality of life
- o To evaluate the effect of novel therapy on safety

3.2.3 Tertiary

- o To evaluate the role of circulating biomarkers and tumour molecular profiles in blood and tumour as prognostic and predictive biomarkers in relapsed neuroblastoma, including neuroblastoma mRNAs, circulating DNA, biomarkers of immune response and the tumour microenvironment and analysis of genomic aberrations in relapsed tumours.

3.3 Outcome Measures

3.3.1 Primary Endpoint

- o Progression-Free Survival time (as per INRC 2017 [2]) – for Tier 1 (randomised comparison)
- o Definition of a safe and tolerable combination regimen – for Tier 2 (dose confirmation cohorts)

3.3.2 Tier 1 Overarching Secondary Endpoints

- o Best objective response (complete or partial response) as per INRC 2017 during trial treatment (12 cycles) as per investigator assessment.
- o Clinical benefit (complete, partial, minor response or stable disease) as per INRC 2017 as per investigator assessment.
- o Duration of response (for responders (CR or PR) only)
- o Overall Survival time
- o Quality of life measured by Peds-QL questionnaires
- o Incidence and Severity of toxicities (AEs & SAEs)

3.3.2.1 Tier 1 BICR Specific Secondary Endpoints (Arms A and B)

- o Confirmed Objective Response (complete or partial response) as per INRC 2017 at any time during 6 and 12 cycles of treatment, responses confirmed by BICR. (N.B the 6 cycle time point forms the primary outcome for the purposes of BLA submission)
- o Duration of Confirmed Objective Response (for BICR confirmed responders (CR or PR))
- o Confirmed Objective Response (complete or partial response) as per INRC 2017 at the end of 6 cycles of treatment, responses confirmed by BICR.
- o Extended Confirmed Objective Response (complete, partial or minor response) as per INRC 2017 at any time during 6 cycles and 12 cycles of treatment, responses confirmed by BICR.
- o Duration of Extended Confirmed Response (for BICR confirmed responders (CR, PR, MR))

3.3.2.2 Tier 2 Specific Secondary Endpoints

- o Best Objective Response (complete or partial response) as per INRC 2017 during trial treatment (12 cycles).
- o Clinical benefit (complete, partial and minor response and stable disease) per the INRC 2017.
- o Quality of life measured by Peds-QL questionnaires
- o Incidence and Severity of toxicity (AEs and SAEs)

3.3.2.3 Tier 1 – Arm A Specific Secondary Endpoints (Laboratory)

- o To measure dinutuximab beta serum concentration immediately pre-Db infusions and immediately post-Db infusions
- o To measure ADA to dinutuximab beta immediately pre-Db infusion
- o To measure CDC immediately pre-Db and immediately post-Db infusion

3.3.3 Exploratory/Tertiary Endpoints

- o Quality of life of caregivers measured by Peds-QL questionnaires
- o Correlation between objective response using INRC 2017 and PFS/OS
- o Changes in circulating biomarkers and tumour molecular profiles in blood and tumour, including mRNAs, analysis of immune response and tumour microenvironment, analyses of genomic aberrations in relapsed neuroblastoma (e.g. MYCN, ALK, RAS/MAPK pathway, ATRX) and development of novel biomarkers.

4 ELIGIBILITY

4.1 Tier 1 Eligibility

Participants meeting the criteria below are eligible to participate in Tier 1 trial treatment. Eligibility must be confirmed by an Investigator (defined as the individual who has the responsibility for the medical care of the participant i.e., typically a consultant level doctor), named on the trial delegation log.

4.1.1 Tier 1 Inclusion Criteria

4.1.1.1 Disease specific

- o Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS)[1] definition
- o High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma)
- o Measurable disease by cross sectional imaging or evaluable disease (uptake on MIBG or FDG PET/CT/MRI scan with or without bone marrow histology), as per INRC [2, 3]. Participants with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study

4.1.1.2 General

- o Age ≥ 1 year
- o Signed informed consent from participant, parent or guardian

4.1.1.3 Performance and organ function

- o Performance Status:
 - o Lansky (for patients ≤ 12 years of age) or Karnofsky (for those > 12) $\geq 50\%$, (Participants who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score)
- o Life expectancy of ≥ 12 weeks
- o Bone marrow function (within 72 hours prior to randomisation):
 - o Platelets $\geq 50 \times 10^9/L$ (unsupported for 72 hours)
 - o ANC $\geq 0.50 \times 10^9/L$ (no G-CSF support for 72 hours)
 - o Haemoglobin > 8 g/dL (transfusions allowed)
- o Renal function (within 72 hours prior to randomisation):

Page 38

- Absence of clinically significant proteinuria (either early morning urine dipstick $\leq 2+$) or if dipstick urinalysis shows $> 2+$ proteinuria, protein: creatinine (Pr/Cr) ratio must be < 0.5 or a 24 hour protein excretion must be $< 0.5\text{g}$
- Serum creatinine ≤ 1.5 ULN for age, if higher, a measured GFR (radioisotope or 24 hour urine calculated creatinine clearance) must be ≥ 60 ml/min/1.73 m²
- Liver function (within 72 hours prior to randomisation):
 - Absence of clinically significant signs of liver dysfunction. AST or ALT ≤ 3.0 ULN and total bilirubin ≤ 1.5 ULN. In patients with liver metastases, AST or ALT ≤ 5 ULN and total bilirubin ≤ 2.5 ULN is allowed.
- Coagulation:
 - Participants must not have an active uncontrolled coagulopathy.
 - Anticoagulation is permitted as long as the INR or APTT is within therapeutic limits (according to the medical standard of the institution) and the participant has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment.
- Blood pressure below 95th centile for age and sex. Participants ≥ 18 years of age should have a blood pressure $\leq 150/90$ mmHg (within 72 hours prior to randomisation). Use of antihypertensive medication is permitted.

4.1.2 Tier 1 Exclusion Criteria

- Known contraindication or hypersensitivity to:
 - Any study drug or component of the formulation
 - Chinese hamster ovary products or other recombinant human or humanised antibodies.
 - Participants with mild previous hypersensitivity reactions to anti-GD2 antibodies may be included, but those with severe (or G4) hypersensitivity reactions to anti-GD2 antibodies will be excluded.
- Clinically significant neurological toxicity, uncontrolled seizures or objective peripheral neuropathy ($>$ Grade 2). (Unresolved neurological deficits from previous spinal cord compression or surgeries are acceptable). Participants with previous $\geq$ Grade 3 motor neurotoxicity secondary to anti-GD2 are excluded, even if recovered
- Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) or any ongoing arterial thrombo-embolic events
- A history of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
- Patients that are allergic to all therapies for Pnemocystis jirovecii pneumonia and can thus not receive prophylaxis for PJP
- Uncontrolled infection
- Inadequate recovery from prior surgery with ongoing $\geq$ Grade 3 surgical complications. Grade ≥ 2 wound dehiscence.
- Recent surgical procedures (at start of trial treatment). Patient can be randomised up to 48hr prior to these periods being completed provided that trial treatment only starts after complying with all of them:
 - Core biopsies within previous 24hr
 - Open excisional biopsies within previous 48hr
 - Major surgery within previous 2 weeks.
 - Bone marrow aspirates/trephines, within previous 48hr
 - Tunnelled central line insertion within previous 48hr
- Washout from prior treatments (at start of trial treatment):
 - Chemotherapy within previous 2 weeks (1 week for oral metronomic chemotherapy regimens)
 - Any anti-GD2 therapy within previous 2 weeks

Page 39

- Craniospinal radiotherapy or MIBG therapy within previous 6 weeks
- Radiotherapy to the tumour bed within previous 2 weeks (no washout for palliative radiotherapy)
- Myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant) within previous 8 weeks
- Allogeneic stem cell transplant within previous 12 weeks (with absence of active $\geq$ G2 acute GVHD)
- 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial
- Bleeding metastases (participants with CNS metastases can be enrolled as long as the metastases are not bleeding). At least 6 months from any $\geq$ G3 haemoptysis or pulmonary haemorrhage
- Use of enzyme inducing anticonvulsants within 72hr of randomisation
- Conditions that increase the risk of bevacizumab-related toxicities:
 - History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
 - History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment
 - Current chronic intestinal inflammatory disease/bowel obstruction
- Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose
- Males or females of reproductive potential may not participate unless they agree to use a highly effective method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the duration of study therapy and for up to 6 months after the last dose of trial drugs. A negative urine or serum pregnancy test must be obtained within 72 hours prior to dosing in females who are post-menarche.
- Pregnant or lactating participant
- Live or live-attenuated vaccines given within previous 28 days prior to study enrolment
- Any uncontrolled medical condition that poses an additional risk to the participant

4.1.2.1 Tier 1 Specific Exclusion Criteria

- More than one relapse event after the start of high risk neuroblastoma therapy
- Previous treatments that are not allowed
 - Bevacizumab for *relapsed* neuroblastoma (patients who have received BIT for *refractory* disease are not excluded, providing no progression of disease during this treatment occurred
 - Treatment with any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy') for treatment of *relapsed* neuroblastoma. Prior treatment with chemo-immunotherapy for *refractory* disease is allowed, provided no disease progression during this therapy.

4.2 Tier 2 Eligibility

Participants must have been previously pre-screened or screened for Tier 1 and found to be ineligible, before being assessed for Tier 2 eligibility. A reason for the ineligibility for Tier 1 must be provided on the Tier 2 Registration form.

Before offering participation on Tier 2, the local team must confirm with the Coordinating Sponsor that a slot is available for treatment in Tier 2.

Participants meeting the criteria below are eligible to participate in Tier 2 of the trial. Eligibility must be confirmed by an Investigator (defined as the individual who has the responsibility for the medical care of the participant i.e., typically a consultant level doctor), named on the trial delegation log.

4.2.1 Tier 2 Inclusion Criteria

4.2.1.1 Disease specific

- o Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS) [1] definition
- o High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma)
- o Measurable disease by cross sectional imaging or evaluable disease (uptake on MIBG or FDGPET/CT/MRI scan with or without bone marrow histology), as per INRC [2, 3]. Participants with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study

4.2.1.2 General

- o Age ≥ 1 year
- o Signed informed consent from participant, parent or guardian

4.2.1.3 Performance and organ function

- o Performance Status:
 - o Lansky (for patients ≤ 12 years of age) or Karnofsky (for those > 12) $\geq 50\%$, (Participants who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score)
- o Life expectancy of ≥ 12 weeks
- o Bone marrow function (within 72hr prior to registration):
 - o Platelets $\geq 50 \times 10^9/L$ (unsupported for 72hr)
 - o ANC $\geq 0.50 \times 10^9/L$ (no G-CSF support for 72hr)
 - o Haemoglobin > 8 g/dL (transfusions allowed)
- o Renal function (within 72 hours prior to registration):
 - o Absence of clinically significant proteinuria (either early morning urine dipstick $\leq 2+$) or if dipstick urinalysis shows $> 2+$ proteinuria, protein: creatinine (Pr/Cr) ratio must be < 0.5 or a 24 hour protein excretion must be $< 0.5g$
 - o Serum creatinine ≤ 1.5 ULN for age, if higher, a measured GFR (radioisotope or 24 hour urine calculated creatinine clearance) must be ≥ 60 ml/min/1.73 m²
- o Liver function (within 72 hours prior to registration):
 - o Absence of clinically significant signs of liver dysfunction. AST or ALT ≤ 3.0 ULN and total bilirubin ≤ 1.5 ULN. In patients with liver metastases, AST or ALT ≤ 5 ULN and total bilirubin ≤ 2.5 ULN is allowed.
- o Coagulation:
 - o Participants must not have an active uncontrolled coagulopathy
 - o Anticoagulation is permitted as long as the INR or APTT is within therapeutic limits (according to the medical standard of the institution) and the participant has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment.

Page 41

- o Blood pressure below 95th centile for age and sex. Participants ≥18 years of age should have a blood pressure ≤150/90 mmHg (within 72 hours prior to registration). Use of antihypertensive medication is permitted.

4.2.1.4 Tier 2 Specific Inclusion Criteria

- o More than one relapse event or ineligible for Tier 1.

NB- The following previous treatments are allowed provided that the principal investigator expects a favourable benefit/risk assessment (e.g. patients could derive potential benefit from the Tier 2 combination):

- o bevacizumab,
- o any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy')
- o previous treatment with temozolomide with irinotecan

4.2.2 Tier 2 Exclusion Criteria

- o Known contraindication or hypersensitivity to:
 - o Any study drug or component of the formulation
 - o Chinese hamster ovary products or other recombinant human or humanised antibodies.
 - o Participants with mild previous hypersensitivity reactions to anti-GD2 antibodies may be included, but those with severe (or G4) hypersensitivity reactions to anti-GD2 antibodies will be excluded.
- o Clinically significant neurological toxicity, uncontrolled seizures or objective peripheral neuropathy (>grade 2). (Unresolved neurological deficits from previous spinal cord compression or surgeries are acceptable). Participants with previous ≥ Grade 3 motor neurotoxicity secondary to anti-GD2 are excluded, even if recovered
- o Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) or any ongoing arterial thrombo-embolic events
- o A history of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
- o Patients that are allergic to all therapies for *Pneumocystis jirovecii* pneumonia and can thus not receive prophylaxis for PJP
- o Uncontrolled infection
- o Inadequate recovery from prior surgery with ongoing ≥Grade 3 surgical complications. Grade ≥2 wound dehiscence.
- o Recent surgical procedures (at start of trial treatment). Patient can be registered up to 48h prior to these periods being completed provided that trial treatment only starts after complying with all of them:
 - o Core biopsies within previous 24hr
 - o Open excisional biopsies within previous 48hr
 - o Major surgery within previous 2 weeks.
 - o Bone marrow aspirates/trephines, within previous 48hr
 - o Tunnelled central line insertion within previous 48hr
- o Wash out from prior treatment (at start of trial treatment):
 - o Chemotherapy within previous 2 weeks (1 week for oral metronomic chemotherapy regimens)
 - o Any anti-GD2 therapy within previous 2 weeks
 - o Craniospinal radiotherapy or MIBG therapy within previous 6 weeks
 - o Radiotherapy to the tumour bed within previous 2 weeks (no washout for palliative radiotherapy)

- Myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant) within previous 8 weeks
- Allogeneic stem cell transplant within previous 12 weeks (with absence of active $\geq$ G2 acute GVHD)
- 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial
- Bleeding metastases (participants with CNS metastases can be enrolled as long as the metastases are not bleeding). At least 6 months from any $\geq$ G3 haemoptysis or pulmonary haemorrhage
- Use of enzyme inducing anticonvulsants within 72 hours of start of treatment
- Conditions that increase the risk of bevacizumab-related toxicities:
 - History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
 - History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment
 - Current chronic intestinal inflammatory disease/bowel obstruction
- Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose
- Males or females of reproductive potential may not participate unless they agree to use a highly effective method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the duration of study therapy and for up to 6 months after the last dose of trial drugs. A negative urine or serum pregnancy test must be obtained within 72 hours prior to dosing in females who are post-menarche.
- Pregnant or lactating participant
- Live or live-attenuated vaccines given within previous 28 days prior to study enrolment
- Any uncontrolled medical condition that poses an additional risk to the participant

5 SCREENING AND CONSENT

5.1 Participant Identification

Participants will be identified by clinicians as per local practice, e.g. in multi-disciplinary teams meetings. Participants may be referred to trial participating sites by local hospitals for eligibility assessment by Investigators.

5.2 Screening

The majority of the screening tests defined in this protocol are standard practice and can be commenced prior to obtaining consent. However, where tests do not form part of standard medical practice for this group of participants, at a specific site, consent (see section 5.3) should be obtained prior to these tests being performed.

Investigators are expected to maintain a Screening/Enrolment Log of all potential participants considered for the trial. This Log will include limited information about the potential participant (e.g. date of diagnosis and gender) and the date and outcome of the screening process (e.g. enrolled into trial, reason for ineligibility or refused to participate).

For participants who appear to meet the criteria for participation in the trial, the Investigator will provide the potential participant with the current approved Participant Information Sheet to allow them to make an informed decision regarding their participation. If informed consent is given (see Section 5.3), the Investigator will conduct a full screening evaluation to ensure that the participant satisfies all inclusion and exclusion criteria (note, participants must meet all the eligibility criteria at the time they are entered into the trial, see sections 4.1 and 4.2). This evaluation should be documented in the medical records. A participant who gives written informed consent and who satisfies all the inclusion and exclusion criteria may be entered into the trial (see section 6). Note that assessments conducted as standard of care do not require trial specific informed consent and may be provided as screening data if conducted within the stipulated time period prior to trial entry. Assessments required at screening are listed in the flowchart of assessments and detailed in sections 7.2 and 8.2.

5.3 Informed Consent

It is the responsibility of the Investigator to obtain written informed consent for each participant prior to performing any trial related procedure. A Participant/Parent Information Sheet (PIS) is provided to facilitate this process. Investigators must ensure that they adequately explain the aim, trial treatment, anticipated benefits and potential hazards of taking part in the trial to the participant. The Investigator should also stress that the participant is completely free to refuse to take part or withdraw from the trial at any time. The participant should be given ample time (e.g. 24 hours) to read the PIS and to discuss their participation with others outside of the site research team. The participant must be given an opportunity to ask questions which should be answered to their satisfaction. The right of the participant to refuse to participate in the trial without giving a reason must be respected.

Specific PIS and Informed Consent Forms (ICF's) are provided for Tier 1 and Tier 2. Country specific PIS are provided.

If the participant, parent or legal guardian expresses an interest in [their child] participating in the trial they should be asked to sign and date one copy of the latest approved version of the ICF. The Investigator must then sign and date the form. For children under the age of 16, a parent or legal guardian will sign the ICF. Written assent can also be obtained from participants under the age of 16 years where possible, using the relevant section on the ICF.

A copy of the ICF should be given to the participant, a copy should be filed in the hospital notes, and the original placed in the Investigator Site File (ISF). Once the participant is entered into the trial the participant's trial number should be entered on the ICF maintained in the ISF. In addition, if the participant has given explicit consent a copy of the signed ICF must be sent in the post to the Trials Office for review.

Details of the informed consent discussions should be recorded in the participant's medical notes, this should include date of, and information regarding, the initial discussion, the date consent was given, with the name of the trial and the version number of the PIS and ICF. Throughout the trial the participant should have the opportunity to ask questions about the trial and any new information that may be relevant to the participant's continued participation should be shared with them in a timely manner.

On occasion it may be necessary to re-consent the participant, for example when the participant reaches the age of majority. Remote discussions and (re)consent are permitted by telephone or video consultation instead of face-to-face consultations. In these circumstances, the appropriate PIS and ICF should be sent to the participant/parent/legal guardian by post or email prior to the call, with adequate time to read the documents. The trial and the consent process is then discussed between the Investigator and the participant/parent/legal guardian

Page 44

who will sign the form at the time of the call. The participant/parent/legal guardian will send or bring the signed ICF back to the site where it will be signed by the member of staff who took informed consent. As the dates of signing will differ, a note to file should be written and filed in the Trial Master File (TMF) to document the reason. Remote consent is only permissible at sites where local procedures are in place and it is allowable according to institutional policies. It may be particularly useful to support re-consenting participants once they reach the age of majority if they have been discharged from paediatric services.

Electronic copies of the approved country-specific PIS and ICF are available and should be printed or photocopied onto the headed paper of the local institution.

Details of all participants approached about the trial should be recorded on the Participant Screening/Enrolment Log. Where appropriate and with the participant's prior consent their General Practitioner (GP) should also be informed that they are taking part in the trial. A GP Letter is provided electronically for this purpose.

6 TRIAL ENTRY

6.1 Time Frame for Trial Entry

Participants should be entered into the trial as soon as possible and within a maximum of 6 weeks from commencement of screening assessments. Trial treatment should ideally start within one week of trial entry.

6.2 Trial Entry Process

Participants can be entered into the trial once the applicable National Coordinating Centre (NCC) has confirmed that all regulatory requirements have been met by the trial site and the site has been activated by the UK Coordinating Centre.

It will be proposed to the participant and/or participant's parent/guardian to participate in the BEACON2 trial by signing the **ICF** (for either **Tier 1** or **Tier 2**). Once informed consent has been obtained, participants are assessed for either Tier 1 participation using Tier 1 screening assessments (see Tier 1 Screening section 8.1) for further details) or Tier 2 participation using Tier 2 screening assessments (see Tier 2 Screening section 8.2) for further details), depending on the number of relapses of neuroblastoma. Tier 1 is only for first relapse neuroblastoma participants and Tier 2 is only for second (and subsequent) relapsed neuroblastoma participants.

The eligibility of a participant for Tier 1 may be able to be assessed without screening assessments (i.e. based on previous treatment and disease history). If the participant is not eligible for Tier 1 (e.g. prior relapse treated with chemo-immunotherapy or BIT, or has had more than one relapse), it may be proposed to the participant and/or participant's parent/guardian to participate in the BEACON2 (Tier 2) trial directly.


The randomisation to Tier 1 or registration to Tier 2 must be performed prior to the commencement of any trial treatment. This procedure is outlined in the diagram (

Figure 3 – Trial Entry Process) below.

Participants that experience progression/relapse on Tier 1 may be considered for participation into Tier 2 arms, if they have received at least 3 cycles of Tier 1 treatment.

In the case that several arms in Tier 2 are open to recruitment at the same time, and participants are eligible for more than one arm, the arm that opened first will be prioritised to facilitate completing of cohorts as rapidly as possible from their opening.

Figure 3 – Trial Entry Process



7 TIER 1 (MAIN RANDOMISATION)

7.1 Tier 1 Screening

No trial specific procedure should be carried out prior to signing the Tier 1 Trial Entry consent form for this study (see section 5.3). All participants who have been consented as part of screening must undergo the following assessments/procedures within 28 days prior to randomisation and as indicated below.

7.2 Tier 1 Screening Assessments (Assessment Timepoint A)

- o Imaging of measurable or evaluable disease (MRI (preferred) or CT including the brain, MIBG scan (ideally with SPECT as well as planar imaging), (or ¹⁸FDG PET/CT/MRI scans if MIBG negative disease) and bilateral bone marrow aspirates and trephines (assessed by local morphology)) must have been performed within 6 weeks prior to trial entry. Screening tumour assessment should be recorded on the Tumour Assessment CRF, recording disease as per INRC 2017 (target and non-target lesions), with cross-sectional imaging (primary tumour and metastatic soft tissue) mIBG according to the SIOPEN score (**calculated on planar images**) and bone marrow assessment (report of bilateral aspirates and trephines).
- o Complete medical history (including past medical history, concurrent medical events and dates of all previous anticancer treatment) within 4 weeks prior to trial entry.
- o Health-related quality of life (HRQoL) assessment will be performed within 1 week prior to trial entry.
- o Full clinical examination (including physical exam, blood pressure, heart rate, temperature, oxygen saturation, weight and height) and performance status at screening and within 24hr prior to trial entry.
- o Haematology [includes Haemoglobin (Hb), white blood cells (WBC), neutrophil count, lymphocytes and platelets] at screening and within 72hr prior to dosing. If more than 72hr elapse from screening to initiation of trial therapy, they should be repeated
- o Biochemistry (includes sodium, potassium, calcium, urea, creatinine, total protein, albumin, bilirubin, and ALT or AST) must be done at screening and within 72hr prior to dosing
- o An estimated GFR must be carried out in participants with serum creatinine ≥ 1.5 ULN for age within 7 days of trial entry
- o A urine (preferred) or serum pregnancy test will be done on females who are post-menarche within 72hr prior to cycle 1 dosing. Results of the tests are needed to determine participant eligibility and testing may need to be repeated so that result from the pregnancy test are available for within 72hr before cycle 1 dosing
- o Sampling:
 - o A blood sample for the molecular monitoring analysis of mRNA (as per BEACON2 Laboratory Manual)
 - o A whole blood sample taken for DNA constitutional analyses at baseline (optional to participant/parent)
 - o A blood sample for circulating biomarkers should be collected before study drug administration
 - o Blood samples for pharmacovigilance analyses should be collected from UK/EU participants at pre-dose and end of infusion during treatment at cycles 1, 2, 5 and 12.
 - o Available tumour sample to be identified prior to starting study medications. If a sample is not available, the local physician must agree the potential study entry with the Coordinating Sponsor and the CI always before starting trial medication. The tumour sample will be shipped on a regular

basis as arranged with the Sponsor. It is acceptable to share DNA that has already been extracted or raw data for those participants that have already been undergone sequencing studies. Where feasible, samples from diagnosis and at the time of relapse will be collected. Please see BEACON2 Laboratory Manual for further details

- o Any ongoing adverse events from previous treatment and concomitant medications must be documented and continued to be assessed throughout the study. Records of ongoing concomitant medications will be collected on the CRF throughout the study.

7.3 Tier 1 Randomisation

Randomisation for Tier 1 of the trial should be performed by sites using the online electronic remote data capture system (eRDC). Informed consent should be obtained prior to any trial-related procedures. Once a paper Tier 1 Eligibility Checklist has been completed, in order to randomise a participant, the online Tier 1 Randomisation Form must be completed. All of the required information, including stratification factors, must be available at the time of randomisation.

Randomisation will be based upon a minimisation randomisation algorithm, following the methods of Pocock and Simon, this method will stratify participants by the following:

- o MYCN amplification (Negative/Positive/Unknown)
- o Prior chemo-immunotherapy for refractory disease with no subsequential progression (No/Yes)
- o Prior BIT treatment (defined as treatment with Bevacizumab, Irinotecan, Temozolomide) for refractory disease with no subsequential progression (No/Yes)
- o Disease Type (Measurable/Evaluable)

A 1:1 allocation ratio will be utilised, and a 10% random element will be implemented within all randomisation algorithms to ensure that the allocation of participants does not become predictable.

Randomisation of participants can be achieved by logging on to:

<https://v4.viedoc.net>

This program will confirm eligibility and allocate treatment via a computerised minimisation algorithm, developed by Viedoc.

A copy of the Randomisation Confirmation Report and the participant's Trial number (TNO) should be printed and retained in the Investigator Site File (ISF) and participant's notes. The TNO should be written on the Informed Consent Form filed in the ISF and used on all serious adverse event (SAE) forms and correspondence relating to that participant. In addition, where possible a copy of the participant's Informed Consent Form must be sent in the post to the National Coordinating Centre Trial Office.

7.4 Tier 1 Emergency Randomisation

In case of any problems with online randomisation, a paper Eligibility Checklist and paper Randomisation Form should be completed. These details can be phoned through to the BEACON2- Trial Office at the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, UK, using the number below:

STUDY ENTRY/ RANDOMISATION

(09:00 to 17:00 GMT / BST, Monday to Friday)

☎+44 (0)121 414 3799/ (0)121 414 5345

7.5 Tier 1 Treatment Details

7.5.1 Tier 1 Investigational Medicinal Products

The following drugs are IMPs in Tier 1:

NB- Topotecan is included as an IMP in instances of severe irinotecan-related toxicity. Please refer to Section 11.3 Chemotherapy Dose modifications.

Table 3 - IMPs in Tier 1

IMP	Formulation
Dinutuximab beta	Infusion
Bevacizumab	Infusion
Irinotecan	Infusion
Topotecan	Infusion
Temozolomide	Capsule
Temozolomide	Oral Suspension

7.5.2 Tier 1 Treatment Schedule

7.5.2.1 Arm A: dbIT

Dinutuximab beta 10 mg/m²/day iv days 1-7, Irinotecan 50 mg/m² iv days 1-5, Temozolomide 100 mg/m² po days 1-5
3 weekly x12 cycles

7.5.2.2 Arm B: BIT

Bevacizumab 15 mg/kg iv day 1, Irinotecan 50 mg/m² iv days 1-5, Temozolomide 100 mg/m² po days 1-5.

3 weekly x12 cycles

Refer to the BEACON2 Pharmacy Manual for further details.

Table 4 - Tier 1 Treatment Schedule

	Day 1	Day 2-5	Day 6-7	Day 22
Treatment duration: 12 cycles = 36 weeks, response assessed pre-cycles 3, 5, 7, 10 and end of treatment				
Arm A: dbIT	Dinutuximab beta 10mg/m ² /day iv Irinotecan 50mg/m ² iv* Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv Irinotecan 50mg/m ² iv* Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv	Day 1 of next cycle starts
Arm B: BIT	Bevacizumab 15mg/kg iv Irinotecan 50mg/m ² iv* Temozolomide 100mg/m ² po	Irinotecan 50mg/m ² iv* Temozolomide 100mg/m ² po		Day 1 of next cycle starts

o *NB- in extreme cases of toxicity, irinotecan may be replaced with topotecan. Refer to 7.5.3 below.

After six cycles of treatment, local control including surgery and radiotherapy may be used in parallel to trial treatment. Trial treatment can be interrupted temporarily to allow for local control. This information will be collected in the CRF.

For participants pursuing other consolidation-type therapies (such as stem cell transplantation), it is acceptable to withdraw from BEACON2 trial treatment after 6 cycles. Data about subsequent therapies received before and after subsequent progression/relapse will be collected in the CRF.

Participants should remain admitted as in-patients during the first course. For subsequent courses, institutional practice can be applied, and participants can be discharged on ambulatory pumps if clinically well.

After 12 cycles of treatment, participants will continue to be followed up as specified in protocol section 16. Treatments received after trial treatment (before or after developing progressive disease) can follow SIOPEN guidelines and the data will be collected in the CRF.

7.5.3 Tier 1 IMP Administration

7.5.3.1 Dinutuximab beta

The dose of dinutuximab beta will be 10 mg/m²/day given through a 24-hour infusion for 7 days (days 1-7). In order to administer dinutuximab beta in combination with chemotherapy without interruptions of dinutuximab beta infusions, it is necessary to have a double access as per routine practice for the administration of chemo-immunotherapy.

Bevacizumab

If allocated to Arm B (BIT) the dose of bevacizumab will be 15 mg/kg given intravenously. Bevacizumab should be administered prior to chemotherapy as per local practice. The total dose will be rounded to the nearest 5mg.

- o Bevacizumab **MUST not** be administered within 48 hours of any minor surgical procedure (e.g. bone marrow exam or insertion of central venous access device [CVAD]) or within 2 weeks of major surgery. In all cases, the investigator should verify that there are no wound healing complications before the administration of bevacizumab.
- o In case of severe toxicity related to bevacizumab, the drug **MUST** be stopped and not dose reduced. See Section 11.2 for criteria. In case of a prolonged dose interruption, the local physician will discuss with the Coordinating Sponsor and the medical team the appropriateness of re-starting treatment with bevacizumab, given that 4 to 6 weeks will be needed to achieve steady-state concentrations again and there is risk of subsequent toxicity related to bevacizumab. For those participants that are near completion of the treatment course it will be advisable to stop bevacizumab permanently. **In case of chemotherapy-related toxicities** require that cycles of chemotherapy are delayed, **the administration of bevacizumab should be kept to schedule** (e.g. 3-weekly) even if discoordinated with administration of chemotherapy.

7.5.3.2 Irinotecan

The dose of irinotecan will be 50 mg/m²/day. Irinotecan will be given intravenously over 1 hour on days 1-5, at least one hour following the administration of temozolomide. The total administered dose of chemotherapy may be rounded up or down to the nearest dose that can be accurately measured. Irinotecan will be administered as per local practice.

Topotecan - In instances of severe irinotecan-related toxicity

The dose of topotecan will be 0.75 mg/m²/day. Topotecan will be given intravenously over 30mins on Days 1-5, at least one hour following the administration of temozolomide. The administered dose of chemotherapy may be rounded up or down to the nearest dose that can be accurately measured.

7.5.3.3 Temozolomide

The dose of temozolomide will be 100 mg/m²/day orally. Where possible, doses will be rounded to the nearest 5mg as per the table in Appendix 5 – Temozolomide Dosing. Temozolomide will be administered as per local practice.

If participants are unable to swallow capsules whole, the capsules may either be left to soften in fruit juice/apple sauce or opened and the contents mixed with fruit juice or apple sauce. Local guidelines already in place may be used provided they follow the principles set out below):

1. If prescribed, give a dose of anti-sickness medicine 30 minutes before each dose of temozolomide.
2. Working over a medicine cup, hold the capsule by each end gently twisting and pulling the capsule open before emptying the contents into the medicine cup. Take care not to inhale any powder.
3. Repeat step 2 for each capsule.
4. Carefully mix the powder into the juice using an oral syringe and then draw up all the liquid into the oral syringe.
5. Place the syringe into the patient's mouth, preferably inside a cheek and slowly push the plunger. If preferred the patient can drink the liquid directly from the medicine cup.
6. If you are using apple sauce, mix the powder with the sauce thoroughly and feed it to the patient using the medicine spoon.

Add some more fruit juice or apple sauce to the medicine cup and mix. Ensure that all the fruit juice or the apple sauce used to mix the powder is given to ensure the entire dose has been given. Repeat if any powder is still visible in the medicine cup.

7.5.4 Tier 1 – Important Administration Information

The participant's height and weight (BW) must be measured prior to each cycle of treatment, and BSA should be calculated using local institutional procedures. It is important that the same procedure is used throughout the trial.

Bevacizumab is prescribed per kg. Temozolomide, irinotecan, topotecan and dinutuximab beta are prescribed per body surface area (BSA).

It is recommended that the same dose is given to the participant every cycle, using the doses calculated using the screening or Cycle 1 BW and BSA, UNLESS the calculated dose(s) have changed by $\geq 10\%$ from the values obtained at screening/cycle 1.

If a participant's BW exceeds that for the 98th centile for their age:

- o Bevacizumab doses should be calculated with the weight for the 98th centile
- o Irinotecan, temozolomide and dinutuximab beta doses should be calculated using the BSA, using the BW for the 98th centile and the participant's actual height.
- o In all cases, the dosing of overweight participants should be discussed and agreed with the Coordinating Sponsor before the administration of any IMP.

For participants with a body weight of ≤ 10 kg, the temozolomide dose will be reduced to 3.3 mg/kg/day, irinotecan to 1.7 mg/kg/day and topotecan to 0.025 mg/kg/day. There is no planned dose reduction of dinutuximab beta for participants that are ≤ 10 kg.

7.6 Tier 1 Treatment Verification

Verification of dosing is recorded by local practice, i.e. in pharmacy records and/or in participant's notes.

7.7 Tier 1 Treatment Breaks and Compensation

NOTE: The toxicity profiles of dinutuximab beta, bevacizumab, irinotecan, topotecan and temozolomide are different. They should be considered separately and any necessary treatment modification to one element of the study treatment should not cause a change or delay to the other element. This is particularly important with respect to bevacizumab which takes 4 – 6 weeks to achieve steady state levels. Any treatment delay will require steady state levels to be re-established. Bevacizumab infusions should be kept at 3 weekly intervals and do not necessarily need to be synchronised with irinotecan and temozolomide. Dinutuximab beta infusions should be aligned with the start of irinotecan-temozolomide treatment cycles.

The maximum delay to the administration of chemotherapy due to adverse events is 36 days. The delay may be extended over 36 days only if the participant is showing a good response to the treatment and agreement is obtained from the Sponsor.

Refer to Section 0 Dose Modifications for more details.

8 TIER 2 (DOSE CONFIRMATION COHORT)

8.1 Tier 2 Screening

No trial specific procedure should be carried out prior to signing the Tier 2 Trial Entry consent form for this study, (see section 5.3). All participants who have been consented as part of screening must undergo the following assessments/procedures within 28 days prior to registration and as indicated below.

8.2 Tier 2 Screening Assessments (Assessment Timepoint A)

- Imaging of measurable or evaluable disease (MRI (preferred) or CT including the brain, MIBG scan (ideally with SPECT as well as planar images) (or ¹⁸-FDG PET/CT/MRI scans if MIBG negative disease) and bilateral bone marrow aspirates and trephines (assessed by local morphology)) must have been performed within 6 weeks prior to trial entry. Screening tumour assessment should be recorded on the Tumour Assessment CRF, recording disease as per INRC 2017 (target and non-target lesions), with cross-sectional imaging (primary tumour and metastatic soft tissue), mIBG (or PET/CT if MIBG scan is negative) according to the SIOPEN score (**calculated on planar images alone**) and bone marrow assessment (report of bilateral aspirates and trephines).
- Complete medical history (including past medical history, concurrent medical events and dates of all previous anticancer treatment) within 4 weeks prior to trial entry.
- Health-related quality of life (HRQoL) assessment will be performed within 1 week prior to trial entry.

- Full clinical examination (including physical exam, blood pressure, heart rate, temperature, oxygen saturation, weight and height) and performance status at screening and within 24hr prior to trial entry.
- Haematology [includes haemoglobin (Hb), white blood cells (WBC), neutrophil count, lymphocytes and platelets] at screening and within 72hr prior to dosing. If more than 72hr elapse from screening to initiation of trial therapy, they should be repeated
- Biochemistry (includes sodium, potassium, calcium, urea, creatinine, total protein, albumin, bilirubin, and ALT or AST) must be done at screening and within 72 hours prior to dosing
- An estimated GFR must be carried out in participants with serum creatinine ≥ 1.5 ULN for age within 7 days prior to trial entry
- A urine (preferred) or serum pregnancy test will be done on girls who are post-menarche within 72hr prior to cycle 1 dosing. Results of the tests are needed to determine participant eligibility and testing may need to be repeated so that result from the pregnancy test are available for within 72hr before cycle 1 dosing
- Sampling:
 - A blood sample for the molecular monitoring analysis of mRNA (as per BEACON2 Laboratory Manual)
 - A whole blood sample taken for DNA constitutional analyses at baseline (optional to participant/parent)
 - A blood sample for exploratory biomarkers should be collected before study drug administration
 - Available tumour sample to be identified prior to starting study medications. If a sample is not available, the local physician must agree the potential study entry with the Coordinating Sponsor and the CI always before starting trial medication. The tumour sample will be shipped on a regular basis as arranged with the Sponsor. It is acceptable to share DNA that has already been extracted or raw data for those participants that have already been undergone sequencing studies. Where feasible, samples from diagnosis and at the time of relapse will be collected. Please see BEACON2 Laboratory Manual for further details.
- Any ongoing adverse events from previous treatment and concomitant medications must be documented and continued to be assessed throughout the study.

Records of ongoing concomitant medications will be collected on the CRF throughout the study.

8.3 Tier 2 Registration

Before offering participation on Tier 2, the local team must confirm with the Coordinating Sponsor that a slot is available. Refer to Section 2.2 TIER 2 (Dose Expansion Cohort).

Registration for Tier 2 treatment should be performed by sites using the online electronic remote data capture system (eRDC). Informed consent should be obtained prior to any trial-related procedures. Once a paper Tier 2 Eligibility Checklist has been completed, in order to register a participant, the online Tier 2 Registration Form must be completed. All of the required information, including stratification factors, must be available at the time of registration.

Registration of participants can be achieved by logging on to:

<https://v4.viedoc.net>

A copy of the Registration Confirmation Report and the participant's Trial Number (TNO) should be printed and retained in the Investigator Site File (ISF) and participant's notes. The TNO should be written on the Informed Consent Form filed in the ISF and used on all serious adverse event (SAE) forms and correspondence relating to that participant. In addition, where possible a copy of the participant's Informed Consent Form must be sent in the post to the National Coordinating Centre Trial Office.

8.4 Emergency Registration

In case of any problems with online registration, a paper Eligibility Checklist and paper Registration Form should be completed. These details can be phoned through to the BEACON2 Trial Office at the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, UK using the numbers below:

STUDY ENTRY/ REGISTRATION

(09:00 to 17:00 GMT / BST, Monday to Friday)

☎+44 (0)121 414 3799/ (0)121 414 45345

8.5 Tier 2 Treatment Details

8.6 Tier 2 Investigational Medicinal Products

The following drugs are IMPs in Tier 2:

NB – Topotecan is included as an IMP in instances of severe irinotecan-related toxicity. Please refer to Section 11.3 Chemotherapy Dose modifications.

Table 5 - IMPs in Tier 2

IMP	Formulation
Dinutuximab beta	Infusion
Bevacizumab	Infusion
Irinotecan	Infusion
Topotecan	Infusion
Temozolomide	Capsule
Temozolomide	Oral Suspension

8.6.1 Tier 2 Treatment Schedule

8.6.1.1 Arm C: dbBIT

Bevacizumab 15 mg/kg/day iv day 1, Dinutuximab beta 10 mg/m²/day iv days 1-7, Irinotecan 50 mg/m² iv days 1-5, Temozolomide 100 mg/m² po days 1-5
3 weekly x12 cycles

Refer to the BEACON2 Pharmacy manual for further details.

Table 6 – Tier 2 Treatment Schedule

	Day 1	Day 2-5	Day 6-7	Day 22
Treatment duration: 12 cycles = 36 weeks, response assessed pre-cycles 3, 5, 7, 10 and end of treatment				
Arm C: dbBIT	Dinutuximab beta 10mg/m ² iv Bevacizumab 15mg/kg iv Irinotecan 50mg/m ² iv* Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv Irinotecan 50mg/m ² /day iv* Temozolomide 100mg/m ² /day po	Dinutuximab beta 10mg/m ² /day iv	Day 1 of next cycle starts

- *NB- in extreme cases of toxicity, irinotecan may be replaced with topotecan. Refer to 8.5.3 below.

After six cycles of treatment, local control including surgery and radiotherapy may be used in parallel to trial treatment. Trial treatment can be interrupted temporarily to allow for local control. This information will be collected in the CRF.

For participants pursuing other consolidation-type therapies, it is acceptable to withdraw from BEACON2 trial treatment after 6 cycles (4 months). Data about subsequent therapies received before and after subsequent progression/relapse will be collected in the CRF.

Participants should remain admitted as in-patients during the first course. For subsequent courses, institutional practice can be applied, and participants can be discharged on ambulatory pumps if clinically well.

After 12 cycles of treatment, participants will continue to be followed up as specified in protocol section 16. Treatments received after trial treatment (before or after developing progressive disease) can follow SIOPEN guidelines and will be collected.

In order to administer dB in combination with chemotherapy without interruptions of dB infusions, it is necessary to have a double central access. This can be achieved through a double lumen central line (Hickman or Port-a-Cath) or two single lumen central lines (e.g. one Port-a-cath and a PICC line).

8.6.2 Tier 2 Administration

8.6.2.1 Dinutuximab beta

The dose of dinutuximab beta will be 10 mg/m²/day given through a 24-hour infusion for 7 days (days 1-7).

For administration of dbBIT, on day 1 participants should first receive iv bevacizumab first, then followed by the start of infusion of dinutuximab beta, and then irinotecan and temozolomide. On the following days (2-7), participants will receive a continuous infusion of dinutuximab beta. Irinotecan will be given through a different line without interrupting the dinutuximab beta infusion.

8.6.2.2 Bevacizumab:

The dose of bevacizumab will be 15 mg/kg given intravenously. Bevacizumab should be administered prior to chemotherapy and as per local practice. The total dose will be rounded to the nearest 5mg.

- o Bevacizumab **MUST not** be administered within 48hr of any minor surgical procedure (e.g. bone marrow exam or insertion of central venous access device [CVAD]) or within 2 weeks of major surgery. In all cases, the investigator should verify that there are no wound healing complications before the administration of bevacizumab.
- o In case of severe toxicity related to bevacizumab, the drug **MUST** be stopped and not dose reduced. See section 11.2 for criteria. In case of a prolonged dose interruption, the local physician will discuss with the Coordinating Sponsor and the medical team the appropriateness of re-starting treatment with bevacizumab, given that 4 to 6 weeks will be needed to achieve steady-state concentrations again and there is risk of subsequent toxicity related to bevacizumab. For those participants that are near completion of the treatment course it will be advisable to stop bevacizumab permanently. **In case of chemotherapy-related toxicities** require that cycles of chemotherapy are delayed, **the administration of bevacizumab should be kept to schedule** (e.g. 3-weekly) even if discoordinated with administration of chemotherapy.

8.6.2.3 Irinotecan

The dose of irinotecan will be 50 mg/m²/day. Irinotecan will be given intravenously over 1 hour on days 1-5, at least one hour following the administration of temozolomide. The total administered dose of chemotherapy may be rounded up or down to the nearest dose that can be accurately measured. Irinotecan will be administered as per local practice.

8.6.2.4 Topotecan - In instances of severe irinotecan-related toxicity

The dose of topotecan will be 0.75 mg/m²/day. Topotecan will be given intravenously over 30mins on days 1-5, at least one hour following the administration of temozolomide. The administered dose of chemotherapy may be rounded up or down to the nearest dose that can be accurately measured.

8.6.2.5 Temozolomide

The dose of temozolomide will be 100 mg/m²/day orally. Where possible, doses will be rounded to the nearest 5mg as per the table in Appendix 5 – Temozolomide Dosing. Temozolomide will be administered as per local practice.

Page 57

8.6.3 Tier 2 Important Administration Information

The participant's height and weight (BW) must be measured prior to each cycle of treatment, and BSA should be calculated using local institutional procedures. It is important that the same procedure is used throughout the trial.

Bevacizumab is prescribed per kg. Dinutuximab beta, irinotecan, topotecan, and temozolomide are prescribed per body surface area (BSA).

It is recommended that the same dose is given to the participant every cycle, using the doses calculated using the screening or Cycle 1 BW and BSA, UNLESS the calculated dose(s) have changed by $\geq 10\%$ from the values obtained at screening/cycle 1.

If a participant's BW exceeds that for the 98th centile for their age:

- o Bevacizumab doses should be calculated with the weight for the 98th centile
- o Irinotecan, temozolomide and dinutuximab beta doses should be calculated using the BSA, using the BW for the 98th centile and the participant's actual height.
- o In all cases, the dosing of overweight participants should be discussed and agreed with the Coordinating Sponsor before the administration of any IMP.

For participants with a body weight of ≤ 10 kg, the temozolomide dose will be reduced to 3.3 mg/kg/day, irinotecan to 1.7 mg/kg/day and topotecan to 0.025 mg/kg/day. There is no planned dose reduction of dinutuximab beta for participants that are ≤ 10 kg.

8.7 Tier 2 Treatment Verification

Verification of dosing is recorded by local practice, i.e. in pharmacy records and/or in participant's notes.

8.8 Tier 2 Treatment Breaks and Compensation

NOTE: The toxicity profiles of dinutuximab beta, bevacizumab, irinotecan, topotecan, and temozolomide are different. They should be considered separately and any necessary treatment modification to one element of the study treatment should not cause a change or delay to the other element. This is particularly important with respect to bevacizumab which takes 4 – 6 weeks to achieve steady state levels. Any treatment delay will require steady state levels to be re-established. Bevacizumab infusions should be kept at 3 weekly intervals and do not necessarily need to be synchronised with dinutuximab beta, irinotecan and temozolomide. Dinutuximab beta infusions should be aligned with the start of irinotecan-temozolomide treatment cycles.

The maximum delay to the administration of chemotherapy due to adverse events is 36 days. The delay may be extended over 36 days only if the participant is showing a good response to the treatment and agreement is obtained from the Sponsor.

Refer to section 0 Dose Modifications for more details.

9 ASSESSMENTS

All participants receiving a single dose or more of study medications will be considered evaluable for toxicity. Safety endpoints include adverse events, clinical examination (including blood pressure, heart rate, temperature, oxygen saturation, weight and height) and laboratory tests (haematology, chemistry).

All study related procedures must be performed at the study site or at accredited centres/laboratories to which the study site refers participants for laboratory tests or imaging if these cannot be routinely performed at the study site.

Laboratory tests and safety assessments as part of standard care can be performed at the participant's local hospital in between cycles, provided they are conducted on time and the local hospital has a procedure to receive and review them in a timely manner.

In the case of laboratory tests, safety assessments and additional investigations not as part of study related procedures being performed at the participant's local hospital, it is the Investigator's responsibility to ensure he/she receives and reviews the results. The results must be recorded on the CRF as required, and the reports from the other hospitals must be available for source data verification. Laboratory reference ranges, including effective dates, and evidence of laboratory accreditation must be obtained from all laboratories used. It is the Principal Investigator's responsibility at each site to obtain these.

9.1 Tumour Assessment

As per INRC2017, the minimum requirement is a cross-sectional image of site of measurable disease by MRI (preferred) or CT, performed within 6 weeks prior to trial entry. A scan including the brain (either CT or MRI) must also be performed at screening to assess participant's eligibility with regard to the presence of bleeding brain metastases. At baseline, MIBG scans (ideally with SPECT as well as planar imaging) (or ¹⁸-FDG PET/CT/MRI scan for participants with MIBG negative disease) and bilateral bone marrow aspirates and trephines are to be done within 6 weeks prior to receiving the first dose of trial treatment. Additional investigations of possible metastatic sites should be done upon presentation of signs and symptoms. Tumour lesions previously irradiated will be considered measurable only if progressing. Scans should be completed up to 7 days pre cycles, 3, 5, 7, 10 and at end of treatment if the participant discontinues treatment early. A brain CT/MRI must be repeated following pre-cycles 3, 5, 7, 10 and end of treatment only if clinically indicated. Follow up MRI or CT scan assessments will be scheduled 3 monthly for 2 years after end of treatment, and then annually at 3, 4 and 5 years after the registration date, unless the patient withdraws consent. Follow up MIBG scan assessments will be scheduled 6 monthly for 2 years after end of treatment, and then at 3 years after end of treatment if standard of care. Participants that progress or develop relapse do not need to continue the post-treatment scanning follow up. Participants that start a non-trial therapy without progression may have follow up scan assessments scheduled as per local standard practice.

Tumour assessments do not have to be repeated where the following cycle is delayed due to toxicity. Response assessment will be performed with the same modalities used at screening (MRI/CT/MIBG/bone marrow histology as appropriate). To ensure comparability, the same scanner, equipment, method and technique used during baseline should be consistently used throughout the study.

Response pre- cycle 3, 5, 7, 10 and end of treatment will be determined for participants with evaluable disease (only MIBG avid disease) using a semi-quantitative score based on planar imaging alone (see Appendix 3 - SIOPEN

scoring methods for neuroblastoma) and the International Neuroblastoma Response Criteria Appendix 2 - Tumour Staging - INRC Classification [2] Participants with MIBG negative scans but lesions on ¹⁸F-DG-PET/CT/MRI scans will be evaluated with ¹⁸F-DG-PET/CT/MRI. For these participants the number of FDG-avid bone lesions will be recorded and be used as score to calculate the % reduction or increase in comparison with baseline.

Participants who fail treatment (i.e. develop PD) early, prior to response evaluation, will be considered to be non-responders.

Response will be categorised as Complete Response (CR), Partial Response (PR), Minor Response (MR), Stable Disease (SD), Progressive Disease (PD – including the appearance of new lesions) or Non Evaluable (NE) as per INRC 2017.

As per INRC guidelines, BM will be assessed at enrollment by bilateral aspirates and biopsies, with cytology of aspirates (and immunocytology if available) and immunohistochemical staining for NB-specific antibodies of trephine biopsies per institutional standards. The percentage of tumor infiltration at each response evaluation time point will be based on the highest percentage seen in any one sample among the bilateral aspirates and biopsies (a total of four samples). Subsequently, BM aspirates and biopsies should be performed at the first timepoint assessment (after 2 cycles, pre-Cycle 3) regardless of BM involvement at the time of enrollment. Subsequent BM assessments will be performed at least at alternating evaluations through the protocol therapy (i.e. baseline, pre cycle 5, 10 and EOT). A BM evaluation must be included if the patient had documented BM involvement at enrollment. For patients without BM involvement at enrollment or for patients who achieve a BM CR confirmed by two consecutive BM evaluations, a BM evaluation will be required only at alternating evaluations (i.e., approximately every 24 weeks). A BM evaluation is not required if CT or 123 I-MIBG scanning demonstrates PD. BM evaluation should be performed at EOT. Bone marrow slides should be stored for each patient and made available for Blinded Independent Central Review according to INRC guideline. CR in BM will be defined when 2 aspirates and 2 trephines are negative in a previously involved BM. PD will be defined as per [56], as either bone marrow without tumour infiltration that becomes >5% tumour infiltration on reassessment, or bone marrow with tumour infiltration that increases by >2-fold and is >20% tumour infiltration on reassessment. The published international guidelines to evaluate response in the bone marrow component will be used at the time of the analysis [56].

9.2 Urinalysis

A Urinalysis test (early morning urine dipstick and/or protein/creatinine ratio) will be performed at screening. For participants receiving bevacizumab, this will be repeated within 24 hours prior to each bevacizumab injection and the start of each cycle of treatment. This will also be repeated at the end of treatment. If there are signs of proteinuria, a sample must be sent for determination of albumin/protein and creatinine in urine, and the albumin or protein/creatinine ratio must be calculated.

9.3 GFR

Estimated GFR should be carried out at screening up to 7 days prior to eligibility assessment in participants with a level of serum creatinine ≥ 1.5 ULN for age.

9.4 Haematology and Blood chemistry

Haematology, biochemistry and clotting blood tests must be done at screening and within 72hr prior to cycle 1 dosing. Unless required by the investigator, safety tests will not be repeated at cycle 1, day 1 prior to dosing. Beginning in cycle 2 and continuing for all subsequent cycles, pre-dose activities can be done within 72hr pre-dose. It is recommended that blood counts are monitored weekly for all participants. Additional safety assessments may be done according to institutional standard of care. Laboratory tests and clinical visits as part of standard care can be performed at the participant's local hospital, provided they are conducted on time and the local hospital and trial site have a procedure to receive and review them timely. Participants should be visited in between cycles as per routine practice. These tests must also be performed at end of treatment.

Haematology includes - haemoglobin (Hb), white blood cells (WBC) with differential count, neutrophils, lymphocytes and platelets. Biochemistry includes - sodium, potassium, calcium, urea, creatinine, total protein, albumin, bilirubin, and ALT or AST. Clotting includes INR and APTT and should only be performed at baseline and when clinically indicated.

9.5 Physical examination / symptom assessment

Performance status will be reported using the Lansky scale for 1-12 year olds and using the Karnofsky scale for older participants. Performance status and physical examination (including blood pressure (BP), heart rate (HR), temperature, oxygen saturation, weight and height) will be performed at screening/baseline and within 24 hours prior to each cycle in all treatment arms. Both examinations will also be performed at the end of treatment visit, and at each follow up visit for 2 years. In participants where bevacizumab infusions become not synchronised with chemotherapy administration, physical examination will also be performed prior to each injection of bevacizumab. A clinical assessment of pupil responses should be conducted before starting each cycle. If there are any concerns about vision or pupil responses during treatment or follow up, a referral to an ophthalmologist should be considered. Patient's weight will be measured at screening, on day 1 of each cycle prior to dosing and at the end of treatment. Body height will be measured at screening, on day 1 of each cycle prior to dosing and at the end of treatment. After end of treatment, weight, and height will be performed at each follow up visit.

Menstrual status (regularity of menstruation) in females of childbearing potential should be assessed at screening, end of treatment and during follow up. For females who are post-menarchal, a urine (preferred) or serum pregnancy test will be done at screening (within 72hr of dosing), prior to each treatment cycle and at end of treatment. If the results are inconclusive, a repeat test must be performed using a urine sample. In addition, a pregnancy test will be done whenever one menstrual cycle is missing during treatment or a potential pregnancy is suspected. Females who become pregnant while on study will be discontinued immediately and the outcome of the pregnancy will be followed. Pregnancy tests may be repeated during study if required by hospital regulations and/or Research Ethics Committees (RECs).

10 SAMPLE COLLECTION

10.1 Tumour tissue

Refer to Section 21 Translational Sub-Study. The evaluation of neuroblastoma related biomarkers will be performed on samples of tumour tissue collected at the time of diagnosis or during frontline therapy and/or at the time of relapse will be collected. Archival tumour tissue either as paraffin embedded (FFPE), unstained slides or frozen material will be collected.

Where molecular profiling has already been performed, available genomic data on study participants will be imported. For patients participating in other sequencing programs, it is acceptable to share DNA or sequencing data extracted from the tumour samples.

Molecular profiling of tumour is mandatory for study entry; if no tumour or molecular profiling is available this should be discussed with the Coordinating Sponsor and the Chief Investigator/Clinical coordinator **before** study entry.

Participants or their parents will be asked to give consent to retrieve any analyses already performed, any previously stored tumour sample (which could be at different hospitals) and any future samples collected during the course of the study treatment or follow up. Tumour tissue obtained at the time of relapse is especially valuable and should be obtained if ethically and clinically indicated. If a biopsy was performed fresh frozen tissue should be sent for analyses. If this is not possible FFPE tumour tissue blocks or unstained sections of these tumours must be sent for analyses instead. After completion of biomarker studies, any tumour blocks not utilised will be returned to sites where requested. Surplus material, extracted DNA and RNA will be stored at the SIOPEN reference laboratories. Please refer to the BEACON2 Laboratory Manual for further details.

Links to the SIOPEN BioPortal will be established and instrumental to retrieving biological data acquired for a given patient at different time points.

10.2 Blood Samples

Blood samples will be obtained at baseline, pre-cycles 3, 5, 7, 10 and EOT for the molecular monitoring analysis. Blood samples for constitutional DNA analyses and bone marrow samples are optional. Tumour, Peripheral blood and bone marrow samples (excepting those for constitutional DNA analyses) will be taken from all participants. Blood samples for PK/PD analysis will be taken from UK and EU participants only at Cycle 1, 2, 5 and 12 at dinutuximab pre-dose and at end of infusion as described in Table 8

Table 7 – Sample collection time-points

Sample type	Tube and volume ¹	Analysis of	Prior treatment	During treatment				
			Screening / Baseline (E1)	Pre-Cycle 3 (E2)	Pre-Cycle 5 (E3)	Pre-Cycle 7 (E4)	Pre-Cycle 10 (E5)	-End of Treatment ⁶ (E6)
Tumour	Frozen	Various	•					
	FFPE sections	Various	•					
Peripheral blood	PAXgene™ blood RNA tube ² (2mL)	mRNA	•	•	•	•	•	•
	Whole blood EDTA ^{2,3,4} (4 mL or 5mL)	cfDNA	•	•	•	•	•	•
Bone Marrow Aspirate	PAXgene™ blood RNA tubes ⁵ (0.5mL from L+R; do not pool)	mRNA	•					
	EDTA ^{3,5} (max 4mL from L+R; do not pool)	cfDNA, IC	•					

Page 63

Bone Marrow Trepine	FFPE sections ⁷	Immunohistochemistry	•					
---------------------	----------------------------	----------------------	---	--	--	--	--	--

Table 8 –PK/PD Sample collection time-points (For UK/EU patients receiving dinutuximab beta only)

Sample Type	Analysis of	Cycle 1		Cycle 2		Cycle 5		Cycle 12		EOT*
		Day 1 Pre-dose	Day 8 End of infusion	Day 1 Pre-dose	Day 8 End of infusion	Day 1 Pre-dose	Day 8 End of infusion	Day 1 Pre-dose	Day 8 End of infusion	
Peripheral blood (Serum 2mL)	DB	X	X	X		X	X	X	X	
Peripheral blood (Serum 2mL)	ADA	X				X		X		X
Peripheral blood (Serum 2mL)	CDC	X	X			X	X	X	X	

* EOT if participant discontinues trial treatment early.

11 DOSE MODIFICATIONS

Participants should be carefully monitored for toxicity. All toxicities will be graded according to version 5.0 of the NCI CTCAE. Doses are to be modified based on the most severe toxicity that the participant experiences, related or possibly related to the study treatment between each cycle of treatment. Dose adjustments, delays and discontinuation should be managed according to local guidelines and at the clinician's discretion.

Participants should be assessed for the development of IMP related adverse events prior to **each** administration. The same criteria used at study entry for haematology renal and liver function should be used to start subsequent cycles. Day 1 of the next cycle may be delayed for up to 14 days of toxicity.

Adverse events should be classified according to whether, in the physician's judgement, these are likely to be related to bevacizumab, dinutuximab beta or chemotherapy (irinotecan/topotecan $\pm$ temozolomide) toxicity. These should be managed separately.

NOTE: The toxicity profiles of the IMPs are different. They should be considered separately and any necessary treatment modification to one element of the study treatment may not need an adjustment or delay to the other element.

The maximum delay to the administration of chemotherapy due to adverse events is 36 days. The delay may be extended over 36 days only if the participant is showing a good response to the treatment and agreement is obtained from the Coordinating Sponsor.

11.1 Dose modifications for dinutuximab beta

Institutional practice should be followed to manage the specific toxicities.

Table 9 – dose modifications for dinutuximab beta

Adverse Event	Severity/Intensity (CTCAE grade)	Action
Anaphylaxis	≤ Grade 2	Maximise anti-histamines and supportive care; consider reducing to 50% rate if worsening symptoms
	Grade 3	Interrupt infusion and give supportive measures. Resume at 50% rate when resolves to ≤ Grade 2
	Recurrent Grade 3 or any Grade 4	Permanently discontinue dinutuximab beta
Capillary leak syndrome	≤ Grade 2	Decrease infusion to 50%. Resume to 100% if resolves with supportive measures
	Grade 3	Interrupt infusion and give supportive measures. Resume at 50% rate when resolves to ≤ Grade 2
	Recurrent Grade 3 or any Grade 4	Permanently discontinue dinutuximab beta
Fever	If persistently 40°C despite maximal supportive measures	Pause dinutuximab beta infusion and resume once toxicity has resolved to ≤ Grade 2 fever
Hypotension	≤ Grade 2	Slow infusion to 50% rate. Resume 100% rate once resolves
	≥ Grade 3	If hypotension not responsive to 20 ml/kg fluid challenge then discontinue dinutuximab beta infusion, support blood pressure with IV fluids, and vaso-pressors if necessary. Dinutuximab

Page 66

		beta infusion may be restarted at 50% once participant stable without blood pressure support, and then increased to 100% rate if tolerated.
	If participant requires ventilator support	Participant should permanently discontinue dinutuximab beta
Neuropathy	Grade 1	Continue infusion and close observation
	Grade 2	Pause dinutuximab beta. Restart at 50% if resolves to Grade 1 or less. If not resolved within 48 hrs then omit from current cycle. If not resolved to Grade 1 by time next cycle due then permanently discontinue
	≥ Grade 3	Permanently discontinue dinutuximab beta Consider high dose systemic steroids / IVIG (Discuss with the coordinating sponsor and CI)
Pain	≥ Grade 3 despite analgesia	Pause dinutuximab beta infusion, resume at 50% rate once pain controlled. Increase to 100% rate as tolerated
Visual acuity or ocular toxicity	Dilated pupils with sluggish responses	Interrupt infusion. Resume at 50% rate once resolves Impaired visual accommodation, correctable with eye glasses does NOT need dose modification, provided that these toxicities are judged to be tolerable by the responsible clinician, as well as the participant and family Accommodation disorders and ophthalmoplegia have been described as common Adverse Events and do not require any dose modifications
	≥ Grade 3	Permanently discontinue dinutuximab beta
Hyponatraemia	≤ Grade 2	Supportive measures. Continue 100% infusion rate
	Grade 3	Continue dinutuximab beta at 100% rate unless symptomatic hyponatraemia in which sodium < 125 mmol/L for more than 48 hours despite corrective measures
	Grade 4 (< 120 mmol/l despite appropriate corrective measures)	Permanently discontinue dinutuximab beta
Dyspnoea	≤ Grade 2: Oxygen supplementation needed to maintain oxygen saturations > 90%	Regular salbutamol +/- epinephrine nebulisers if bronchospasm or stridor. If saturations not maintained then stop dinutuximab beta infusion; restart at 50% rate if symptoms resolve (saturations > 90% in air) and then increased to 100% if tolerated.

Page 67

	Grade 3	Stop dinutuximab infusion. If symptoms resolve with supportive measures as above, and saturations > 90% in air, then restart dinutuximab beta at 50% and then increase to 100% as tolerated
	Grade 4	Permanently discontinue dinutuximab beta
Cardiac toxicity (including tachycardia, cardiac failure, left ventricular dysfunction and pericardial effusion)	≥ Grade 3	Permanently discontinue dinutuximab beta
GI symptoms (diarrhoea / vomiting)	Grade 4	Pause dinutuximab beta infusion, restart infusion when symptoms settle
Infection	In the case of any ≥ Grade 3 infection occurring during dinutuximab beta infusion	Dinutuximab beta should be omitted until infection is controlled. In the case of uncomplicated bacteraemia or febrile neutropenia in clinically stable children it may then be restarted, but for any other ≥ Grade 3 infections it should be aborted until the next cycle. Temperature alone, in the absence of other signs of infection, should not be considered a reason to stop dinutuximab beta

11.2 Dose modifications for bevacizumab

Bevacizumab takes 4 – 6 weeks to achieve steady state levels. Any treatment delay will require steady state levels to be re-established. Bevacizumab administration should be delayed if any of the side effects, outlined below, has been observed. Once a participant has met the re-treatment criteria (refer to section 7.5 and section 8.5), bevacizumab administration should recommence. Regardless of the reason for the delay in bevacizumab, participants must discontinue bevacizumab when the administration of bevacizumab had to be interrupted for more than 6 weeks.

Table 10 - Toxicities requiring bevacizumab dose delay

Adverse Event	Severity/Intensity (CTCAE grade)	Bevacizumab Action
Infusion-related Reaction/Infusional Site Extravasation	Grade ≤4	Infusion and allergic reactions should be managed by local standards. Bevacizumab must be delayed or discontinued in the case of any reactions of Grade 4
Hypertension	Grade 2-3	Guidelines to age-specific percentiles of blood pressure can be accessed at http://www.nhlbi.nih.gov/health/heart/hbp/hbp_ped.pdf Delay bevacizumab administration Initiate anti-hypertensive therapy Resume bevacizumab once systolic and/or diastolic BP for age and sex is below the 95 th percentile
	Grade 4	Discontinue bevacizumab
Wound healing complications	Any grade	Delay bevacizumab until the wound has satisfactorily healed
Proteinuria	Grade 2-3	Delay bevacizumab until recovery to grade 1
	Grade 4	Discontinue bevacizumab
Venous thrombosis/embolism (including vascular access device)	Grade 3	Delay bevacizumab Bevacizumab may be resumed once the participant has been fully anticoagulated and if the participant has not experienced a Grade 3 or 4 haemorrhagic event Low-molecular-weight heparin should be prescribed and the treatment monitored in compliance with the approved product labelling or according to local clinical practice guidelines Similarly, for participants on a coumarin derivative or unfractionated heparin, the INR and APPT, respectively, should be within therapeutic range. Permanently discontinue bevacizumab if the VTE worsens or recurs after resuming therapy
Any other clinically significant (CTCAE Grade 3/4) AEs that, according to the	Grade 3 or 4	Delay bevacizumab until recovery to grade 1 or resolution

physician's discretion, are not clearly associated with chemotherapy and could be related to Bevacizumab		
--	--	--

Permanently discontinue bevacizumab for any of the following toxicities:

Left ventricular systolic dysfunction	Grade 3 or 4
Heart failure	Any grade
Gastrointestinal (GI) perforation	Any grade
Tracheo-oesophageal fistula	Any grade
Any non-tracheo-oesophageal fistula	Grade 4
Recto-vaginal fistulae	Grade 3-4
Proctalgia	Grade 3-4
Haemorrhage: Non-pulmonary or non-CNS	Grade 3-4
Haemorrhage: Pulmonary or CNS	Grade 2/3/4
Posterior reversible encephalopathy syndrome (PRES)	Any grade
Venous thrombosis/embolism	Grade 4
Any arterial thrombosis/embolism	Any grade
Myocardial infarction	Any grade
Cerebrovascular ischemia	Transient ischaemic attacks (TIAs), Cerebrovascular accidents (stroke)
Osteonecrosis	Any grade
Eye disorders	Grade 4
Necrotising fasciitis	Any grade

Page 70

Weight decrease	Grade 3
-----------------	---------

11.3 Chemotherapy dose modifications

The following dose modifications are provided as recommendations. In case an alternative management strategy is thought to be beneficial for the participant, the case will be discussed with the Coordinating Sponsor.

Note: All platelets cut-off values require no platelet transfusions within 72 hours of starting the cycle.

Table 11 – Dose levels for dose adjustments

Drug	Starting dose	Reduction 20% Dose level – 1	Reduction 40% Dose level – 2
Temozolomide	100mg/m ² /d for 5 days every 3 weeks	80 mg/m ² /d for 5 days every 3 weeks	60 mg/m ² /d for 5 days every 3 weeks
Irinotecan	50mg/m ² /d for 5 days every 3 weeks	40 mg/m ² /d for 5 days every 3 weeks	30 mg/m ² /d for 5 days every 3 weeks

*If not recovered 15 days after expected date of start (i.e. day 36 after start of cycle), refer to Coordinating Sponsor to discuss individual case

Table 12 – Dose modifications for toxicity

	Bevacizumab	Dinutuximab beta	Irinotecan	Temozolomide
ANC < 0.5 x 10 ⁹ /L or Platelet count < 50 x10 ⁹ /L But recovered on day 21 after the start of a cycle	No dose reduction	No dose reduction	No dose reduction	No dose reduction
ANC < 0.5 x 10 ⁹ /L or Platelet count < 50 x10 ⁹ /L But recovered between day 22 to 28 after the start of a cycle	No dose reduction	No dose reduction	No dose reduction	2 nd occurrence: Decrease to dose level -1
ANC < 0.5 x 10 ⁹ /L or Platelet count < 50 x10 ⁹ /L But recovered between day 29 to 35 after the start of a cycle	No dose reduction	No dose reduction	1 st occurrence: Decrease to dose level -1 2 nd occurrence: Decrease to dose level -2	1 st occurrence: Decrease to dose level -1 2 nd occurrence: Decrease to dose level -2
ANC < 0.5 x 10 ⁹ /L or Platelet count < 50 x10 ⁹ /L On day 36 after the start of the cycle	No dose reduction	No dose reduction	Consider discontinuation of study treatment*	Consider discontinuation of study treatment*
Elevated ALT, AST, ALP, Bilirubin Grade 2	No dose reduction	No dose modification	No dose modification	No dose modification
Elevated ALT, AST, ALP, Bilirubin Grade 3 that recovers to grade ≤2 before day 35	No dose reduction	No dose modification	No dose modification	No dose modification
Elevated ALT, AST, ALP, Bilirubin Grade 3 not recovered to grade ≤2 before day 35	No dose reduction	No dose modification	2 nd occurrence: Discontinue study treatment	1 st occurrence: Decrease to dose level -1

Page 72

				2 nd occurrence: Discontinue study treatment
Elevated ALT, AST, ALP, GGT, Bilirubin Grade 4	No dose reduction	Reduce to 50% for cycle; can be increased to 100% for subsequent cycles providing improved to Grade 2	2 nd occurrence: Discontinue study treatment	1 st occurrence: Decrease to dose level -1 2 nd occurrence: Discontinue study treatment
Diarrhoea > 3 days despite maximum Loperamide therapy Grade 3 or 4	No dose reduction	For Grade 3 no reduction; For Grade 4, pause Dinutuximab beta infusion, restart infusion when symptoms settle.	1 st occurrence: Decrease to dose level -1. 2 nd occurrence: Contact Coordinating Sponsor and consider switch to Topotecan.	No dose reduction

11.3.1 Topotecan

In instances of severe irinotecan-related toxicity, topotecan may be substituted for irinotecan.

The dose of topotecan will be 0.75mg/m²/day. Topotecan will be given intravenously over 30mins on Days 1-5, at least one hour following the administration of temozolomide. The administered dose of chemotherapy may be rounded up or down to the nearest dose that can be accurately measured.

Table 13 – Treatment Administration Summary per arm using Topotecan as a Substitute for Irinotecan

	Day 1	Day 2-5	Day 6-7	Day 22
Treatment duration: 12 cycles = 36 weeks, response assessed pre cycles 3, 5, 7, 10 and end of treatment				
Arm A: dbToT	Dinutuximab beta 10mg/m ² /day iv Topotecan 0.75mg/m ² iv Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv Topotecan 0.75mg/m ² iv Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv	Day 1 of next cycle starts
Arm B: BToT	Bevacizumab 15mg/kg iv Topotecan 0.75mg/m ² iv Temozolomide 100mg/m ² po	Topotecan 0.75mg/m ² iv Temozolomide 100mg/m ² po		Day 1 of next cycle starts
Arm C: dbBToT	Dinutuximab beta 10mg/m ² /day iv Bevacizumab 15mg/kg iv Topotecan 0.75mg/m ² iv Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv Topotecan 0.75mg/m ² iv Temozolomide 100mg/m ² po	Dinutuximab beta 10mg/m ² /day iv	Day 1 of next cycle starts

12 SUPPORTIVE TREATMENT

12.1 Supportive Care

Supportive care should be given according to local institutional guidelines. The below guidance is recommended.

12.1.1 Irinotecan-related diarrhoea

Irinotecan-related diarrhoea should be managed as per local guidelines. The use of cefixime (in the absence of any contraindications), atropine (for early onset) or loperamide (for delayed onset diarrhoea) are highly recommended.

12.1.2 Nausea and Vomiting

Anti-emetics may be used, at the investigator's discretion, for the prevention and/or treatment of nausea and vomiting. Local anti-emetic policies for chemotherapy should be followed, when necessary.

12.1.3 Growth Factors

Prophylactic and therapeutic usage of G-CSF should be at the discretion of the treating physician on an individual case basis. For participants in Tier 2, prophylactic use of G-CSF is not allowed during cycle 1.

12.1.2 Fever and neutropenia

Antibiotics should be administered on the basis of institutional policy.

12.1.3 Blood products

Therapeutic use of blood products will be permitted. A platelet count of 50 is required to start each cycle of chemotherapy, therefore platelet infusion can occur where clinically indicated.

12.1.4 Pneumocystis jirovecii pneumonia (PJP) prophylaxis

PJP prophylaxis is highly recommended for participants receiving temozolomide. Drugs and schedules for PJP prophylaxis should be according to institutional policies.

12.2 Pain management

It is anticipated that participants receiving dinutuximab beta by the continuous infusion schedule will be able to be managed largely on an outpatient patient basis, with oral opioid or non-opioid medication providing adequate pain control. However, since neuropathic pain is an anticipated side effect even in a prolonged continuous infusion setting, all participants should receive premedication with gabapentin from at least 3 days prior to the start of the dinutuximab beta, as well as intravenous morphine prior to and during antibody infusions as required.

Concomitant standard pain management should be established with or without IV opioid analgesia and should follow standard WHO guidelines including medications as follows:

12.2.1 Gabapentin

- o Prior to receiving dinutuximab beta, the patient should be primed with oral gabapentin, starting 3 days prior to the start of the dinutuximab beta infusion.
- o The recommended oral dose of gabapentin is 10 mg/kg/dose once daily on day 1, increasing to 10 mg/kg/dose twice daily on day 2 and 10 mg/kg three times a day thereafter.
- o Gabapentin may either be stopped at the end of each continuous antibody infusion (and restarted 3 days prior to subsequent cycle) or continued throughout cycles and stopped after the end of the last infusion, according to local guidelines.
- o Maximum single dose for Gabapentin as per institutional guidelines.

12.2.2 Intravenous morphine

- o An intravenous opioid (e.g. morphine infusion 0.03 mg/kg/hr or equivalent) should be commenced 1-2 hour prior to starting the first dinutuximab beta infusion (Cycle 1). Thereafter, it is recommended to administer a continuous morphine (or alternative intravenous opioid at equivalent dose) infusion rate of up to 0.03 mg/kg/hour on the first day, with additional boluses as required (in accordance with local guidelines).
- o Ideally intravenous morphine can be weaned off on a daily basis over the first 5 days (e.g. to 0.02 mg/kg/hour to 0.01 mg/kg/h to 0.005 mg/kg/hour).
- o Boluses can then be given as required either self-administered or nurse administered at 0.02 mg/kg/dose. If continuous opioid is required for more than 5 days then the dose should be weaned at the end of treatment

by 20% each day. It is expected that the IV opioid can be rapidly tapered off, depending on the individual patient's pain tolerance.

- Subsequent cycles may be started with intravenous morphine as above, depending on the amount of opioid required in the previous cycle, until a safe and well tolerated out-patient pain management regime is in place for the individual patient.

12.2.3 Oral and transdermal opioids: e.g. oral morphine

- Can be administered at a dose of 0.2 - 0.4 mg/kg every 4-6 hours. It is not advised to use long acting morphine in this situation as it takes 48 hours to stabilise the dose and probably is not useful. Oral tramadol may be considered once oral morphine is sufficient at lower doses to control pain satisfactorily. Alternatively transdermal application of fentanyl patches may be used in centres where fentanyl patches are regularly used for pain control. The equivalent transdermal fentanyl dose rate in µg/hr will be calculated from the current use of IV morphine according to the manufacturer's guidelines. This allows for pain management during continuous infusion of dinutuximab beta in an outpatient setting.

12.2.4 Non-steroidal anti-inflammatory drugs (NSAIDs)

- Used as per local guidelines, dosing and availability as a fixed regimen during antibody treatment.
- Paracetamol
 - Recommended dosages as per institutional guidelines.
- Ibuprofen
 - This is the most widely used NSAID in paediatrics. It is approved from age 6 months onwards and has a longer duration of action (6-8 hours). Recommended dosages as per institutional guidelines. Ibuprofen should be used according to local clinical practice. Caution must be taken if platelet count < 50 x 10⁹/L due to increased risk of bleeding.
- Metamizole
 - Because of its spasmolytic properties metamizole is particularly suitable for visceral pain or colicky pain. More useful than repeated short infusions, is a long-term infusion with a dosage of 2.5 to 3.0 mg/kg/h, always with close monitoring of blood pressure values. Metamizole is approved for use from the age of three months onwards. A risk assessment for agranulocytosis in children receiving metamizole therapy is not possible at present.
 - Recommended dosage of Metamizole: 10 mg/kg PO every 6 hours as needed or long-term infusion with a dosage of 2.5 to 3.0 mg/kg/h. However, in some European countries, the use of Metamizole is not permitted in paediatric patients and this national guidance needs to be respected.
- Other NSAIDs, e.g. Indomethacin or Ketoralac
 - May be used as per institutional guidelines, as an alternative to ibuprofen if fever not controlled.

12.2.5 Hyoscine-butyl-bromide or hyoscyamine

- May be used for children for abdominal pain not responding to morphine, as per institutional guidelines.

13 CONCOMITANT MEDICATION

Participants must be instructed not to take any additional medications, including over-the-counter (OTC) products and herbal remedies, during the study without prior consultation with their doctor (local PI).

No chemotherapy, hormonal anticancer therapy, or experimental anticancer medications other than those that are study-related will be permitted while the participant is receiving study treatment.

Page 76

Caution must be taken for participants receiving bevacizumab if intravenous bisphosphonates are given simultaneously or sequentially.

Due to their immunosuppressive activity, concomitant treatment with corticosteroids is not recommended within 2 weeks prior to the first treatment course until 1 week after the last treatment course with dinutuximab beta, except for life-threatening conditions.

Concomitant use of intravenous immunoglobulins is not recommended as they may interfere with dinutuximab beta-dependent cellular cytotoxicity.

Concomitant administration of irinotecan with a strong inhibitor (e.g. ketoconazole) or inducer (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, apalutamide) of CYP3A4 may alter the metabolism of irinotecan and should be avoided.

Treatment-related adverse events related to concomitant medication should be treated according to local practice.

Palliative radiotherapy to non-target lesions present at trial entry, or symptomatic target lesions in participants that have other target lesions that allow evaluation of response will be permitted.

Immunisation with live vaccine will not be permitted. All vaccinations (including influenza and covid-19) should be avoided during administration of dinutuximab beta until 10 weeks after the last treatment course, due to immune stimulation through dinutuximab beta and possible risk for rare neurological toxicities. Live vaccines, in addition to prohibition during conduct of the study, must be prohibited for three months after the last dose of chemotherapy.

14 CONTRACEPTION

Females of childbearing potential who are sexually active with a non-sterilised male partner and non-sterilised male participants with a partner of childbearing potential must use at least one highly effective method of contraception (see Table) for 6 months after the last dose of Investigational Medicinal Product plus a barrier method of contraception, e.g. condom. Not engaging in sexual activity for the total duration of the drug treatment is acceptable; however, periodic abstinence, the rhythm method and the withdrawal method are not acceptable.

A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

It is advised that sperm or egg preservation should be offered prior to treatment with temozolomide and bevacizumab respectively as per standard practice to participants at risk of irreversible infertility, where appropriate.

Male participants should refrain from sperm donation for 6 months after receiving the last dose of study treatment.

Table 14 – Highly Effective Methods of Contraception* (<1% Failure Rate)

Highly Effective Contraception Methods*	Contraceptive measures Not Considered Highly Effective
---	--

Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation ¹	Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
Progestogen-only hormonal contraception associated with inhibition of ovulation ¹	Male or female condom with or without spermicide ⁵
Intrauterine device ²	Cap, diaphragm, or sponge with spermicide ⁵
Intrauterine hormone-releasing system ²	
Bilateral tubal occlusion ²	
Vasectomised partner ^{2,3}	
Sexual abstinence ⁴	

* Highly effective methods of contraception, is defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly.

1. Hormonal contraception may be susceptible to interaction with the Investigational Medicinal Product, which may reduce the efficacy of the contraception method.
2. Contraception methods that in the context of this guidance are considered to have low user dependency.
3. Vasectomised partner is a highly effective birth control method, provided that the partner is the sole sexual partner of the woman considered to be of childbearing potential and that the vasectomised partner has received medical assessment of the surgical success.
4. In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
5. A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) are not considered acceptable birth control methods in this clinical trial.

15 TREATMENT COMPLIANCE

Dinutuximab beta, bevacizumab, irinotecan and topotecan will be administered intravenously and temozolomide will be given orally. Information regarding the dates for all drugs and doses of treatment administered will be recorded in the participant's medical records. Sites should complete the Home Drug Administration Discussion Checklist, to document the discussion between site and patient/caregiver, regarding the safe and effective administration of oral temozolomide and dinutuximab beta at home.

Participants and/or parents must be instructed to return any unused capsules, dinutuximab beta and oral suspension of temozolomide if dispensed for home use and the amount of remaining returned IMP will be recorded. Sites should follow their local practice for destruction of unused capsules and oral suspension. For more information regarding accountability procedures for the supply and administration of medicinal products to participants, please refer to the Pharmacy Manual. Copies of master drug accountability logs will be requested by the Trial Office for central monitoring every 6 months.

16 PARTICIPANT FOLLOW UP

Participants in Tier 1 will be followed up for a minimum of 5 years from the date of registration/randomisation, or until death if sooner. Participants within Tier 2, will be followed up until the end of trial treatment.

16.1 Tier 1: Follow up visits until progression or relapse occurs will include:

Three-monthly visits up to 2 years from the end of treatment will include the following assessments:

- o Tumour assessment (a minimum of a cross-sectional image of site of measurable disease by MRI (preferred) or CT
- o MIBG scans (ideally with SPECT as well as planar imaging) required at the following timepoints from the end of treatment: 6, 12, 18, and 24
- o Vital signs and physical exam
- o Survival status (including progression)
- o Treatments received (if any)
- o Additional assessments as per local practice may be included

Beyond 2 years from end of treatment, follow-up visits will be carried out annually at 36 months, 48 months and 60 months after the registration/randomisation date and will include the following assessments only:

- o Survival status
- o Treatments received
- o Additional assessments as per local practice
- o AEs and late effects
- o Tumour assessment by MRI (preferred) or CT and MIBG or PET scans only if indicated according to local standard of care

NB - Participants that start a non-trial therapy without progression may have follow up scan assessments scheduled as per local standard practice.

16.2 After progression or relapse occurs:

Follow up visits will be done annually for a minimum of 5 years from the date of registration/randomisation and will include the following assessments only:

- o Survival status
- o AEs and late effects (including the occurrence of second malignant neoplasms (SMN))
- o Treatments received
- o Additional assessments as per local practice may be included.

Laboratory tests and safety assessments as part of standard care can be performed at the participant's local hospital at follow up time-points, provided they are conducted on time and the local hospital has a procedure to receive and review them in a timely manner. It is the Investigator's responsibility to ensure he/she receives and reviews the results. The results must be recorded on the CRF as required, and the reports from the other hospitals must be available for source data verification. Laboratory reference ranges, including effective dates, and evidence of laboratory accreditation must be obtained from all laboratories used. It is the Principal Investigator's responsibility at each site to obtain these.

Additional follow up visits will be scheduled as needed, to monitor any sustained unresolved, treatment emergent adverse events.

In the event of progression/relapse, the type of progression/relapse will be recorded (local/metastatic/combined) as well as all treatment that is started after trial participation.

17 TRIAL TREATMENT DISCONTINUATION AND PARTICIPANT WITHDRAWAL

17.1 Treatment Discontinuation

Participants should discontinue trial treatment in the following circumstances:

- o In the event of progression (as per INRC 2017)
- o In the event of unacceptable toxicity (see section 0)
- o At the request of the participant (see section 17.2 Participant Withdrawal)

In the event of a female participant becoming pregnant (see section 1.2.4.2 and section 18.1.6) A Treatment Discontinuation Form should be completed to document the reason for treatment discontinuation. Follow up visits continue as scheduled, unless the participant withdraws from data collection (see section 17.2).

17.2 Participant Withdrawal

Participants may withdraw from study treatment at any time at their own request or at the request of their parents (if participant under 16 years of age), or they may stop study treatment at any time at the discretion of the treating Investigator or CI for safety, behavioural, or administrative reasons. If a participant does not return for a scheduled visit, every effort should be made to contact the participant. In any circumstance, every effort should be made to document participant outcome where possible.

The Investigator should:

- o Enquire about the reason for withdrawal
- o Request the participant return for a final visit, if applicable
- o Follow up with the participant regarding any unresolved adverse events
- o Perform a physical exam on the participant (including height, weight, oxygen saturation and blood pressure/pulse)
- o Arrange for a tumour assessment and all safety labs (full blood count and biochemistry) to be collected

Participants who withdraw from trial treatment will continue to be followed up as per the protocol for at least 5 years after registration.

Participants/parents/legal guardians may withdraw consent at any time during the trial. The details of the withdrawal should be clearly documented and communicated to the BEACON2 Trial Office.

There are three types of withdrawal as detailed below:

- o Participant or their parent(s)/legal guardian would like to withdraw the participant from the trial, but is willing for the participant to be followed-up according to the trial schedule (follow-up data can be collected and used in the trial analysis)
- o Participant or their parent(s)/legal guardian does not wish for the participant to attend trial follow-up visits but is willing for the participant to be followed-up at standard clinic visits (follow-up data can be collected at standard clinic visits and used in the trial analysis)
- o Participant or their parent(s)/legal guardian is not willing for the participant to be followed up for trial purposes at any further visits (any data collected prior to the withdrawal of consent will be used in the trial analysis)

The following should be clearly documented in the medical notes:

- o The date the participant or their parent(s)/legal guardian withdraw consent
- o The reason, if given
- o Type of withdrawal

If a participant withdraws from the trial, please complete and return a Treatment Discontinuation Form and a Withdrawal of Consent Form if applicable.

18 ADVERSE EVENT REPORTING

The collection and reporting of Adverse Events (AEs) will be in accordance with the Medicines for Human Use Clinical Trials Regulations 2004 (UK Statutory Instruments 2004 No. 1031) and subsequent amendments and the EU Regulation on Clinical Trials (Regulation (EU) No 536/2014) and other country specific regulations as applicable. Definitions of different types of AE are listed in Appendix 7. The Investigator should assess the seriousness and causality (relatedness) of all AEs experienced by the participant (this should be documented in the source data) with reference to the Summary of Product Characteristics or Investigator Brochure as appropriate.

18.1 Reporting Requirements

18.1.1 Tier 1 Adverse Events

AEs (see Appendix 7 - Definition of Adverse Events for definition) are commonly encountered in participants receiving adjuvant chemotherapy. As the safety profiles of the Investigational Medicinal Products used in this trial are well characterised, only Grade 3 and Grade 4 (by CTCAE v5.0) AEs experienced during treatment will be reported.

An abnormal laboratory value should only be reported if it:

- o Results in participant early discontinuation from the study treatment
- o Requires treatment, modification or interruption of dose, or any other therapeutic intervention (including blood product transfusion), or is judged to be of significant clinical importance

If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis or syndrome should be recorded.

18.1.2 Tier 2 Adverse Events

All medical occurrences which meet the definition of an AE (see Appendix 7 - Definition of Adverse Events for definition) should be reported. Please note this includes abnormal laboratory findings.

18.1.3 Serious Adverse Adverts

Investigators should report AEs that meet the definition of an SAE (see Appendix 7 - Definition of Adverse Events for definition) and are not excluded from the reporting process as described below.

18.1.4 Events That Do Not Require Reporting on a Serious Adverse Event Form

The following events should not be reported on an SAE Form.

[Page 81](#)

Hospitalisations for:

- o Protocol defined treatment
- o Pre-planned elective procedures unless the condition worsens
- o Treatment for progression of the participant's cancer
- o Progression or death as a result of the participant's cancer, as this information is captured elsewhere on the Case Report Form
- o Events that do not require expedited (immediate) reporting which will be reported on an Expected Serious Adverse Reaction Form

18.1.5 Expected Serious Adverse Reactions

Participants receiving adjuvant chemotherapy may require admission to hospital for appropriate medical intervention following development of some of the more severe known side effects of treatment. For this reason, the following SAEs do not require expedited (immediate) reporting by site and are not regarded as unexpected for the purpose of this trial:

- o Admissions to control nausea and vomiting unless the condition is life threatening or proves fatal
- o Admissions for supportive treatment (i.e. transfusions or blood products for anaemia/thrombocytopenia/severe infections, management of diarrhoea, stoma site (line) infections) during an episode of myelosuppression, unless this proves fatal or requires admission to a high dependency or intensive care facility
- o Uncomplicated febrile neutropenia
- o Admission for transfusion or allergic reaction that resolves within 24h (unless the condition is life threatening or proves fatal)
- o Prolongation of inpatient hospitalisation due to fever related to dinutuximab beta (unless the condition is life threatening or proves fatal)

An Expected Serious Adverse Reaction Form can be completed for these specific events instead of a Serious Adverse Event Form. However, if there is any doubt over whether an event meets the relevant definition above, a Serious Adverse Event Form should be completed.

18.1.6 Monitoring pregnancies for potential Serious Adverse Events

It is important to monitor the outcome of pregnancies of participants in order to provide SAE data on congenital anomalies or birth defects.

If a female participant becomes pregnant during the course of the trial, trial treatment should be discontinued immediately.

In the event that a participant or their partner becomes pregnant during the course of the trial and for six months after last dose of study drug, please complete a Pregnancy Notification Form (providing the participant's details) and return to the Trials Office as soon as possible. If it is the participant who is pregnant, provide outcome data on a follow-up Pregnancy Notification Form. Where the participant's partner is pregnant consent must first be obtained and the participant should be given a pregnancy release of information form to give to their partner. If the partner is happy to provide information on the outcome of their pregnancy, they should sign the pregnancy release of information form. Once consent has been obtained provide details of the outcome of the pregnancy on a follow-up Pregnancy Notification Form. If appropriate also complete an SAE Form as detailed below.

Page 82

18.1.7 Post-trial Suspected Unexpected Serious Adverse Reactions

Serious Adverse Events that are judged to be at least possibly related to the Investigational Medicinal Product and are unexpected must still be reported in an expedited manner irrespective of how long after Investigational Medicinal Product administration the reaction occurred.

18.1.8 Overdose

An overdose is defined as a subject receiving a dose of Investigational Medicinal Product(s) in excess of 20% of the planned trial treatment within the current cycle.

Any overdose with or without associated Adverse Events/Serious Adverse Events, is required to be reported within 24 hours of first knowledge of the event to the Trial Office.

If the overdose results in an Adverse Event, this must also be recorded on an Adverse Event Form.

18.1.9 Medication Error

A medication error is an unintended failure or mistake in the treatment of a participant that either causes harm or has the potential to cause harm.

A medication error is a human or process related failure while the drug is under control of the trial site staff or participant.

Examples of events to be reported as medication errors include:

- o Dispensing error e.g., medication prepared incorrectly
- o Drug not administered or taken as indicated, e.g., wrong site of administration, tablet crushed instead of taken whole
- o Wrong participant received the medication
- o Wrong drug administered to participant

Examples of events that **do not** require reporting as medication errors include:

- o Participant accidentally missed drug dose(s) e.g., forgot to take medication
- o Accidental overdose (will be captured as an overdose)
- o Participant failed to return unused medication or empty packaging

Medication errors are not regarded as an Adverse Event, but an Adverse Event may occur as a consequence of the medication error.

Any medication error with or without associated Adverse Event/Serious Adverse Event is required to be reported within 24 hours of first knowledge of the event to the Trial Office.

If the medication error results in an Adverse Event, this must also be recorded on an Adverse Event Form.

18.2 Reporting Period

Details of all AEs (except those listed above) will be documented and reported from the date of commencement of protocol defined treatment until 30 days after the administration of the last trial treatment.

SAEs that are judged to be at least possibly related to the IMPs must still be reported in an expedited manner irrespective of how long after IMP administration the reaction occurred.

18.3 Reporting Procedure

18.3.1 Site

18.3.1.1 Adverse Events

For more detailed instructions on Adverse Event reporting refer to the Adverse Event Form Completion Guidelines contained in section 6 of the Investigator Site File

Adverse Events (as defined in Appendix 7) should be reported on an Adverse Event Form and where applicable on a Serious Adverse Event Form. Serious adverse events which have been identified in the protocol as not requiring immediate reporting (i.e. events listed in section 18.1.4) should be recorded on the Adverse Event Form instead. An Adverse Event Form should be completed at each cycle. AEs will be reviewed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (see Appendix 8 - Common Toxicity Criteria Gratings). Any AEs experienced by the participant but not included in the CTCAE should be graded by an Investigator and recorded on the AE Form using a scale of (1) mild, (2) moderate or (3) severe. For each sign/symptom, the highest grade observed since the last visit should be recorded.

18.3.1.2 Serious Adverse Events

For more detailed instructions on Serious Adverse Event reporting refer to the Serious Adverse Event Form Completion Guidelines contained in section 5 of the Investigator Site File.

Adverse Events defined as serious and that require reporting as a Serious Adverse Event (excluding events listed in section 18.1.4) should be reported on a Serious Adverse Event Form. When completing the form, the Investigator will be asked to define the causality and the severity of the Adverse Event which should be documented using the Common Terminology Criteria for Adverse Events version 5.0.

The form should be emailed to the Trial Office as soon as possible and no later than 24 hours after first becoming aware of the event.

Email Serious Adverse Event Form to:

Reg@trials.bham.ac.uk

CC to beacon2@trials.bham.ac.uk

Include "BEACON2 SAE" in the subject line

On receipt the Trial Office will allocate each Serious Adverse Event a unique reference number. The site will be informed of the Serious Adverse Event reference number in an email acknowledging receipt of the event. If confirmation of receipt is not received within 1 working day please contact the Trial Office. The Serious Adverse Event reference number should be quoted on all correspondence and follow-up reports regarding the Serious

Page 84

Adverse Event. The email from the Trial Office acknowledging receipt should be filed with the Serious Adverse Event Form in the Investigator Site File.

For Serious Adverse Event Forms completed by someone other than the Investigator, the Investigator will be required to countersign the original SAE Form to confirm agreement with the causality and severity assessments. The form should then be returned to the Trial Office and a copy kept in the Investigator Site File.

Investigators should also report Serious Adverse Events to their own Trust in accordance with local practice.

18.3.1.3 Provision of follow-up information

Participants should be followed up until resolution or stabilisation of the event. Follow-up information should be provided on a new SAE Form (refer to the SAE Form Completion Guidelines for further information).

18.3.2 BEACON2 Trials Office

On receipt of an SAE Form seriousness and causality will be determined independently by a Clinical Coordinator. An SAE judged by the Investigator or Clinical Coordinator to have a reasonable causal relationship with the trial medication will be regarded as a Serious Adverse Reaction (SAR). The Clinical Coordinator will also assess all SARs for expectedness. If the event meets the definition of a SAR that is unexpected (i.e. is not defined in the Summary of Product Characteristics, or Investigator Brochure as applicable) it will be classified as a Suspected Unexpected Serious Adverse Reaction (SUSAR).

18.3.3 Reporting to the Competent Authority and main Research Ethics Committee

18.3.3.1 Suspected Unexpected Serious Adverse Reactions

Individual events categorised as SUSARs will be reported to the EudraVigilance Clinical Trial Module (EVCTM) and to each non-EU country as required. Events will be reported in accordance within the regulatory specified time frame:

- Fatal or life threatening SUSARs within a maximum of 7 days with a detailed follow-up report within an additional 8 days
- All other SUSARs within a maximum of 15 days

The UK Coordinating Centre will provide SUSARs reports to the NCCs who will report SUSARs to the relevant REC and Competent Authority (where required), within the time frame specified above, and to Principal Investigators within their country. The UK Coordinating Centre will assume responsibility for reporting to these parties in the UK.

18.3.3.2 Serious Adverse Reactions

The UK Coordinating Centre will produce a Development Safety Update Report (including Serious Adverse Reactions and Suspected Unexpected Serious Adverse Events) annually from the date of the first Clinical Trial Authorisation received for the trial in any country until the submission of the End of Trial Declaration. The National Coordinating Centres will be provided with a copy of this report and where contractually required to do so, will report to the relevant Competent Authority and Research Ethics Committee.

18.3.3.3 Adverse Events

Details of all Adverse Events will be reported to the Competent Authority on request.

Page 85

18.3.3.4 Other safety issues identified during the course of the trial

The Competent Authority and Research Ethics Committee(s) will be notified immediately if a significant safety issue is identified during the course of the trial.

18.3.4 Investigators

Details of all Suspected Unexpected Serious Adverse Events and any other safety issue which arises during the course of the trial will be reported to Principal Investigators. A copy of any such correspondence should be filed in the Investigator Site File.

18.3.5 Data Monitoring Committee

The independent Data Monitoring Committee will review all Serious Adverse Events and Adverse events of special interest (Tier 2 only).

18.3.6 Manufacturer of Investigational Medicinal Product

All Serious Adverse Events will be reported to the relevant manufacturer of the Investigational Medicinal Product, in line with contractually agreed terms.

19 CENTRAL REVIEW PROCESSES

As an additional measure of quality control, at least one independent blinded radiologist and at least one nuclear medicine physician will review all CT, MRI, MIBG and PET/CT scans at baseline and at tumour assessment time-points (pre cycle 3, 5, 7, 10 and EOT), for all participants. Bone Marrow samples will also be collected as part of the independent review. Further details to be provided by the Trial Office.

Tier 1 (Arm A and Arm B) specific Blinded Independent Central Review process

An independent assessment is planned for response-based endpoints, for Tier 1, Arm A and Arm B.

A Blinded Independent Central Review (BICR) process will be implemented in order to centrally review tumour assessment images in an unbiased and standardized manner at each timepoint. Bone Marrow samples will also be collected for BICR assessment.

The BICR review will be performed by independent assessors, according to the revised International Neuroblastoma Response Criteria (INRC) (Park J et al, 2017).

The process will be described in a separate Blinded Independent Review Charter.

20 QUALITY OF LIFE STUDY

20.1 Purpose of Quality of Life

HRQOL is a multi-dimensional concept commonly used to examine the impact of health status on quality of life. There is an increasing recognition in oncology of the importance of improving patients' QOL throughout the disease course [57, 58]. Studies conducted with paediatric population suggest that HRQOL in children during cancer therapy is significantly lower than in the healthy population [59, 60]. Also, association between intensity of treatment and child-reported HRQOL has been assessed: high-risk children reported poorer QOL than children with a low or moderate risk [61]. Therefore, there is a growing acclaim in paediatric cancer research of the importance of improving patients' QOL throughout the new therapies [62]. Key aspects of the HRQOL in paediatric oncology include the child's physical (physical functioning, symptoms), psychological (body image, self-esteem, distress, behavioural problems, cognitive functioning), and social health (interpersonal relationships, social functioning, and general health perceptions [63]. Parents and patient's family members are also affected by the cancer diagnosis and treatment and may also be instrumental in the management of the disease [64-66]. Hence, optimal assessment of how children's health affects their families is of both clinical and research importance.

As most of these aspects are subjective, both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recommended the use of patient-reported outcome (PRO) measures to support labelling claims in oncology [67, 68]. In addition, paediatric HRQOL measurement instruments must be sensitive to cognitive development and integrate both child self-report and parent/guardian proxy-report to reflect their potentially unique perspectives. With this goal in mind, in this study, HRQOL is evaluated as a secondary objective to determine the impact of each treatment arm in patient's and family's QOL.

20.2 Questionnaires

HRQOL will be assessed with the Pediatric Quality of Life Inventory (PedsQL) 3.0 Cancer Module [69] and with the PedsQL Family Impact Module [70].

The PedsQL 3.0 Cancer Module is a modular instrument designed to measure pediatric cancer specific HRQOL in children, adolescents, young people and adults. The PedsQL 3.0 Cancer Module has been translated in over 49 languages according to a standardized translation procedure.

The questionnaires comprise parallel child self-report and parent proxy-report formats. Child self-report includes ages 5–7 years (young child), ages 8–12 years (child), ages 13–18 years (adolescent), ages 18-25 (young people) and 26+ years (adults). Parent proxy-report includes ages 2–4 years (toddler), 5–7 years (young child), 8–12 years (child), and 13–18 years (adolescent). The parent proxy-report forms are designed to assess the parent's/guardian's perceptions of their child's HRQOL. The items for each of the forms are essentially the same, differing in developmentally proper language, and first or third person tense. The 27-item multidimensional PedsQL 3.0 Cancer Module encompasses 8 scales: 1) pain and hurt (2 items), 2) nausea (5 items), 3) procedural anxiety (3 items), 4) treatment anxiety (3 items), 5) worry (3 items), 6) cognitive problems (5 items), 7) perceived physical appearance (3 items), and 8) communication (3 items).

The instructions ask how much of a problem each item has been during the past 1 month. A 5-point Likert response scale is utilized across child self-report for ages 8–18+ years and parent proxy-report (0 = never a problem; 1 = almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = almost always a problem). To further increase the ease of use for the young child self-report (ages 5–7 years), the Likert scale is reworded and simplified to a 3-point scale (0 = not at all a problem; 2 = sometimes a problem; 4 = a lot of a problem), with each response

choice anchored to a happy to sad faces scale. Parent proxy-report also includes the toddler age range (ages 2–4 years), which does not include a self-report form given developmental limitations on self-report for children younger than 5 years of age and includes only 3 items for the school functioning scale.

Items are reverse-scored and linearly transformed to a 0–100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher PedsQL 3.0 scores indicate better HRQOL. Scale scores are computed as the sum of the items divided by the number of items answered. If more than 50% of the items in the scale are missing, the scale score is not computed.

The PedsQL Family Impact Module [70] was designed to measure the impact of pediatric chronic health conditions on parents and the family. Despite it is not specific to evaluate QOL in parents of children and AYA with cancer, the questionnaire has demonstrated reliability and validity in families with children with complex chronic health conditions. Implemented as a complement to the PedsQL Cancer Module, the PedsQL Family Impact Module gives a quantitative indicator of the parent's self-reported HRQOL and family functioning as a result of their child's cancer disease. The PedsQL Family Impact Module has been translated in over 20 languages according to a standardized translation procedure.

The PedsQL Family Impact Module measures parent/guardian self-reported physical, emotional, social, and cognitive functioning, communication, and worry. The 36-item PedsQL Family Impact Module Scales encompass 6 scales measuring parent self-reported functioning: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) Social Functioning (4 items), 4) Cognitive Functioning (5 items), 5) Communication (3 items), 6) Worry (5 items), and 2 scales measuring parent/guardian reported family functioning; 7) Daily Activities (3 items) and 8) Family Relationships (5 items).

The scale has five response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Regarding the interpretation of the scale, higher scores indicate better functioning (less negative impact). The PedsQL Family Impact Module Total Scale Score is calculated as the sum of the 36 item scores divided by the number of items answered. If more than 50% of the items in the scale are missing, the scale score is not computed.

20.3 Target Accrual

HRQOL questionnaires will be performed in all trial participants.

20.4 Time Points and Procedure

Questionnaires will be filled at baseline (within 7 days before treatment initiation), at assessment time-points (cycles 2, 4, 6) and at EOT visit (21 days after cycle 12 dose or last dose given), according to Table 1 - Schedule of Events. HRQOL data must be collected regardless of the participant's progression status and treatment completion. However, HRQOL data may be omitted in cases where its collection may cause distress to the patient or their family

Sites will be provided with a supply of the HRQOL questionnaires at site initiation. Questionnaires must be filled out on paper at the hospital when participants come for the scheduled visit according to the "PedsQL™ Administration Guidelines" (see Appendix 9 – PedsQL™ Administration Guidelines). The questionnaire will be handed out to the participants by the investigator or a study nurse before seeing the doctor for clinical evaluations. Participants should complete the questionnaires by themselves in their own language during the visit as completely and accurately as possible. It is recommended that a key person at each centre should be responsible for questionnaire data collection in order to optimize the compliance of the patient and to ensure the completeness of the data.

Data will be entered onto the eCRF database by site staff. QoL questionnaires are considered as source data and should be kept at sites.

21 TRANSLATIONAL SUB-STUDY/ BIOLOGICAL STUDIES

21.1 Purpose of Translational Sub-study

In relapsed neuroblastoma, biological studies of the primary tumour, metastatic sites and liquid biopsies for analysis of prognostic and especially predictive biomarkers are of utmost importance. These studies require rigorous sample collections, according to well-defined standard operating procedures (SOPs).

- o Genome and expression profile of DNA and RNA isolated from tumour at relapse whenever possible; constitutional DNA will be required for genomic studies.

21.1.1 Primary tumour tissue

Samples of tumour tissue collected at the time of diagnosis, during frontline therapy and/or at the time of relapse (where possible) will be collected for genome and expression profile of DNA and RNA. **This sample is mandatory for study entry; if no tumour or subsequent molecular profiling is available this will be discussed with the Coordinating Sponsor and the Chief Investigator before study entry.**

Whenever possible, analysis of tumour tissue of the primary tumour, or a metastatic site, obtained at relapse, should be performed: following tissue sampling both frozen tumour tissue and formalin fixed paraffin embedded tumour tissue are to be collected at diagnosis according to local SOPs and processes.

In situations where no tumour tissue can be obtained (due to the clinical situation of the patient, or sampling difficulties, or because no primary was identified) the following analyses may be done on a representative metastatic sample (invaded bone marrow, invaded lymph node), possibly following enrichment techniques. If neither a primary tumour nor a metastatic site can be obtained at relapse, a blood sample for analysis of circulating tumour DNA should be obtained at study entry and at all protocol-defined timepoints.

The following investigations will be performed for all participants on tumour tissue:

Genetic analyses:

- o MYCN copy number status (clinical decision making at diagnosis)

The following genetic analyses are highly recommended:

- o Whole exome or whole genome sequencing (> 100 x) of paired tumour and germline material should be performed for calling of SNVs/mutations, structural variations, and overall copy number profile and indels. RNAseq should be performed for expression profiling. Results should be analysed and reviewed by a molecular biologist, with a report highlighting clinically relevant biological findings. Alternatively, NGS panel sequencing (minimal consensus of 17 genes, including ALK) and Genomic copy number profile (high resolution aCGH and/or SNP and/or lcWGS) can be applied.
- o Telomere maintenance mechanism and ALT status.
- o The report of the molecular profile should be recorded as in ongoing precision medicine programs [71]
- o It is mandatory to analyse the ALK copy number status (amplified yes/no) and mutation status (mutated yes/no) on a new sample obtained at relapse/progression (primary tumour and/or metastatic site). If no

Page 89

tumour sample can be obtained at relapse/progression, the ALK status may be determined on circulating tumour DNA extracted from blood or bone marrow plasma.

21.1.2 Liquid biopsy samples

Blood samples for the analysis of circulating biomarkers and immunological studies should be collected from all participants at the same time points as those required for standard clinical care:

- Baseline
- Pre cycles 3, 5, 7, 10
- End of Treatment

Core studies include analysis of circulating RNAs [72, 73] and DNAs [74-76].

Constitutional DNA taken once at any time will be required for pharmacogenetic studies and is *optional*.

Bone marrow aspirate taken at baseline will be required for circulating biomarker analysis and is *optional*.

21.1.3 PK/PD Samples

- PK parameters (dinutuximab beta Cmax and trough levels) for this chemo-immunotherapy regimen will be described. A preliminary correlation of the different biomarkers [e.g. MYCN copy number status, Complement-Dependent Cytotoxicity (CDC), and Anti-Drug Antibodies (ADAs)] will be made with parameters of anti-tumour activity (response rate, PFS and OS).
- ADA. Antidrug antibodies have been described in different proportions in the different anti-GD2 antibodies developed. The presence and development of ADA during treatment with chemoimmunotherapy in this trial will be collected retrospectively, but without clinical implications
- CDC (complement dependent cytotoxicity) has also been shown in studies using anti-GD2 antibodies in the maintenance setting as a potential pharmacodynamics and predictive biomarker, and it will be collected here in the chemo-immunotherapy setting.

21.2 Samples to be Collected

Quality control of samples for diagnostic and research procedures and the collaboration within the SIOPEN network are of high importance.

21.2.1 Tumour tissue

For the Tumour tissue samples, FFPE blocks, unstained slides or frozen samples are required from diagnosis, and from relapse if available. Analysis includes, but is not limited to, MYCN, copy number profile or NGS panel sequencing, telomere maintenance mechanism and/or ALT status. Samples should be sent to a central accredited laboratory identified by the country National Coordinating Centre and Coordinating Sponsor.

As a clinically decision-making biomarker, ALK amplification/mutation status on a sample obtained at relapse/progression should be determined.

21.2.2 Blood samples for circulating Biomarker Analysis

Blood for analysis of circulating biomarkers and circulating tumour cells should be collected at time points: Baseline, pre-cycle 3, 5, 7, 10 and end of treatment (if not received 12 cycles). Samples should be sent to a central accredited laboratory identified by the country National Coordinating Centre and Coordinating Sponsor. Please see BEACON2 Laboratory manual. The maximum volume of blood (including the routine blood specimen collected for clinical care) will not exceed the maximum according to body weight, as indicated in the Guidelines for Paediatric Blood Volume for Research Purposes/HREC [77] and guidance by the European Medicines Agency (EMA 2008).

The following samples should be collected:

- Blood samples for CTC and circulating biomarker studies

21.2.3 Blood samples for PK/PD

Peripheral blood samples to obtain 2ml of serum will be taken for the quantitative analysis of dinutuximab beta, ADA and CDC by validate ELISA methodologies from UK and EU participants only, at Cycle 1, 2, 5 and 12 at dinutuximab beta pre-dose and at end of infusion as detailed in Table 8.

21.2.4 OPTIONAL - Bone marrow samples for circulating Biomarker Analysis

Bone marrow aspirates for analysis of circulating biomarkers and characterisation of circulating tumour cells may be collected at baseline/entry into the study.

The following samples should be collected:

- Bone marrow samples for CTC and circulating biomarker studies
- Bone marrow samples for characterisation of neuroblastoma cells and the tumour microenvironment and preclinical model development

21.2.5 OPTIONAL - Blood plasma for constitutional DNA

Blood plasma should be collected at any time point for constitutional DNA analysis and pharmacogenomics, where patient/parent guardian consent is obtained. Samples should be sent to a central accredited laboratory identified by the country National Coordinating Centre and Coordinating Sponsor. Quality control of samples for diagnostic and research procedures and the collaboration within the SIOPEN network are of high importance.

21.2.6 Where to send the samples

Please refer to the BEACON2 Laboratory Manual for details on sample preparation, sample conservation, shipping and reference laboratories.

21.3 End of Trial Arrangements

Any biological samples remaining at the end of the trial will be transferred to a central tissue bank identified by the country National Coordinating Centre and Coordinating Sponsor or made available to another approved ethical project.

22 DATA HANDLING AND RECORD KEEPING

This trial will use an electronic remote data capture (eRDC) system which will be used for completion of CRFs. Access to the eRDC system will be granted to individuals via the BEACON2 Trial Office.

SAE reporting will be entirely paper-based throughout the course of the trial.

22.1 Data Collection

22.1.1 CRF

This trial will use an electronic Case Report Form system to capture the Case Report Form data, obtained from the participant's medical notes as per the site's standard procedures. Paper Case Report Forms will also be available as a backup. Access to the electronic Case Report Form system will be granted to individuals by the Trial Office.

<https://v4.viedoc.net>

The Investigator will ensure all data from all participant visits are promptly entered into the electronic Case Report Form system in accordance with the CRF Completion Guidelines. The Case Report Form must be completed by the Investigator or an authorised member of the site research team (as delegated on the Site Signature and Delegation Log). The exceptions to this are the Eligibility Checklist, Serious Adverse Event Form and Expected SAR Form which can be completed by an authorised member of the site research team but must be co-signed by the Investigator.

For the purposes of this trial Serious Adverse Event Forms and Expected SAR Forms will be captured on paper and entered onto the electronic Case Report Form system by the Trial Office. QoL questionnaires are considered as source data and should be kept at sites.

A master copy of the paper Case Report Form is available in the Investigator Site File. If the electronic Case Report Form system is unavailable for any length of time the Trial Office may instruct sites to complete the paper Case Report Form to ensure timely monitoring of participant data. These forms may be entered onto the system by the Trial Office.

For paper SAE and expected SAR Forms, the completed originals should be sent to the Trial Office and a copy filed in the Investigator Site File.

Entries on the paper Case Report Form should be made in ballpoint pen, in blue or black ink, and must be legible. Any errors should be crossed out with a single stroke, the correction inserted and the change initialled and dated. If it is not obvious why a change has been made, an explanation should be written next to the change.

Data reported on the Case Report Form should be consistent with the source data or the discrepancies should be explained. If information is not known, this must be clearly indicated on the form. All missing and ambiguous data will be queried. All sections are to be completed before returning.

In all cases it remains the responsibility of the Investigator to ensure that the Case Report Form has been completed correctly and that the data are accurate.

The Case Report Form may be amended from time to time by the Trial Office throughout the duration of the trial. Whilst this will not constitute a protocol amendment, new versions of the Case Report Form must be implemented by participating sites immediately on receipt.

The following data may not be captured in the source data, e.g., Quality of Life which will be recorded directly onto the Case Report Form.

22.2 Archiving

It is the responsibility of the Principal Investigator to ensure all essential trial documentation and source records (e.g. signed Informed Consent Forms, Investigator Site Files, Pharmacy Files, participants' hospital notes, copies of CRFs etc.) at their site are securely retained for at least 25 years after the end of the trial or following the processing of all biological material collected for research, whichever is the later. Do not destroy any documents without prior approval from the CRCTU Document Storage Manager.

23 QUALITY MANAGEMENT

23.1 Site Set-up and Initiation

All sites will be required to sign appropriate contracts with their National Coordinating Centre prior to participation. In addition, all participating Investigators will be asked to sign the necessary agreements and registration forms and supply a current CV with evidence of recent GCP training to the Trials Office. All members of the site research team will also be required to sign the Site Signature and Delegation Log, which should be returned to the Trials Office. Prior to commencing recruitment all sites will undergo a process of initiation. Key members of the site research team will be required to attend either a meeting or a teleconference covering aspects of the trial design, protocol procedures, Adverse Event reporting, collection and reporting of data and record keeping. Sites will be provided with an Investigator Site File and a Pharmacy File containing essential documentation, instructions, and other documentation required for the conduct of the trial. The Trials Office must be informed immediately of any change in the site research team.

23.2 On-site Monitoring

Monitoring will be carried out as required following a risk assessment and as documented in the BEACON2 Quality Management Plan and the National Coordinating Centre Monitoring Plan for each respective country. It is the responsibility of the participating National Coordinating Centre to ensure that the level and process of monitoring described in the National Coordinating Centre Monitoring Plan for that country is in accordance with their national regulations and to inform the Coordinating Sponsor of any issues.

Additional on-site monitoring visits may be triggered for example by poor CRF return, poor data quality, low SAE reporting rates, excessive number of participant withdrawals or deviations. If a monitoring visit is required, the Trials Office will contact the site to arrange a date for the proposed visit and will provide the site with written confirmation. Investigators will allow the BEACON2 trial staff access to source documents as requested. More information on monitoring will be detailed in the UK Quality Management Plan and the International Monitoring Plan.

23.3 Central Monitoring

Where a participant has given explicit consent sites are requested to send in copies of signed Informed Consent Forms for in-house review.

Trials staff will be in regular contact with the site research team to check on progress and address any queries that they may have. Trials staff will check incoming Case Report Forms for compliance with the protocol, data consistency, missing data and timing. Sites will be sent Data Clarification Forms requesting missing data or clarification of inconsistencies or discrepancies.

Sites may be suspended from further recruitment in the event of serious and persistent non-compliance with the protocol and/or GCP, and/or poor recruitment. Any major problems identified during monitoring may be reported to BEACON2 Trial Management Group, and the relevant regulatory bodies. This includes reporting serious breaches of GCP and/or the trial protocol to the main Research Ethics Committee (REC) and the Medicines for Healthcare products Regulatory Agency (MHRA).

23.4 Audit and Inspection

The Investigators and institutions involved in the clinical trial will permit trial-related monitoring, audits, ethical review, and regulatory inspection(s) including by foreign agencies at their site, providing direct access to source data/documents. Supporting pharmaceutical partners may, on occasion, request to carry out site audits. Any such audits will be conducted as co-audits with the Sponsor.

Sites are requested to notify the applicable NCC of any inspections by the relevant competent authority. NCC's will notify the UK coordinating centre of any significant audit findings.

23.5 Notification of Serious Breaches

In accordance with Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 and its amendments and the European Union Clinical Trials Regulation 2014 the Coordinating Sponsor of the trial is responsible for notifying the licensing authority in writing of any serious breach of:

- o The conditions and principles of GCP in connection with that trial or;
- o The protocol relating to that trial, within 7 days of becoming aware of that breach

For the purposes of this regulation, a "serious breach" is a breach which is likely to effect to a significant degree:

- o The safety or physical or mental integrity of the subjects of the trial; or
- o The scientific value of the trial

National Coordinating Centres and sites are therefore requested to notify the Trials Office of a suspected trial-related serious breach of GCP and/or the trial protocol. Where the Trials Office is investigating whether or not a serious breach has occurred sites are also requested to cooperate with the Trials Office in providing sufficient information to report the breach to the MHRA and other relevant regulatory authorities where required and in undertaking any corrective and/or preventive action.

24 END OF TRIAL DEFINITION

The trial ends when (a) decision has been taken that no further arms will be added to either tier and (b) the last arm reaches an arm-dropping criterion or maximum sample size and (c) on the date of the last patient last follow-up. The National Coordinating Centre will notify the Competent Authority and Research Ethics Committee that the trial has ended and will provide them with a summary of the clinical trial report within 12 months of the end of trial.

The trial results will be included on the clinical trial registry (ISRCTN) and on the Clinical Trials Information System. A lay summary will be included on the UK Health Research Authority website, the Clinical Trials Information System, and the trial website (<https://www.birmingham.ac.uk/research/crctu/trials/beacon2/index.aspx>) and the Cancer Research UK website.

25 STATISTICAL CONSIDERATIONS

25.1 Definition of Outcome Measures

25.1.1 Primary Outcome

For Tier 1 (the main randomised comparison) the outcome measure will be: Progression-Free Survival time at 1-, 2- and 5-years (per INRC 2017)

The estimand is described by the following attributes:

- Population: participants aged ≥ 1 years old with historically proven neuroblastoma with high risk relapsed neuroblastoma with measurable disease, enrolled in tier 1, as per inclusion/exclusion criteria
- Endpoint: PFS time defined as the time from randomisation to first event (relapse/progression/death whichever occurs first)
- Treatment condition: Randomised treatment
- Intercurrent events (ICE) and handling strategy: Prior to the first PFS event:
 - Trial treatment discontinuation (for progression) => Following composite strategy, the progression is included in the endpoint.
 - New therapy started for lack of efficacy reason, Trial treatment switching, Trial treatment discontinuation (not for progression), Lost to follow up => Following treatment policy strategy, ICEs will be ignored.
 - New therapy started for purpose of consolidation, Trial treatment discontinuation (for consolidation purposes), => Following treatment policy strategy, ICEs will be ignored.
 - New therapy started for non-efficacy related reasons (e.g. toxicities) => Following hypothetical strategy by censoring PFS at the time of the last available tumour assessment.
- Population-level summary: Stratified hazard ratio between arm and control

A supplementary estimand will consider the treatment policy strategy for the initiation of new therapy started for non-efficacy related reasons. Additional supplementary estimand(s) will be detailed in the SAP.

For Tier 2 (dose confirmation cohorts) the primary outcome is toxicity, based on the definition of a safe and tolerable combination regimen.

25.1.2 Tier 1 - Overarching Secondary Outcomes

- Best objective response (complete or partial response) as per INRC 2017 during trial treatment (12 cycles) as per investigator assessment.

Page 95

- Clinical benefit (complete, partial, minor response or stable disease) as per INRC 2017 as per investigator assessment.
- Duration of response (for responders (CR or PR) only)
- Overall Survival time
- Quality of life measured by Peds-QL questionnaires
- Incidence and Severity of toxicities (AEs & SAEs)

25.1.3 Tier 1 - BICR Specific Secondary Outcomes (Arms A and B)

- Confirmed Objective Response (complete or partial response) as per INRC 2017 during 6 and 12 cycles of treatment, responses confirmed by BICR. (N.B the 6-month time point forms the primary outcome for the purposes of BLA submission)
- Duration of Confirmed Objective Response (for BICR confirmed responders (CR or PR) only)
- Confirmed Objective Response (complete or partial response) as per INRC 2017 at the end of 6 cycles of treatment, responses confirmed by BICR.
- Extended Confirmed Objective Response (complete, partial or minor response) as per INRC 2017 at any time during 6 cycles and 12 cycles of treatment, responses confirmed by BICR.
- Duration of Extended Confirmed Response (for BICR confirmed responders (CR, PR, MR) only)

25.1.4 Tier 2 - Secondary Endpoints

- Best objective response (complete or partial response) as per INRC 2017 during trial treatment (12 cycles)
- Clinical benefit (complete, partial, minor response or stable disease) as per INRC 2017.
- Quality of life measured by Peds-QL questionnaires
- Incidence and Severity of toxicity (AEs & SAEs)

25.1.5 Tier 1 – Arm A Specific Laboratory

- To measure dinutuximab beta serum concentration immediately pre-Db infusion and immediately post-Db infusions
- To measure ADA to dinutuximab beta immediately pre-Db infusions
- To measure CDC immediately pre-Db and immediately post-Db infusions

Estimands for secondary objectives will be detailed in the SAP.

25.1.6 3.3.13.3 Exploratory/Tertiary Outcome

See Section 3.3.2 for details

- Quality of life of caregivers measured by Peds-QL questionnaires
- Correlation between objective response using INRC 2017 and PFS/OS
- Changes in circulating biomarkers and tumour molecular profiles in tumour and blood, including analysis circulating RNAs and CDNAs, immune response and tumour microenvironment, analyses of genomic aberrations in relapsed neuroblastoma (e.g. MYCN, ALK, RAS/MAPK, ATRX among others) and development of novel biomarkers.

25.2 Trial Design

25.2.1 General Principles

BEACON2 is designed as a two stage, Phase I/II multi-arm platform trial, with the possibility of extending recruitment into a Phase III evaluation, and additional dose confirmation cohorts (Tier 2) to be conducted (where necessary) before introduction of new agents to the main randomisation (Tier 1). The trial aims to recruit a maximum of 75 participants per arm, with an interim analysis at the end of the first stage, when 40 participants have completed six cycles of treatment and have available response assessments. At the interim analysis, arms that are clearly inferior can be terminated.

When stage 2 is completed (75 participants per arm), recruitment will be paused. At this stage, an ad-hoc DMC report will be produced and the DMC will consider this, alongside the feasibility of continued recruitment to an arm (considering drug availability, changes in the treatment landscape, potential new novel therapies and combinations), a decision will then be made regarding the continuation, if deemed feasible and necessary randomisation will re-open to allow for recruitment of 112 participants per arm.

The design allows the introduction of novel agents or regimens as new trial arms, following approval of a substantial amendment by the relevant Competent Authority (the MHRA in the UK). This trial will use Bayesian statistical methods, due to ease of result interpretation in limited populations, allowing for the quantification of the probability of benefit.

25.2.2 Sample Size

Due to the rare nature of relapsed neuroblastoma, the sample size is necessarily limited. The target sample sizes have been determined pragmatically, considering the need to maintain clinical engagement, the desire for the trial to rapidly evaluate and report upon treatments as well as retaining reasonable operating characteristics for both the interim and final analyses. The target sample size for Tier 1 is 75 participants per arm. Based on simulations, this sample size provides a good probability of identifying a beneficial effect of treatment if the true hazard ratio between the intervention and comparator is 0.7 or lower, and a low probability of identifying a beneficial effect of treatment if a treatment is in fact ineffective or harmful across a number of scenarios (Table 15). As there is not extensive data available for the expected event rate in the comparator group (Arm A), for the purposes of simulations, three plausible scenarios have been explored.

These three scenarios explored include a scenario where we observe a high event rate, this is that approximately 30% of participants are event free after 1-year; a scenario in which a medium event rate is observed, approximately 55% of participants event free after 1-year and finally a scenario in which a low event rate is observed, approximately 70% of participants event free after 1-year (see Statistical Analysis Plan [SAP] for more details).

These scenarios are based on the data observed within the BEACON trial and the improvements in survival observed within this trial, currently the most relevant scenario for the arms randomised within the trials is the medium event rate of 55%.

The proportion of simulations in which the probability of finding a hazard ratio of less than 1 between the intervention arm and comparator was greater than 0.80 and greater than 0.95 (based on 1000 simulations). We assume a recruitment rate of 45 participants per year.

Table 15 – Operating characteristics for analysis at 75 participants per arm.

True Hazard Ratio	Comparator Event Rate	P(HR <1) > 0.8	P(HR<1) > 0.95
0.6	High	0.957	0.849
0.7	High	0.866	0.620
0.8	High	0.623	0.317
1.0	High	0.192	0.050
1.1	High	0.077	0.017
1.25	High	0.017	0.002
0.6	Medium	0.921	0.723
0.7	Medium	0.785	0.488
0.8	Medium	0.563	0.262
1.0	Medium	0.209	0.059
1.1	Medium	0.098	0.019
1.25	Medium	0.025	0.004
0.6	Low	0.803	0.543
0.7	Low	0.653	0.345
0.8	Low	0.460	0.191
1.0	Low	0.196	0.060
1.1	Low	0.123	0.025
1.25	Low	0.046	0.014

The trial has a good probability of finding, at the analysis of 75 participants per arm, a convincing probability of benefit, in scenarios where the true hazard ratio is 0.7 or lower, and the comparator event rate is medium or high. Scenarios where the intervention is inactive or harmful (hazard ratio of 1 or higher) are very unlikely to lead to an erroneous conclusively positive result (please see the right-hand column, showing the proportion of simulations finding a probability that the hazard ratio is less than 1 of > 0.95).

After completion of stage 2, the DMC may request randomisation to continue (if feasible), up to a total of 112 per arm. Table 16 (below) gives the same operating characteristics for this larger sample size. As expected, the increased sample size would give higher probabilities of correctly concluding effectiveness.

Table 16 – Operating characteristics for analysis at 112 participants per arm.

The proportion of simulations in which the probability of finding a hazard ratio of less than 1 between the intervention arm and comparator was greater than 0.80 and greater than 0.95 (based on 1000 simulations).

True Hazard Ratio	Comparator Event Rate	P(HR <1) > 0.8	P(HR<1) > 0.95
0.6	High	0.988	0.943
0.7	High	0.925	0.763
0.8	High	0.765	0.453
1.0	High	0.212	0.049
1.1	High	0.061	0.012

True Hazard Ratio	Comparator Rate	Event	P(HR <1) > 0.8	P(HR<1) > 0.95
1.25	High		0.006	0
0.6	Medium		0.973	0.875
0.7	Medium		0.874	0.625
0.8	Medium		0.674	0.377
1.0	Medium		0.181	0.052
1.1	Medium		0.087	0.015
1.25	Medium		0.019	0.002
0.6	Low		0.926	0.730
0.7	Low		0.770	0.477
0.8	Low		0.549	0.271
1.0	Low		0.188	0.043
1.1	Low		0.097	0.018
1.25	Low		0.015	0.003

25.3 Analyses

25.3.1 Comparisons

The randomised question with BEACON2 is designed as a multi-arm, two stage Phase II/III trial, evaluating novel treatments and combinations of drugs. There is no defined standard care treatment for this population, so the trial does not contain a standard of care arm. Each intervention arm will be compared with a concurrently recruiting comparator arm (we do not use the terms control or standard care arm in this trial because variation in standard clinical practice exists). Arm A will initially be the comparator arm, as this represents the current best treatment agreed by the clinical community. Hence for the first arm to open (Arm B) the primary comparison will be between this arm and Arm A. In the future, if another arm is found to be superior to Arm A, the comparator arm may be changed.

The randomisation will begin with two arms (A versus B), with the potential for inclusion of tolerable Tier 2 arms when these are completed. No more than three arms (i.e. one comparator and two intervention arms) will be open simultaneously. This restriction on the number of treatment arms reflects the rare nature of this disease. Should more than three treatment arms be open simultaneously, recruitment to all arms would be reduced and therefore the time taken to evaluate novel interventions extended. Randomisation to the comparator arm will remain open until it is replaced as comparator, or the trial ends.

In Tier 1, primary comparisons will be conducted between each intervention arm and the concurrent control arm participants. This means that for participants randomised to future intervention arms in Tier 1, comparisons will be made between all participants in the new intervention arm and those in the relevant comparator arm during the time the new intervention arm was active. Tier 2

For Tier 2, an assessment will be made after 10 evaluable participants have completed the AESI assessment period. At this stage a decision will be made as to whether the treatment is tolerable, or not. If a treatment is deemed tolerable, the intervention will be considered for incorporation into the main Tier 1 randomisation.

A Tier 2 arm will be considered tolerable if <3/10 AESIs are identified. This would indicate a greater than 90% posterior probability that the true DLT rate is less than 0.5.

The decision to move an arm from Tier 2 to the main randomisation (Tier 1) will be taken by the TMG based on preclinical rationale, mechanism of action, early signs of activity, low proportion of AESIs, lack of overlapping toxicities and feasibility of the combination. For more details, see Section 2 Trial Design.

25.3.2 Stage 1 interim analysis

As part of Tier 1, there is a formal statistical interim analysis defined, this analysis will be conducted when 40 patients have been recruited to the relevant intervention arm(s) and comparator arm (80 participants in total per comparison), have reached six cycles of treatment and have available response assessments. The timing of this interim analysis, regarding treatment cycles received and the number of participants required, is a compromise between the need for an early evaluation of treatments, allowing enough time for a reasonable number of events to occur and having a sample size that provides reasonable operating characteristics on which to base termination decisions to ensure confidence that the correct decision is made at this stage (i.e., that a treatment arm that is no better, or even worse, than the current comparator, doesn't remain open and vice versa).

At this interim analysis, there are two possible decisions that can be made:

- Termination of randomisation to the experimental arm, if it does not meet the statistical guidelines for continuation.
- Continuation of randomisation to both experimental and comparator arms.

This interim analysis is designed to allow the termination of treatment arms in which either there are early signs that participants response to treatment is inferior to that of the comparator arm, or the toxicity profile is worse in the intervention arm compared to the comparator arm. The justification behind the inclusion of this interim analysis, and the data on which the stopping guidelines are based, is to maximise the probability of participants being randomised to the most promising treatment arms, whilst minimising exposure to treatments that have an increased toxicity profile without sufficient efficacy gain.

In order to determine whether an arm should be terminated, we will calculate two posterior probabilities, these are the probabilities that the true response rate and true toxicity rate within the treatment arm are at least 10% worse compared to the response rate in the comparator arm. Arm termination decisions will then be based on the following guidelines:

Treatment arms will be terminated if there is a greater than 80% probability that the response rate is at least 10% worse compared to the comparator arm, or if there is a greater than 90% probability that the toxicity rate is at least 10% worse compared to the comparator arm.

$$Prob(response\ at\ least\ 10\%\ worse) > 0.8\ OR\ Prob(toxicity\ at\ least\ 10\%\ worse) > 0.9$$

Here response is defined to be the observation of a complete or partial response at the end of 6 cycles of treatment, as per investigator assessment, toxicity is defined to be the presence of any grade 3 or above events (excluding lab abnormalities and haematological events, as these have little clinical implications)

These guidelines utilise two different probabilities to reflect the level of surety we want to have to terminate a treatment arm. For example, in the case of toxicity we want to be surer of a worsened toxicity profile to terminate a treatment arm, especially in the instance that the guideline for stopping due to lack of efficacy is not met, i.e., the response rate is the same or improved. Alternatively, we want to terminate treatment arms that look to have early signs of worsened effectiveness, as such a lower certainty of 80% is accepted here.

The below table presents the operating characteristics for the above guidelines, at 40 participants per arm. These operating characteristics have been calculated under the assumption that in the current comparator arm we expect to observe a response rate of 30% and a toxicity rate of 25%. A range of scenarios have been simulated, including scenarios where response and toxicity rates are the same within each arm, response rate is the same, but toxicity rates differ, toxicity rates are the same, but response rates differ and scenarios where both response and toxicity rates differ from the comparator arm.

Composite scenario number	Outcomes		Probability of stopping
	Simulated Response Rate - Intervention Arm (Control Rate 30%)	Simulated Toxicity Rate – Intervention Arm (Control Rate 25%)	
1	0.3	0.25	0.05
2	0.3	0.35	0.132
3	0.3	0.45	0.401
4	0.3	0.15	0.04
5	0.3	0.05	0.04
6	0.2	0.25	0.215
7	0.2	0.35	0.286
8	0.2	0.45	0.501
9	0.2	0.15	0.208
10	0.2	0.05	0.208
11	0.1	0.25	0.619
12	0.1	0.35	0.653
13	0.1	0.45	0.758
14	0.1	0.15	0.617
15	0.1	0.05	0.617
16	0.4	0.25	0.014
17	0.4	0.35	0.101
18	0.4	0.45	0.378
19	0.4	0.15	0.004
20	0.4	0.05	0.004
21	0.5	0.25	0.010
22	0.5	0.35	0.097
23	0.5	0.45	0.375
24	0.5	0.15	0
25	0.5	0.05	0

From these operating characteristics in scenarios where response rates in the intervention arm is the same as the comparator arm (scenarios 1-5), only 4-5% of scenarios recommend termination of the treatment arm, based on the guidelines provided if toxicity is equal or better than the comparator (scenarios 1, 4 & 5). If toxicity is worse in

the intervention arm compared to the comparator arm, more scenarios recommend termination of the treatment arm, 13% in scenario 2 and 40% in scenario 3.

In scenarios where response is 20% worse in the intervention arm, compared to the comparator arm (scenarios 11-15), a minimum of 60% of the scenarios recommend termination of the treatment arm, with this increasing if toxicity is also worse compared to the comparator arm. In scenarios where response is 10% worse, the probability of termination recommendation is dependent on the toxicity rates observed, with most scenarios recommending termination 20% of the time.

If response rate is better in the intervention arm (scenarios 16-25), a small proportion reach stopping criteria if toxicity is the same or favourable (< 1.5%). If toxicity is 20% worse, a higher proportion stop as per the guidance criteria.

For all interim analysis decisions, the DMC will be presented with both above posterior probabilities, as well as a recommendation based upon the guidelines presented. Should the DMC feel that there is sufficient evidence presented to terminate an arm, this recommendation will be made. However, should the DMC feel that there is reason to continue recruitment to a treatment arm, they can also make this recommendation against the guidelines, with justification as to why this decision was made. Progression to stage 2 is also dependent on there being no external or operational reasons for terminating randomisation to that arm (e.g. unavailability of the drug). Results of the interim analyses will be provided to the DMC, who will make recommendations about progression or termination of trial arms.

25.3.3 Completion of stage 2

After 75 participants have completed 12 cycles of treatment and have available response assessment, the trial phase II question will be completed and recruitment to that arm will be paused. An analysis will be conducted and supplied in confidence to the DMC, reporting the primary outcome and key secondary outcomes. Most intervention arms are expected to be completed at this stage, however, the DMC can recommend continuation of a comparison in exceptional circumstances. If the DMC recommend continuation and the TSC/TMG feel this is feasible, randomisation to the arm will be re-opened, and recruitment will continue up to a total of 112 participants (operating characteristics for analysis at this stage are presented in Table 16). The exceptional decision to move to phase III will be taken by the TMG, advised by the DMC and TSC, considering the following aspects:

- o Compelling evidence that further randomisation is necessary
- o Availability of drug supply for intervention and comparator arms
- o Potential competition with other arms
- o Feasibility in terms of expected completion of the phase 3 evaluation

If an arm remains open to recruit up to 112 participants, the relevant comparator arm will also remain open to allow for concurrent control analysis.

25.4 Analysis of Outcome Measures

The main analytical approaches are summarised here. Full details will be specified in the SAP which will be prepared by the trial statisticians and finalised before any analysis is undertaken.

25.4.1 Statistical Methods

The primary analysis for each intervention arm will be conducted when recruitment to the arm has closed and all participants have been followed up for at least 1 year post randomisation. The final analysis will be conducted when all participants have been followed up for at least five years post randomisation.

All analyses will be undertaken in respect to the defined estimands, full definitions of each defined estimand are included within the SAP. The comparison for each treatment arm will be conducted as per 27.3.1.1, with each arm compared with concurrently recruited participants from the relevant comparator arm. Throughout the analyses, we will use a Bayesian statistical approach, as such presentation of the results will utilise posterior distributions of the parameters of interest derived from the analysis models. Priors utilised within analyses will be minimally informative, further defined within the statistical analysis plan.

25.4.2 Primary Outcome

Progression-free survival is defined as the time from randomisation to the first failure event (progression or death). Participants who are alive and progression free at the time of analysis will be censored at the date they were last known to be alive.

PFS will be presented descriptively using Kaplan-Meier plots, number and proportion of participants who have experienced an event, outlining the event type experienced (progression or death) in addition to survival estimates at 1-, 2- and 5-years alongside 95% Credible Intervals (CrI).

Hazard ratios will be estimated between intervention arms and comparator arms using appropriate survival modelling techniques, such as Cox proportional hazard models, these models will include, at a minimum, the factors used for minimisation. Plots of the posterior distributions of the hazard ratio will be presented, alongside the calculated HR and 95% CrI.

25.4.3 Secondary Outcomes

Analysis of secondary time-to-event outcomes (OS, DoR, DoCR (where applicable)) will be conducted and presented as per the primary outcome. Analysis of binary response outcomes will use logistic regression models, incorporating relevant covariates, as for the primary outcome. Plots of the posterior distributions of parameters will be presented, with point estimates and 95% CrI. For analysis of quality of life, we will use longitudinal models to analyse the trajectory of quality of life through time in each randomised group. We will estimate the quality-of-life scores at assessment time-points (pre-cycle 3, 5, 7) and at EOT visit (21 days after cycle 12 dose or last dose given) and the probabilities that differences exceed the clinically important threshold of 10 points.

Change from baseline per timepoint will be reported in a descriptive manner to provide support for the main results. An overall effect of the treatment on the QOL scores will be determined. Differences will only be considered as clinically relevant if they exceed the 10-point threshold. The proportion of participants experiencing a clinically relevant change will be provided as well. For all QOL domains and items, cross-sectional descriptions of the average scores will be presented by treatment arm together with credible intervals and a graphical display of the patterns of change over time will be provided. Missing data is a potential major source of bias in HRQOL assessment. In case overall compliance is deemed too low (<50%), only a descriptive analysis will be performed instead of the defined analysis above.

Adverse events will be classified according to CTCAE, and a tabular summary of reported AEs, SAEs and SUSARs will be produced.

25.4.4 Interim Analysis

Analytical methods for the interim analysis will be the same as for the final analysis (see 25.4.1).

25.4.5 Subgroup Analyses

There are no formal subgroup analyses defined for any of the defined clinical outcomes.

25.4.6 Laboratory Analyses

Analysis of laboratory data, obtained from translational work, will be performed as specified within the analysis plan specific to this work.

26 TRIAL ORGANISATIONAL STRUCTURE

26.1 Sponsor

The University of Birmingham is the Coordinating Sponsor for this study.

26.2 Coordinating Sponsor

The University of Birmingham is the Coordinating Sponsor. The Coordinating Sponsor has delegated the set-up, management, and analysis of the trial to the UK Coordinating Centre. The role of the UK Coordinating Centre is assumed by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham. The trial will be set-up, managed and analysed in the UK in accordance with CRCTU standard policy and procedures.

26.3 National Coordinating Centres

National Coordinating Centres are responsible for the conduct of the trial within their own country. The UK Coordinating Centre will undertake the responsibilities of National Coordinating Centre in the UK.

Each National Coordinating Centre (see the introductory pages for the list) will manage the trial in accordance with the trial protocol and their standard policy and procedures.

26.4 Trial Management Group

A Trial Management Group will be established, and will include the Chief Investigator, University of Birmingham Lead Investigator, Pharmacist, Clinical Coordinators, Co-investigators, Patient and Public Involvement and Engagement Representatives, the Trial Management Team Leader (or delegate), the Trial Biostatistician, the Trial Coordinator, and the Monitor. Other key trial personnel may be invited to join the Trial Management Group as appropriate to ensure representation from a range of professional groups.

26.5 Trial Steering Committee

An independent Trial Steering Committee will be set up to oversee the conduct of the trial. The Committee will be chaired by an independent Chair. Membership will include independent clinicians and at least one participant advocate. Selected members of the Trial Management Group including the Chief Investigator and Trial Biostatistician will report to the Trial Steering Committee. A secretariat will be provided by the Trial Coordinator.

The Trial Steering Committee will operate in accordance with a trial specific charter based upon the template created by the Damocles Group.

The Trial Steering Committee will meet shortly before commencement of the trial and then annually thereafter (usually be held remotely) after the Data Monitoring Committee meeting.

The Trial Steering Committee will supervise the conduct of the trial, monitoring progress including recruitment, data completeness, losses to follow-up, and deviations from the protocol. They will make recommendations about conduct and continuation of the trial to the Coordinating Sponsor.

26.6 Data Monitoring Committee

Data analyses will be supplied in confidence to an independent Data Monitoring Committee, which will be asked to give advice on whether the accumulated data from the trial, together with the results from other relevant research, justifies the continuing recruitment of further participants.

The Data Monitoring Committee will operate in accordance with a trial specific charter based upon the template created by the Damocles Group.

In relation to the Tier 1 question, the Data Monitoring Committee will meet in-person or remotely every 12 months while participants are on treatment. Additional meetings may be called if recruitment is much faster than anticipated and the DMC may, at their discretion, request to meet more frequently. An emergency meeting may also be convened if a safety issue is identified.

For the Tier 2 question, the DMC will act as a Safety Review and Dose Decision Committee. Due to the oversight of AESIs required for this Tier, the committee will meet more regularly. DMC reports will be provided for the first three participants in each cohort, following completion of the AESI assessment period (Cycle 1). Following this, the frequency of meetings and reports will be determined by the DMC, following on from the data already provided. The Data Monitoring Committee includes members of the TMG, independent members, and Principal Investigators with participants enrolled in the trial.

The Data Monitoring Committee will report to the TMG who will convey the findings of the Data Monitoring Committee to the Trial Steering Committee. The Data Monitoring Committee may consider recommending the discontinuation of the trial if the recruitment rate or data quality are unacceptable or if any issues are identified which may compromise participant safety. The trial would also stop early if the interim analyses showed differences between treatments that were deemed to be convincing to the clinical community.

26.7 Participant and Public Involvement and Engagement

Members of the public will be mainly represented by patient advocates. They will be involved in all steps of the development of the clinical trial:

Page 105

- o Design of the research. A PPIE representative will be included on the Trial Management Group and active in design discussions. Protocol design will be presented at international conferences, committees and cooperative groups with PPIE involvement (e.g. ITCC, SIOPEN or NCRI)
- o Management and conduct of the research. A PPI Representative will be included in the TMG. The TSC will also include PPIE representatives.
- o Analysis of results: PPIE representatives, members of the TMG and TSC will participate to the analysis of the results.
- o Dissemination of findings: Results will be presented at PPIE forum and national/international meetings.

Patient representatives and patient advocacy organisations have been involved in the trial from its inception by making substantial contributions to the design of the trial, as well as being on the Trial Management Group, Trial Steering Committee and reviewing trial documentation. This will continue throughout the trial. Advocates mainly pushed to avoid having chemotherapy-only arms (all current novel arms within the trial include novel promising combinations), as chemotherapy alone would not be acceptable for parents; and also for the incorporation of the evaluation of QoL for patients and caregivers. Advocates from ITCC and SIOPEN advocate committees have also reviewed and supported BEACON2, and will continue to work throughout the trial to disseminate it and promote recruitment.

26.8 Peer Review

This clinical trial proposal underwent international peer review from the funding organisation (Fight Kids Cancer) as well as scientific bodies (SIOPEN, ITCC & NCRI neuroblastoma subgroup).

27 FINANCE

This is a clinician-initiated and clinician-led trial funded with core funding from Fight Kids Cancer.

Dinutuximab beta is provided free of charge by RecordatiUK Ltd, including distribution. Bevacizumab, irinotecan and temozolomide will not be provided free of charge by the Coordinating Sponsor and are available commercially.

Recordati UK Ltd will also be providing funding to support the research costs and management of those treatment arms containing dinutuximab beta (Arm A [dBIT], Arm B [BIT] and Arm C [dDbBIT]).

Data will be provided to pharmaceutical partners for regulatory filing purposes.

No individual per participant payment will be made to Investigators or participants.

The Sponsor will enter into an agreement with each NCC. NCCs will receive funds which will be used to deliver the trial. A per patient cost will be included in this budget.

Sites will be compensated for their research activities carried out in relation to the trial as defined in the Clinical Study Site Agreement. Participating sites will receive a per patient payment for research costs incurred while taking part in this trial. Payments will be arranged between the NCC and the Site.

The BEACON2 trial is a National Institute for Health Research (NIHR) Clinical Research Network (CRN) Portfolio study.

28 ETHICAL AND REGULATORY CONSIDERATIONS

The trial will be performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland, June 1964, amended at the 48th World Medical Association General Assembly, Somerset West, Republic of South Africa, October 1996 (website: <http://www.wma.net/en/30publications/10policies/b3/index.html>).

The trial will be conducted in accordance with the protocol, Research Governance Framework for Health and Social Care, the applicable UK Statutory Instruments, (which include the Medicines for Human Use Clinical Trials 2004 and subsequent amendments and the Data Protection Act 2018, Human Tissue Act 2008 and Good Clinical Practice (GCP)) and the applicable European regulations (which include the Clinical Trials Regulation (No 536/2014) and subsequent amendments) in European Countries. This trial will be carried out under a Clinical Trial Authorisation in accordance with the Medicines for Human Use Clinical Trials regulations. The protocol will be submitted to and approved by the main Research Ethics Committee (REC) prior to circulation.

Before any participants are enrolled into the trial, the Principal Investigator at each site is required to obtain local R&D approval. Sites will not be permitted to enrol participants until written confirmation of R&D approval is received by the Trials Office.

It is the responsibility of the Principal Investigator to ensure that all subsequent amendments gain the necessary local approval. This does not affect the individual clinicians' responsibility to take immediate action if thought necessary to protect the health and interest of individual participants.

29 CONFIDENTIALITY AND DATA PROTECTION

Personal data (participants and research staff) recorded on all documents will be regarded as strictly confidential and will be handled and stored in accordance with the Data Protection Act 2018 or other relevant data protection legislation in each country. The following organisations will act as Data Controllers for this trial:

- The University of Birmingham (Data Protection Officer)
- Recordati UK Ltd
- ORPHELIA Pharma
- SIOPEN

Data collected as part of this trial will be shared with the relevant industry partner, and participants will explicitly consent to this data sharing.

Further information about how data is handled by the University of Birmingham and the CRCTU can be found within the CRCTU Privacy Notice (<https://www.birmingham.ac.uk/crctu>).

With the participant's consent, their participant identifiers e.g. National Health Service (NHS) number, or in Scotland the Community Health Index (CHI), will be collected at trial entry to allow tracing through the Cancer Registries and the NHS Information Centre for Health and Social Care (service formally provided by the Office of National Statistics) and to assist with long-term follow-up via other health care professionals (e.g. participant's GP). Participants will be identified using only their unique trial number on the Case Report Form and correspondence between an NCC and the participating sites in its country. However, if local regulation/guidance permits, participants are asked to give permission for the applicable NCC to be sent a copy of their signed Informed Consent Form which will not be anonymised. This will be used to perform in-house monitoring of the consent process and may also be forwarded to other health care professionals involved in the treatment of the participant (e.g. participant's GP) if local regulation/guidance permits.

The Investigator must maintain documents not for submission to the applicable NCC (e.g. Participant Identification Logs) in strict confidence. In the case of specific issues and/or queries from the regulatory authorities, it will be necessary to have access to the complete trial records, provided that participant confidentiality is protected.

The NCCs will maintain the confidentiality of all participant's data and will not disclose information by which participants may be identified to any third party other than those directly involved in the treatment of the patient and organisations for which the patient has given explicit consent for data transfer. Representatives of the BEACON2 trial team may be required to have access to participant's notes for quality assurance purposes but participants should be reassured that their confidentiality will be respected at all times.

Pseudo-anonymised data, bone marrow slides, images and laboratory reports may be provided to the relevant pharmaceutical partner. Participants will be informed and will give explicit consent for this data transfer.

30 INSURANCE AND INDEMNITY

The Coordinating Sponsor will obtain adequate insurance to cover negligent harm arising from the design of the protocol and its liabilities in relation to the trial.

The NCCs are responsible for obtaining insurance to set up and run the trial in their respective countries and for ensuring that sites in their country are adequately covered.

University of Birmingham employees are indemnified by the University insurers for negligent harm caused by the design or co-ordination of the clinical trials they undertake whilst in the University's employment.

In terms of liability at a site, NHS Trust and non-Trust hospitals have a duty to care for participants treated, whether or not the participant is taking part in a clinical trial. Compensation is therefore available via NHS indemnity in the event of clinical negligence having been proven.

The University of Birmingham cannot offer indemnity for non-negligent harm. The University of Birmingham is independent of any pharmaceutical company, and as such it is not covered by the Association of the British Pharmaceutical Industry (ABPI) guidelines for participant compensation.

31 PUBLICATION POLICY

Results of this trial will be submitted for publication in a peer reviewed journal. The manuscript will be prepared by the TMG and authorship will be determined by mutual agreement.

Any secondary publications and presentations prepared by Investigators must be reviewed by the TMG. Manuscripts must be submitted to the TMG in a timely fashion and in advance of being submitted for publication, to allow time for review and resolution of any outstanding issues. Authors must acknowledge that the trial was performed with the support of the University of Birmingham and where applicable other NCCs and other funding bodies. Intellectual property rights will be addressed in the corresponding contracts between Coordinating Sponsor and National Coordinating Centres/sites.

Individual countries will be allowed to publish their efficacy results, however the publication of efficacy results from the pooled analysis will take precedence over efficacy result publications of individual countries, unless the TMG decides otherwise.

Funders must be acknowledged in all publications arising from the trial in accordance with applicable laws and relevant terms and conditions. agreed with such funders. Please contact the Sponsor for further details.

32 DATA AND SAMPLE SHARING

The Sponsor is committed to providing the relevant trial data to each pharmaceutical partner for the treatment arm(s) concerned in accordance with contractual obligations.

The CRCTU is committed to responsible and controlled sharing of anonymised clinical trial data with the wider research community to maximise potential participant benefit while protecting the privacy and confidentiality of trial participants. Data anonymised in compliance with the Information Commissioners Office requirements, using a procedure based on guidelines from the Medical Research Council (MRC) Methodology Hubs and Information Commissioners Office, will be available for sharing with researchers outside of the trials team within 6 months of the primary publication.

Data resulting from the first randomisation within this trial, Arm A vs Arm B, will be shared with Recordati UK Ltd to contribute to approval of dB within the USA. Data on the first 80 patients recruited will be shared for the purposes of obtaining a BLA, this data sharing will be performed as per a data sharing agreement.

Data resulting from this trial will be shared with the International Neuroblastoma Risk Group (INRG) to contribute to the Data Commons database to facilitate international, multi-institutional, interdisciplinary research in childhood neuroblastoma. Linked anonymised data (linked using trial, SIOPEN, INRG or another unique identification number) may be provided to other 3rd parties (e.g., pharmaceutical companies or other academic institutions) for research and safety monitoring. These regulatory authorities or research organisations could be within the UK or abroad. This may be to countries outside of Europe where data protection regulations differ. Any such request is carefully considered and will only be granted if the necessary procedures and approvals are in place.

The trial data will participate in the BIOPORTAL study and linkage of data to other SIOPEN studies.

More detailed information on the CRCTU's Data Sharing Policy and the mechanism for obtaining data can be found on the CRCTU website: <https://www.birmingham.ac.uk/research/activity/mds/trials/crctu/index.aspx>.

33 REFERENCE LIST

1. Brodeur, G.M., et al., *Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment*. J Clin Oncol, 1993. **11**(8): p. 1466-77.
2. Park, J.R., et al., *Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting*. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. **35**(22): p. 2580-2587.
3. Park, J.R., et al., *Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting*. Cancer, 2022. **128**(21): p. 3775-3783.
4. Cohn, S.L., et al., *The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report*. J Clin Oncol, 2009. **27**(2): p. 289-97.
5. London, W.B., et al., *Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials*. Cancer, 2017. **123**(24): p. 4914-4923.
6. Yanik, G.A., et al., *Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group*. J Nucl Med, 2013. **54**(4): p. 541-8.
7. London, W.B., et al., *Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project*. J Clin Oncol, 2011. **29**(24): p. 3286-92.
8. Yanik, G.A., et al., *Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1*. J Nucl Med, 2018. **59**(3): p. 502-508.
9. Basta, N.O., et al., *Factors associated with recurrence and survival length following relapse in patients with neuroblastoma*. Br J Cancer, 2016. **115**(9): p. 1048-1057.
10. Herd, F., et al., *A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma*. Eur J Cancer, 2019. **111**: p. 50-58.
11. Moreno, L., et al., *Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials*. Pediatr Blood Cancer, 2017. **64**(1): p. 25-31.
12. Gray, J., et al., *BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC—International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial*. Journal of Clinical Oncology, 2022. **40**(16_suppl): p. 10002-10002.
13. Wheatley, K., et al., *Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed or refractory high-risk neuroblastoma (RR-HRNB): First survival results of the ITCC-SIOPEN BEACON-Neuroblastoma phase II trial*. Journal of Clinical Oncology, 2020. **38**(15_suppl): p. 10501-10501.
14. Moreno, L., et al., *A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma - BEACON-Neuroblastoma, a European Innovative Therapies for Children with Cancer (ITCC) - International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial*. Journal of Clinical Oncology, 2015. **33**(15_suppl): p. TPS10082-TPS10082.
15. Moreno, L., et al., *LBA64 - Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial*. Annals of Oncology, 2019. **30**: p. v901.
16. Moreno, L., et al., *Bevacizumab, irinotecan or topotecan added to temozolomide for children with relapsed and refractory neuroblastoma. Results of the ITCC-SIOPEN BEACON Neuroblastoma Trial*. Journal of Clinical Oncology, 2023.

17. Corbacioglu, S.e.a., *Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized Rist trial*. Journal of Clinical Oncology, 2023. **41**(16_suppl): p. 10001-10001.
18. Rubie, H., et al., *Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study*. J Clin Oncol, 2006. **24**(33): p. 5259-64.
19. Bagatell, R., et al., *Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study*. J Clin Oncol, 2011. **29**(2): p. 208-13.
20. Di Giannatale, A., et al., *Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study*. Eur J Cancer, 2014. **50**(1): p. 170-7.
21. Rossler, J., et al., *The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts*. Int J Cancer, 2011. **128**(11): p. 2748-58.
22. Rossler, J., et al., *Angiogenesis as a target in neuroblastoma*. Eur J Cancer, 2008. **44**(12): p. 1645-56.
23. Canete, A., et al., *Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients*. J Clin Oncol, 2000. **18**(1): p. 27-34.
24. Sims, T.L., et al., *Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease*. Surgery, 2008. **144**(2): p. 269-75.
25. Segerstrom, L., et al., *The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts*. Pediatr Res, 2006. **60**(5): p. 576-81.
26. Dickson, P.V., et al., *Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy*. Clin Cancer Res, 2007. **13**(13): p. 3942-50.
27. Modak, S., et al., *Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study*. Pediatr Blood Cancer, 2017. **64**(8).
28. Grill, J., et al., *Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma*. J Clin Oncol, 2018. **36**(10): p. 951-958.
29. Chisholm, J.C., et al., *Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)*. Eur J Cancer, 2017. **83**: p. 177-184.
30. Yu, A.L., et al., *Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma*. N Engl J Med, 2010. **363**(14): p. 1324-34.
31. Ladenstein, R., et al., *Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial*. Lancet Oncol, 2018. **19**(12): p. 1617-1629.
32. Mody, R., et al., *Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial*. Lancet Oncol, 2017. **18**(7): p. 946-957.
33. Mody, R., et al., *Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group*. J Clin Oncol, 2020. **38**(19): p. 2160-2169.
34. Furman, W.L., et al., *Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A*. J Clin Oncol, 2022. **40**(4): p. 335-344.
35. Webb, E.R., et al., *Immune characterization of pre-clinical murine models of neuroblastoma*. Scientific Reports, 2020. **10**(1): p. 16695.
36. Garaventa, A., et al., *Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study*. J Clin Oncol, 2021. **39**(23): p. 2552-2563.

Page 111



37. Bird, N., et al., *When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma*. J Clin Oncol, 2022. **40**(2): p. 120-126.
38. Bird, N., et al., *When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma*. Journal of Clinical Oncology, 2022. **40**(2): p. 120-126.
39. McCabe, M., et al., *Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)*. Journal of Clinical Oncology, 2022. **40**(17_suppl): p. LBA2-LBA2.
40. Moreno, L., et al., *Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial*. J Clin Oncol, 2024. **42**(10): p. 1135-1145.
41. Modak, S., et al., *Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study*. Journal of Clinical Oncology, 2022. **40**(16_suppl): p. 10028-10028.
42. Rahma, O.E. and F.S. Hodi, *The Intersection between Tumor Angiogenesis and Immune Suppression*. Clin Cancer Res, 2019. **25**(18): p. 5449-5457.
43. Tamura, R., et al., *The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications*. Med Oncol, 2019. **37**(1): p. 2.
44. Tamura, R., et al., *Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab*. Cancer Sci, 2019. **110**(2): p. 499-508.
45. Bocca, P., et al., *Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model*. Oncoimmunology, 2017. **7**(1): p. e1378843.
46. McDermott, D.F., et al., *Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma*. Nat Med, 2018. **24**(6): p. 749-757.
47. Gao, F. and C. Yang, *Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic*. Curr Cancer Drug Targets, 2020. **20**(1): p. 3-18.
48. Liu, J.F., et al., *Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial*. JAMA Oncol, 2019. **5**(12): p. 1731-1738.
49. Naylor, S., *Biomarkers: current perspectives and future prospects*. Expert Rev Mol Diagn, 2003. **3**(5): p. 525-9.
50. Sawyers, C.L., *The cancer biomarker problem*. Nature, 2008. **452**(7187): p. 548-52.
51. Tan, D.S., et al., *Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development*. Cancer J, 2009. **15**(5): p. 406-20.
52. Yap, T.A., et al., *Envisioning the future of early anticancer drug development*. Nat Rev Cancer, 2010. **10**(7): p. 514-23.
53. Garrido-Laguna, I., M. Hidalgo, and R. Kurzrock, *The inverted pyramid of biomarker-driven trials*. Nat Rev Clin Oncol, 2011. **8**(9): p. 562-6.
54. Eisenhauer, E.A., et al., *New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)*. Eur J Cancer, 2009. **45**(2): p. 228-47.
55. Bautista, F., et al., *Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium*. European Journal of Cancer, 2017. **86**: p. 275-284.
56. Burchill, S.A., et al., *Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group*. 2017. **123**(7): p. 1095-1105.
57. Jacobsen, P.B., K. Davis, and D. Cella, *Assessing quality of life in research and clinical practice*. Oncology (Williston Park), 2002. **16**(9 Suppl 10): p. 133-9.
58. Rothmund, M., et al., *Updating our understanding of health-related quality of life issues in children with cancer: a systematic review of patient-reported outcome measures and qualitative studies*. Qual Life Res, 2022: p. 1-12.



59. Meeske, K., et al., *Parent proxy-reported health-related quality of life and fatigue in pediatric patients diagnosed with brain tumors and acute lymphoblastic leukemia*. Cancer, 2004. **101**(9): p. 2116-25.
60. Eiser, C., J.R. Eiser, and C.B. Stride, *Quality of life in children newly diagnosed with cancer and their mothers*. Health Qual Life Outcomes, 2005. **3**: p. 29.
61. Magal-Vardi, O., et al., *Psychiatric morbidity and quality of life in children with malignancies and their parents*. The Journal of nervous and mental disease, 2004. **192**(12): p. 872-875.
62. Riedl, D., et al., *Rare use of patient-reported outcomes in childhood cancer clinical trials - a systematic review of clinical trial registries*. Eur J Cancer, 2021. **152**: p. 90-99.
63. Anthony, S.J., et al., *Considering quality of life for children with cancer: a systematic review of patient-reported outcome measures and the development of a conceptual model*. Qual Life Res, 2014. **23**(3): p. 771-89.
64. Houtzager, B.A., et al., *One month after diagnosis: quality of life, coping and previous functioning in siblings of children with cancer*. Child Care Health Dev, 2005. **31**(1): p. 75-87.
65. Ortiz, M.C. and R.A. de Lima, *Experiences of families with children and adolescents after completing a cancer treatment: support for the nursing care*. Rev Lat Am Enfermagem, 2007. **15**(3): p. 411-7.
66. McCaffrey, C.N., *Major stressors and their effects on the well-being of children with cancer*. J Pediatr Nurs, 2006. **21**(1): p. 59-66.
67. *Patient-reported outcome measures: use in medical product development to support labeling claims rockville: Food and drug administration. FDA. 2009; Available from: <https://www.fda.gov/media/77832/download>*.
68. *Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies*. London European Medicines Agency (EMA), 2016; Available from: https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf.
69. Varni, J.W., et al., *The PedsQL in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module*. Cancer, 2002. **94**(7): p. 2090-106.
70. Varni, J.W., et al., *The PedsQL Family Impact Module: preliminary reliability and validity*. Health Qual Life Outcomes, 2004. **2**: p. 55.
71. al., B.e., *The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies*. Cancer Discovery, 2022. **12**(5): p. 1266-1281.
72. Viprey, V.F., et al., *Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET*. Eur J Cancer, 2007. **43**(2): p. 341-50.
73. van Zogchel, L.M.J., et al., *Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR*. Cancers (Basel), 2021. **13**(1).
74. Durand, S., et al., *ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations*. Oncotarget, 2019. **10**(48): p. 4937-4950.
75. Van Paemel, R., et al., *The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples*. Eur J Cancer, 2022. **160**: p. 12-23.
76. Peitz C, S.A., Linke RB, Astrahantseff K, Grimaldi M, Schmelz K, Toedling J, Schulte JH, Fischer M, Messerschmidt C, Beule D, Keilholz U, Eggert A, Deubzer HE, Lodrini M., *Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction*. The Journal of Molecular Diagnostics 2020. **22**: p. 1309-1323.
77. *European Union Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric Population*. European Journal of Health Law, 2008. **15**(2): p. 223-250.
78. Brisse, H.J., et al., *Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project*. Radiology, 2011. **261**(1): p. 243-57.



79. Matthay, K.K., et al., *Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force*. Br J Cancer, 2010. **102**(9): p. 1319-26.

APPENDIX 1 – ABBREVIATIONS

AE	ADVERSE EVENT
AESI	ADVERSE EVENT OF SPECIAL INTEREST
ALT	ALANINE AMINOTRANSFERASE
ANC	ABSOLUTE NEUTROPHIL COUNT
APTT	ACTIVATED PARTIAL THROMBOPLASTIN TIME
AST	ASPARTATE AMINOTRANSFERASE
AR	ADVERSE REACTION
AYA	ADOLESCENT AND YOUNG ADULT
BIT	BEVACIZUMAB + IRINOTECAN + TEMOZOLOMIDE ARM
BM	BONE MARROW
BP	BLOOD PRESSURE
BSA	BODY SURFACE AREA
CI	CHIEF INVESTIGATOR
COG	CHILDREN'S ONCOLOGY GROUP
CNS	CENTRAL NERVOUS SYSTEM
CR	COMPLETE RESPONSE
CRF	CASE REPORT FORM
CR UK	CANCER RESEARCH UK
CRCTU	CANCER RESEARCH UK CLINICAL TRIALS UNIT (UNIVERSITY OF BIRMINGHAM)
CRN	CLINICAL RESEARCH NETWORK
CSR	CLINICAL STUDY REPORT
CT	COMPUTERISED TOMOGRAPHY
CTC	COMMON TERMINOLOGY CRITERIA
CTCAE	COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS



dbIT	DINUTUXIMAB BETA + IRINOTECAN + TEMOZOLOMIDE ARM
dbBIT	DINUTUXIMAB BETA + BEVACIZUMAB + IRINOTECAN + TEMOZOLOMIDE ARM
DLT	DOSE LIMITING TOXICITY
DMC	DATA MONITORING COMMITTEE
DNA	DEOXYRIBONUCLEIC ACID
efs	EVENT FREE SURVIVAL
ema	eUROPEAN MEDICINES AGENCY
eRDC	ELECTRONIC REMOTE DATA CAPTURE
EOT	END OF TREATMENT
FDG-PET	FLUORODEOXYGLUCOSE - POSITRON EMISSION TOMOGRAPHY
FFPE	FORMALIN-FIXED PARAFFIN EMBEDDED
GCP	GOOD CLINICAL PRACTICE
G-CSF	GRANULOCYTE COLONY STIMULATING FACTOR
GD2	GANGLIOSIDE EXPRESSED ON THE SURFACE OF THE MAJORITY OF NEUROBLASTOMA TUMOURS
GFR	GLOMERULAR FILTRATION RATE
GM-CSF	GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR
GGT	GAMMA-GLUTAMYL TRANSPEPTIDASE
GP	GENERAL PRACTITIONER
HR	HEART RATE
IB	INVESTIGATOR BROCHURE
ICF	INFORMED CONSENT FORM
ICH	INTERNATIONAL CONFERENCE ON HARMONISATION
IMP	INVESTIGATIONAL MEDICINAL PRODUCT
INR	INTERNATIONAL NORMALISED RATIO
INRC	INTERNATIONAL NEUROBLASTOMA RESPONSE CRITERIA

INRG	INTERNATIONAL NEUROBLASTOMA RISK GROUP
INSS	INTERNATIONAL NEUROBLASTOMA STAGING SYSTEM
IRF	INSTITUTIONAL REVIEW BOARD
ISF	INVESTIGATOR SITE FILE
ITCC	INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER
IV	INTRAVENOUS
MIBG	META-iodo-benzyl-guanidine
MHRA	MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
MRI	MAGNETIC RESONANCE IMAGING
MYCN	MYELOCYTOMATOSIS VIRAL RELATED ONCOGENE
NCI	NATIONAL COORDINATING INVESTIGATORS
NCC	NATIONAL COORDINATOR
NR	NO RESPONSE
OS	OVERALL SURVIVAL
OTC	OVER THE COUNTER
PD	PROGRESSIVE DISEASE
PFS	PROGRESSION FREE SURVIVAL
PI	PRINCIPAL INVESTIGATOR
PIS	PARTICIPANT INFORMATION SHEET
PJP	PNEUMOCYSTIS JIROVECI PNEUMONIA
PK	PHARMACOKINETICS
PRES	POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
PO	ORALLY
PR	PARTIAL RESPONSE
REC	RESEARCH ETHICS COMMITTEE
RNA	RIBONUCLEIC ACID

SAE	SERIOUS ADVERSE EVENT
SAR	SERIOUS ADVERSE REACTION
SD	STABLE DISEASE
SIOPEN	INTERNATIONAL SOCIETY PAEDIATRIC ONCOLOGY EUROPEAN NEUROBLASTOMA GROUP
SNP	SINGLE NUCLEOTIDE POLYMORPHISM
SPC	SUMMARY OF PRODUCT CHARACTERISTICS
SUSAR	SUSPECTED UNEXPECTED SEVERE ADVERSE REACTION
TH	TYROSINE HYDROXYLASE
TMG	TRIAL MANAGEMENT GROUP
TSC	TRIAL STEERING COMMITTEE
UAR	UNEXPECTED ADVERSE REACTION
ULN	UPPER LIMIT OF NORMAL
VTE	VENOUS THROMBO-EMBOLISM
VEGF	VASCULAR ENDOTHELIAL GROWTH FACTOR
VGPR	VERY GOOD PARTIAL RESPONSE
WMA	WORLD MEDICAL ASSOCIATION

APPENDIX 2 - TUMOUR STAGING - INRC CLASSIFICATION [2]

Primary Tumor

Response of primary tumor using both RECIST criteria and MIBG (or FDG if tumor is MIBG nonavid) uptake will be used. In patients with bilateral adrenal lesions, response will be based on the sum of the longest dimensions of both sites unless biopsy proves one to be ganglioneuroma. In patients with multifocal nonadrenal disease, the largest tumor will be considered the primary tumor, and additional lesions will be assessed as metastatic sites unless biopsy proven to be ganglioneuroma.

In some patients, it may be difficult to distinguish postoperative changes in soft tissues in the primary tumor bed from true residual neuroblastoma using anatomic imaging alone. This is particularly true when residual soft tissue masses are small (1 cm at longest diameter). For this reason, patients with MIBG-nonavid lesions measuring less than 1 cm in diameter would be considered to have achieved complete response (CR) in the primary site if the tumor was initially MIBG avid. For patients with MIBG-nonavid tumors at the time of diagnosis, small residual tumors must not demonstrate increased metabolic activity by FDG-PET imaging and, if biopsied, must not demonstrate neuroblastoma or ganglioneuroblastoma .

Primary (soft tissue) Tumor Response

Response	Anatomic + MIBG (FDG-PET†) Imaging
CR	< 10 mm residual soft tissue at primary site AND Complete resolution of MIBG or FDG-PET uptake (for MIBG-nonavid tumors) at primary site
PR	≥ 30% decrease in longest diameter of primary site AND MIBG or FDG-PET uptake at primary site stable, improved, or resolved
PD	> 20% increase in longest diameter taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) AND Minimum absolute increase of 5 mm in longest dimension‡
SD	Neither sufficient shrinkage for PR nor sufficient increase for PD at the primary site

Abbreviations: CR, complete response; FDG, [¹⁸F]fluorodeoxyglucose; MIBG, metaiodobenzylguanidine; PD, progressive disease; PET, positron emission tomography; PR, partial response; SD, stable disease.
 *Not for use in assessment of metastatic sites.
 †Used for MIBG-nonavid tumors.
 ‡Mass that does not meet PD measurement criteria but has fluctuating MIBG avidity will not be considered PD.

Metastatic Soft Tissue and Bone Disease

Tumour Response at Metastatic Soft Tissue and Bone Sites

A combination of anatomic imaging and radionuclide scans will be used to assess response in soft tissue (including lymph node and non-lymph node) and bone metastases. MIBG semiquantitative scoring systems have been previously used for response assessment with international consensus developed for use of these scoring systems in disease response.

Although differences exist in the approach to absolute scoring in the various systems, comparisons of the relative scores as defined by the SIOPEN scoring system and the Curie scoring system (used in COG) have yielded consistent designations of response and have validated MIBG relative scoring as prognostic for overall response and patient outcome in patients with newly diagnosed neuroblastoma. The consensus recommendation is to use the MIBG relative score on bone sectors (the absolute score of bone lesions at time of response assessment divided by the absolute score of bone lesions at baseline before therapeutic interventions) for response assessment. The same scoring method (e.g., Curie, SIOPEN) should be used at each time point of response assessment.

For the purposes of this trial, planar MIBG images should be used for scoring purposes.

Response	Anatomic + MIBG (FDG-PET*) Imaging
CR	Resolution of all sites of disease, defined as: Nonprimary target and nontarget lesions measure < 10 mm AND Lymph nodes identified as target lesions decrease to a short axis < 10 mm AND MIBG uptake or FDG-PET uptake (for MIBG-nonavid tumors) of nonprimary lesions resolves completely
PR	≥ 30% decrease in sum of diameters† of nonprimary target lesions compared with baseline AND all of the following: Nontarget lesions may be stable or smaller in size AND No new lesions AND ≥ 50% reduction in MIBG absolute bone score (relative MIBG bone score ≥ 0.1 to ≤ 0.5) or ≥ 50% reduction in number of FDG-PET-avid bone lesions‡§
PD	Any of the following: Any new soft tissue lesion detected by CT/MRI that is also MIBG avid or FDG-PET avid Any new soft tissue lesion seen on anatomic imaging that is biopsied and confirmed to be neuroblastoma or ganglioneuroblastoma Any new bone site that is MIBG avid A new bone site that is FDG-PET avid (for MIBG-nonavid tumors) AND has CT/MRI findings consistent with tumor OR has been confirmed histologically to be neuroblastoma or ganglioneuroblastoma > 20% increase in longest diameter taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) AND minimum absolute increase of 5 mm in sum of diameters of target soft tissue lesions Relative MIBG score ≥ 1.2§
SD	Neither sufficient shrinkage for PR nor sufficient increase for PD of nonprimary lesions

Abbreviations: CR, complete response; CT, computed tomography; FDG, [¹⁸F] fluorodeoxyglucose; MIBG, metaiodobenzylguanidine; MRI, magnetic resonance imaging; PD, progressive disease; PET, positron emission tomography; PR, partial response; SD, stable disease.

*Used for MIBG-nonavid tumors

†Sum of diameters is defined as the sum of the short axis of discrete lymph nodes (ie, cervical, axillary nodes) added to the sum of the longest diameters of non-lymph node soft tissue metastases. Masses of conglomerate nondiscrete lymph nodes will be measured using longest diameter.

‡For patients with soft tissue metastatic disease, resolution of MIBG and/or FDG-PET uptake at the soft tissue sites is not required; all size reduction criteria must be fulfilled.

§Relative MIBG score is the absolute score for bone lesions at time of response assessment divided by the absolute score for bone lesions at baseline before therapeutic interventions. The same scoring method (eg, Curie or International Society of Pediatric Oncology European Neuroblastoma) must be used at all assessment time points. MIBG single-photon emission computed tomography (SPECT) or MIBG-SPECT/CT may be used for scoring purposes, but the same imaging methodology should be used for all evaluations.

Bone Marrow Metastases

Bone Marrow Metastasis Response*

Exact quantification of bone marrow involvement at all sites should be reported; the percentage of tumor infiltration of bone marrow space assessed by histologic evaluation of trephine or biopsy (with immunohistochemical staining encouraged) or counting of the number of tumor cells in aspirates by cytology or immunocytology (recommended if available) divided by the number of hematopoietic or mononuclear cells evaluated to obtain a percentage of involvement (methodology described by Burchill et al). The bone marrow sample with the highest percentage of tumor infiltration is used in the response algorithm. Neuroblastoma infiltration in the marrow can be heterogeneously distributed throughout the skeleton. Because the clinical impact of this heterogeneity has not yet been fully evaluated, detection of more than 0% to ≤ 5% tumor infiltration in bone marrow will represent a new category of minimal disease.

Response	Cytology†/Histology‡
CR	Bone marrow with no tumor infiltration on reassessment, independent of baseline tumor involvement
PD	Any of the following: Bone marrow without tumor infiltration that becomes > 5% tumor infiltration on reassessment OR Bone marrow with tumor infiltration that increases by > two-fold and has > 20% tumor infiltration on reassessment
MD	Any of the following: Bone marrow with ≤ 5% tumor infiltration and remains > 0 to ≤ 5% tumor infiltration on reassessment OR Bone marrow with no tumor infiltration that has ≤ 5% tumor infiltration on reassessment OR Bone marrow with > 20% tumor infiltration that has > 0 to ≤ 5% tumor infiltration on reassessment
SD	Bone marrow with tumor infiltration that remains positive with > 5% tumor infiltration on reassessment but does not meet CR, MD, or PD criteria

NOTE. In the case of discrepant results between aspirations or core biopsies from two or more sites taken at the same time, the highest infiltration result should be reported using the criteria in this table.
Abbreviations: CR, complete response; MD, minimal disease; PD, progressive disease; SD, stable disease.
*Response will be compared with baseline disease evaluations before enrollment in a clinical trial or, for newly diagnosed patients, with baseline at specific times during therapy (ie, at diagnosis and before start of therapy, before specific phases of therapy such as induction, high-dose chemotherapy with stem-cell rescue consolidation, or postconsolidation immunotherapy).
†Accompanied by immunocytology (recommended, not mandatory).
‡Accompanied by immunohistochemistry; specific recommendations included in article by Burchill et al.¹⁹

Overall Response

Determination of Overall Response

Overall response will be defined by combining response of the individual components (i.e., soft tissue, bone, and bone marrow disease). All components must be evaluated and of sufficient quality to fully assess overall response. An overall CR requires that all involved components have a CR. An overall partial response includes a partial response of all soft tissue and bone sites or noninvolvement in one of these components but allows residual minimal disease in the bone marrow. The prior category of mixed response has been eliminated, and a new category, minor response, has been included. Minor response requires a partial response or CR in at least one component, stable disease for at least one component, and no evidence of progressive disease in any component. Progressive disease in any one component defines overall progressive disease.

Response	Criterion
CR	All components meet criteria for CR
PR	PR in at least one component and all other components are either CR, MD* (bone marrow), PR (soft tissue or bone), or NI†; no component with PD
MR	PR or CR in at least one component but at least one other component with SD; no component with PD
SD	SD in one component with no better than SD or NI† in any other component; no component with PD
PD	Any component with PD

Abbreviations: CR, complete response; MD, minimal disease; MR, minor response; NI, not involved; PD, progressive disease; PR, partial response; SD, stable disease.
*For bone marrow assessment only.
†Site not involved at study entry and remains uninvolved.


Primary Tumor	Soft Tissue or Bone Metastatic Disease (MIBG or FDG-PET)	Bone Marrow Metastatic Disease (cytology*/histology†)	Overall
CR	CR	CR	CR
CR for one response component with either CR or NI for other components			CR
CR	CR	MD	PR
CR	PR	CR	PR
CR	PR	MD	PR
CR	PR	NI	PR
CR	NI	MD	PR
PR	CR	CR	PR
PR	CR	NI	PR
PR	CR	MD	PR
PR	PR	CR	PR
PR	PR	NI	PR
PR	PR	MD	PR
PR	NI	CR	PR
PR	NI	NI	PR
PR	NI	MD	PR
NI	CR	MD	PR
NI	PR	CR	PR
NI	PR	MD	PR
CR	CR	SD	MR
CR	PR	SD	MR
CR	SD	CR	MR
CR	SD	MD	MR
CR	SD	SD	MR
CR	SD	NI	MR
CR	NI	SD	MR
PR	CR	SD	MR
PR	PR	SD	MR
PR	SD	CR	MR
PR	SD	MD	MR
PR	SD	SD	MR
PR	SD	NI	MR
PR	NI	SD	MR
SD	CR	CR	MR
SD	CR	MD	MR
SD	CR	SD	MR
SD	CR	NI	MR
SD	PR	CR	MR
SD	PR	MD	MR
SD	PR	SD	MR
SD	PR	NI	MR
SD	SD	CR	MR
SD	NI	CR	MR
NI	CR	SD	MR
NI	PR	SD	MR
NI	SD	CR	MR
SD	SD	MD	SD
NI	SD	MD	SD
SD	NI	MD	SD
NI	NI	MD	SD
SD	SD	SD	SD
SD	NI	SD	SD
SD	NI	SD	SD
NI	SD	SD	SD
NI	SD	NI	SD
NI	NI	SD	SD
PD in any one component			PD
Response of not evaluable for any one of the three components that had measurable/evaluable tumor at study enrollment and no PD for any component			Not evaluable
No response evaluation performed for any of the three components			Not done

Abbreviations: CR, complete response; MD, minimal disease; MR, minor response; NI, not involved (site not involved at study entry and remains uninvolved); PD, progressive disease; PR, partial response; SD, stable disease.

*Accompanied by immunocytology (recommended, not mandatory).

†Accompanied by immunohistochemistry; specific recommendations included in article by Burchill et al.¹⁹

APPENDIX 3 - SIOPEN SCORING METHODS FOR NEUROBLASTOMA



The SIOPEN Method

The SIOPEN method: the skeletal distribution of MIBG is recorded in 12 anatomical body segments as follows: skull, thoracic cage, proximal right upper limb, distal right upper limb, proximal left upper limb, distal left upper limb, spine, pelvis, proximal right lower limb, distal right lower limb, proximal left lower limb and distal left lower limb. The extent and pattern of skeletal MIBG involvement is scored using a 0–6 scale to discriminate between focal discrete lesions and patterns of more diffuse infiltration.

Each segment is scored as 0. no involvement; 1. one discrete lesion; 2. two discrete lesions; 3. three discrete lesions; 4. > 3 discrete foci or a single diffuse lesion involving < 50% of a bone; 5. diffuse involvement of > 50 to 95% of an entire bone; 6, diffuse involvement of the entire bone, with a maximum score of 72. The SIOPEN score is the current method being used in Europe for the prospective phase 3 neuroblastoma trial. [78, 79]

Where the MIBG is negative, FDG-PET/CT/MRI is used. The total number of discrete metastatic and bone-avid lesions should be recorded.

APPENDIX 4 – LANSKY AND KARNOFSKY

LANSKY PLAY SCALE

100 %	Fully active, normal
90%	Minor restrictions in strenuous physical activity
80%	Active, but tired more quickly
70%	Greater restriction of play <i>and</i> less time spent in play activity
60%	Up and around, but active play minimal; keeps busy by being involved in quieter activities
50%	Lying around much of the day, but gets dressed; no active playing participates in all quiet play and activities
40%	Mainly in bed; participates in quiet activities
30%	Bedbound; needing assistance even for quiet play
20%	Sleeping often; play entirely limited to very passive activities
10 %	Doesn't play; does not get out of bed
0%	Unresponsive



KARNOFSKY AND ECOG SCALES

Karnofsky Index	Description
Able to carry on normal activity; no special care is needed.	
100	Normal, no complaints, no evidence of disease.
90	Able to carry on normal activity, minor symptoms or signs of disease.
80	Normal activity with effort, some signs or symptoms of disease.
Unable to work, able to live at home and care for most personal needs, varying amount of assistance needed.	
70	Cares for self, unable to carry on normal activity or to do work.
60	Requires occasional assistance from others, but able to care for most needs
50	Requires considerable assistance from others and frequent medical care.
Unable to care for self, requires institutional or hospital care or equivalent, disease may be rapidly progressing.	
40	Disabled, requires special care and assistance.
30	Severely disabled, hospitalisation indicated, death not imminent.
20	Very sick, hospitalisation necessary, active supportive treatment necessary.
10	Moribund, fatal processes progressing rapidly.
0	Dead

APPENDIX 5 – TEMOZOLOMIDE DOSING

These tables are to be followed where possible. In other circumstances, please round to nearest practical dose:

BSA (m ²)	Temozolomide 100mg/m ² /day	
	Calculated Dose (mg)	Administered Dose (mg)
.20 – .50	3.35 mg/kg/day	3.35 mg/kg/day
.51	51	50
.52 – .53	52 – 53	50
.54 – .56	54 – 56	55
.57 – .58	57 – 58	55
.59 – .61	59 – 61	60
.62 – .63	62 – 63	60
.64 – .66	64 – 66	65
.67 – .68	67 – 68	65
.69 – .71	69 – 71	70
.72 – .73	72 – 73	70
.74 – .76	74 – 76	75
.77 – .78	77 – 78	75
.79 – .81	79 – 81	80
.82 – .83	82 – 83	80
.84 – .86	84 – 86	85
.87 – .88	87 – 88	85
.89 – .91	89 – 91	90
.92 – .93	92 – 93	90
.94 – .96	94 – 96	95
.97 – .99	97 – 99	95

APPENDIX 6 - WMA DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI

Recommendations guiding physicians
in biomedical research involving human subjects
Adopted by the 18th World Medical Assembly
Helsinki, Finland, June 1964
and amended by the
29th World Medical Assembly, Tokyo, Japan, October 1975
35th World Medical Assembly, Venice, Italy, October 1983
41st World Medical Assembly, Hong Kong, September 1989
and the

48th General Assembly, Somerset West, Republic of South Africa, October 1996

INTRODUCTION

It is the mission of the physician to safeguard the health of the people. His or her knowledge and conscience are dedicated to the fulfillment of this mission.

The Declaration of Geneva of the World Medical Association binds the physician with the words, "The Health of my participant will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act only in the participant's interest when providing medical care which might have the effect of weakening the physical and mental condition of the participant."

The purpose of biomedical research involving human subjects must be to improve diagnostic, therapeutic and prophylactic procedures and the understanding of the aetiology and pathogenesis of disease.

In current medical practice most diagnostic, therapeutic or prophylactic procedures involve hazards. This applies especially to biomedical research.

Medical progress is based on research which ultimately must rest in part on experimentation involving human subjects.

In the field of biomedical research a fundamental distinction must be recognized between medical research in which the aim is essentially diagnostic or therapeutic for a participant, and medical research, the essential object of which is purely scientific and without implying direct diagnostic or therapeutic value to the person subjected to the research.

Special caution must be exercised in the conduct of research which may affect the environment, and the welfare of animals used for research must be respected.

Because it is essential that the results of laboratory experiments be applied to human beings to further scientific knowledge and to help suffering humanity, the World Medical Association has prepared the following recommendations as a guide to every physician in biomedical research involving human subjects. They should be kept under review in the future. It must be stressed that the standards as drafted are only a guide to physicians all over the world. Physicians are not relieved from criminal, civil and ethical responsibilities under the laws of their own countries.

I. BASIC PRINCIPLES

Biomedical research involving human subjects must conform to generally accepted scientific principles and should be based on adequately performed laboratory and animal experimentation and on a thorough knowledge of the scientific literature.

The design and performance of each experimental procedure involving human subjects should be clearly formulated in an experimental protocol which should be transmitted for consideration, comment and guidance to a specially appointed committee independent of the investigator and the sponsor provided that this independent committee is in conformity with the laws and regulations of the country in which the research experiment is performed.

Biomedical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given his or her consent.

Biomedical research involving human subjects cannot legitimately be carried out unless the importance of the objective is in proportion to the inherent risk to the subject.

Every biomedical research project involving human subjects should be preceded by careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to others. Concern for the interests of the subject must always prevail over the interests of science and society.

The right of the research subject to safeguard his or her integrity must always be respected. Every precaution should be taken to respect the privacy of the subject and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.

Physicians should abstain from engaging in research projects involving human subjects unless they are satisfied that the hazards involved are believed to be predictable. Physicians should cease any investigation if the hazards are found to outweigh the potential benefits.

In publication of the results of his or her research, the physician is obliged to preserve the accuracy of the results. Reports of experimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication.

In any research on human beings, each potential subject must be adequately informed of the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it may entail. He or she should be informed that he or she is at liberty to abstain from participation in the study and that he or she is free to withdraw his or her consent to participation at any time. The physician should then obtain the subject's freely-given informed consent, preferably in writing.

When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress. In that case the informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.

In case of legal incompetence, informed consent should be obtained from the legal guardian in accordance with national legislation. Where physical or mental incapacity makes it impossible to obtain informed consent, or when the subject is a minor, permission from the responsible relative replaces that of the subject in accordance with

national legislation. Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained in addition to the consent of the minor's legal guardian.

The research protocol should always contain a statement of the ethical considerations involved and should indicate that the principles enunciated in the present Declaration are complied with.

II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE (Clinical Research)

In the treatment of the sick person, the physician must be free to use a new diagnostic and therapeutic measure, if in his or her judgement it offers hope of saving life, reestablishing health or alleviating suffering.

The potential benefits, hazards and discomfort of a new method should be weighed against the advantages of the best current diagnostic and therapeutic methods.

In any medical study, every participant - including those of a control group, if any - should be assured of the best proven diagnostic and therapeutic method. This does not exclude the use of inert placebo in studies where no proven diagnostic or therapeutic method exists.

The refusal of the participant to participate in a study must never interfere with the physician-participant relationship.

If the physician considers it essential not to obtain informed consent, the specific reasons for this proposal should be stated in the experimental protocol for transmission to the independent committee (1, 2).

The physician can combine medical research with professional care, the objective being the acquisition of new medical knowledge, only to the extent that medical research is justified by its potential diagnostic or therapeutic value for the participant.

III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (Non-Clinical Biomedical Research)

In the purely scientific application of medical research carried out on a human being, it is the duty of the physician to remain the protector of the life and health of that person on whom biomedical research is being carried out.

The subject should be volunteers - either healthy persons or participants for whom the experimental design is not related to the participant's illness.

The investigator or the investigating team should discontinue the research if in his/her or their judgement it may, if continued, be harmful to the individual.

In research on man, the interest of science and society should never take precedence over considerations related to the wellbeing of the subject.

APPENDIX 7 - DEFINITION OF ADVERSE EVENTS

Adverse Event (AE)

Any untoward medical occurrence in a participant or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

An AE can therefore be any unfavourable and unintended sign (including abnormal laboratory findings), symptom or disease temporally associated with the use of an investigational medicinal product, whether or not related to the investigational medicinal product.

Adverse Reaction (AR)

All untoward and unintended responses to an IMP related to any dose administered.

An AE judged by either the reporting Investigator or Sponsor as having causal relationship to the IMP qualifies as an AR. The expression reasonable causal relationship means to convey in general that there is evidence or argument to suggest a causal relationship.

Serious Adverse Event (SAE)

Any untoward medical occurrence or effect that at any dose:

- o Results in death (unrelated to original cancer)
- o Is life threatening*
- o Requires hospitalisation** or prolongation of existing in-participant hospitalisation
- o Results in persistent or significant disability or incapacity
- o Is a congenital anomaly/birth defect
- o Or is otherwise considered medically significant by the Investigator***

The term severe is often used to describe the intensity (severity) of a specific event. This is not the same as serious, which is based on participants/event outcome or action criteria.

* Life threatening in the definition of a Serious Adverse Event refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.

**Hospitalisation is defined as an unplanned, formal in participant admission, even if the hospitalisation is a precautionary measure for continued observation. Thus, hospitalisation for protocol treatment (e.g., line insertion), elective procedures (unless brought forward because of worsening symptoms) or for social reasons (e.g., respite care) are not regarded as an SAE.

*** Medical judgment should be exercised in deciding whether an Adverse Event is serious in other situations. Important Adverse Events that are not immediately life threatening or do not result in death or hospitalisation but may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above, should be considered serious.

Serious Adverse Reaction (SAR)

An Adverse Reaction which also meets the definition of a Serious Adverse Event.

Suspected Unexpected Serious Adverse Reaction (SUSAR)

A Serious Adverse Reaction that is unexpected i.e., the nature, or severity of the event is not consistent with the applicable product information.

A Suspected Unexpected Serious Adverse Reaction should meet the definition of an Adverse Reaction, Unexpected Adverse Reaction and Serious Adverse Reaction.

Unexpected Adverse Reaction (UAR)

An Adverse Reaction, the nature or severity of which is not consistent with the Reference Safety Information.

When the outcome of an Adverse Reaction is not consistent with the Reference Safety Information, the Adverse Reaction should be considered unexpected.

Related Event

An event which resulted from the administration of any of the research procedures.

Unexpected and Related Event

An event which meets the definition of both an Unexpected Event and a Related Event.

Unexpected Event

The type of event that is not listed in the protocol as an expected occurrence.

APPENDIX 8 - COMMON TOXICITY CRITERIA GRADINGS

Toxicities will be recorded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The full CTCAE document is available on the National Cancer Institute (NCI) website and is provided in the Investigator Site File.

APPENDIX 9 – PEDSQL™ ADMINISTRATION GUIDELINES

The following guidelines are intended for use by individuals trained in the administration of standardized questionnaires. The PedsQL™ administrator is crucial in developing rapport with the respondents, emphasizing the importance of the questionnaire, addressing concerns, and ensuring that the PedsQL™ is completed accurately and confidentially.

General Protocol

Create a procedure for assigning identification numbers that will allow for parent/child comparisons as well as comparisons of baseline/follow-up data.

If feasible, the PedsQL™ should be completed *before* the respondents complete any other health data forms and *before* they see their physician or healthcare provider.

The parent/child should first complete the PedsQL™ Generic Core Scales and then complete any additional PedsQL™ Module.

Parents, Children (8-12) and Teens (13-18) may self-administer the PedsQL™ after introductory instructions from the administrator. If the administrator determines that the child or teen is unable to self-administer the PedsQL™ (e.g., due to illness, fatigue, reading difficulties), the PedsQL™ should be read aloud to the child or teen. For the Young Child (5-7), the PedsQL™ should be administered by reading the instructions and each item to the young child word for word. At the beginning of each subscale repeat the recall interval instructions (one month or 7 days) to remind the young child to respond only for that specific recall interval. Use the separate page with the three faces response choices to help the young child understand how to answer. When reading items aloud to a child, intonation should be kept neutral to avoid suggesting an answer.

If a child has difficulty understanding the age-appropriate PedsQL™, the preceding age group version may be administered to the child (e.g., administering the Young Child (5-7) Self-Report version with the three faces response choices to an 8 year old). However, if a child presents with severe cognitive impairments (as determined by the administrator), the PedsQL™ may not be appropriate for that child. In such cases, only the Parent-Proxy Report should be administered to the child's parent.

The parent and child must complete the questionnaires *independently* of one another. Discourage the parent, child, or other family members from consulting with one another during the completion of the questionnaire. Let them know that they can feel free to discuss their answers following completion of the questionnaires, but that it is important to get both the parent's and the child's *individual* perspectives. If you are administering the questionnaire to the child, the child should be facing away from the parent.

If the child or parent has a question about what an item means or how they should answer it, do not interpret the question for them. Repeat the item to them verbatim. Ask them to answer the item according to what *they think the question means*. If they have trouble deciding on an answer, ask them to choose the response that comes closest to how they feel. The child and/or the parent has the option of not answering a question if they truly do not understand the question.

If a parent/child asks you to interpret the responses, tell her/him that you are not trained to interpret or provide a score for the answers given. If the PedsQL™ is being used for a clinical study, let the parent/child know that their answers will be combined with other participants' answers and analyzed as a group rather than as individual respondents.

Document all reasons for refusals and non-completions of the PedsQL™.

Administering the PedsQL™

The following scripts have been developed as a guide to introduce the PedsQL™ to the child and his/her parent(s). Modify the language to a style that is most appropriate for you and the respondent.

For the child:

The PedsQL™ asks you questions about how you feel and what you think about your health. It is not a test, and there are no right or wrong answers. It takes about 5 minutes to complete. If you have any questions, please let me know.

For the parent:

The PedsQL™ is a questionnaire that assesses health-related quality of life in children and adolescents. It contains questions about your child's physical, emotional, social, and school functioning **in the past one month** (or for the Acute version, **in the past 7 days**).

The PedsQL™ is brief and typically takes less than 5 minutes to complete. It is not a test, and there are no right or wrong answers. Please be sure to read the instructions carefully and choose the response that is the closest to how you truly feel. Please do not compare your answers with your child's responses. We are interested in your and your child's **individual** perspectives. However, feel free to discuss the questionnaire with your child **after** you have both completed it and returned it to me. If you have any questions, please let me know.

General Protocol

Provide the respondent with a pen or pencil and a solid writing surface. If a table is not available, the participant should be provided with an item such as a clipboard. Remain nearby should questions or concerns arise.

When the parent/child returns the PedsQL™, look it over and check to see that all answers have been completed. Verify that no item has more than one response. If any responses are incomplete, illegible, or there are multiple responses for an item, please ask the parent or child to indicate their response.

Ask the participants if they had any difficulties completing the questionnaire or if they have any other comments regarding the questionnaire. Document any important feedback.

Thank the parent and child for taking the time to complete the questionnaire. If the study design involves following up with these respondents, let them know that they may be asked to complete the PedsQL™ again at another time. Indicate when they can expect to be contacted again if known.



Cancer Research UK Clinical Trials Unit (CRCTU),
School of Medical Sciences
University of Birmingham, Edgbaston, Birmingham. B15 2TT

☎ +44 (0)121 414 3788

☎ +44 (0)121 414 9520

✉ BEACON2@bham.ac.uk

Trial Database

<https://v4.viedoc.net>

Serious Adverse Event Reporting

Reg@trials.bham.ac.uk

CC beacon2@trials.bham.ac.uk

Include "BEACON2 SAE" in the subject line